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Melanoma development
Of all skin tumors, cutaneous malignant melanoma is less common than basal 
and squamous cell tumors of the skin, but is much more fatal. Over the last 
decades, increasing trends in incidence have been observed for all Caucasian 
populations.1
Since the mid 1960s the incidence rate has risen by 3-8% per year. Despite 
this increase, and an overall rise in mortality, the survival rate has improved 
substantially.2 However, cutaneous melanoma causes disproportionate mortality 
in those of young and middle age, such that an average of 18.6 potential life 
years are lost for each melanoma death, one of the highest rates for adult-onset 
cancers.2 In the Netherlands, incidence rates between 1989 and 1998, increased 
from 9.5 to 11.5 per 100.000 person-years for males, and from 13.3 to 14.8 per 
100.000 person-years for females.1,2 In Europe, melanoma is the 17th most 
commonly diagnosed cancer in males and 8th most common in females, while 
in the USA it is the 5th and 7th and in Australia the 4th and 3rd most commonly 
diagnosed cancer, respectively.2,3
Melanoma develops upon the malignant transformation of melanocytes. The 
main environmental risk factor for the development of melanoma is exposure to 
ultraviolet radiation, especially when individuals are exposed at a young age.4,5
Intermittent sun exposure and severe sunburns, especially during childhood, 
and the use of tanning beds have been associated with an increased risk of 
cutaneous melanoma.6,7 Ultraviolet radiation promotes malignant changes in the 
skin by a direct mutagenic effect on DNA, by disturbing the immune defense 
system in the skin, and by promoting reactive oxygen species of melanin that 
cause DNA damage and suppress apoptosis.2,8
A major host factor related to the risk of developing melanoma, is skin type; 
melanoma is mainly a disease of white people.1-3 Having pigmented lesions, 
including freckles 9,10 and either common 11,12 or clinically atypical moles 13,14, is 
also associated with an increased risk of developing cutaneous melanoma. There 
is also a genetic factor. The risk of developing a melanoma is greatly increased 
if there is a positive family history.15,16 Patients with a strong family history and 
multiple clinically atypical moles are at greatest risk for developing cutaneous 
melanoma.17-20 Familial melanoma is caused by inheritance of mutations in the 
cyclin dependent kinase inhibitor 2A (CDKN2A) gene.21-23 Mutation of this gene 
results in the production of defective protein leading to uncontrolled cell cycle 
progression.24 Even in those patients predisposed to melanoma by inheriting this 
mutated gene, incidence is markedly higher in people living at lower latitudes.25
This fact indicates close interaction between environmental ultraviolet exposure 
and genetic susceptibility in the development of melanoma.
The prognosis of melanoma patients depends mainly on 2 factors; the thickness 
of the primary tumor (Breslow thickness) and the presence or absence of 
metastatic cells in the regional lymph nodes. Other factors which should also be 
taken into account are tumor ulceration, sex, age, site of the primary melanoma 
and lymphatic invasion. Five-year overall survival decreases from 93% for Stage 
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1 patients (Breslow thickness <1.0 mm), 68% for Stage 2 patients (Breslow 
thickness >2 mm), 45% for Stage 3 patients (regional lymph node metastasis), 
to 11% for Stage 4 patients (systemic metastasis).26-28
Lymphatic spread of melanoma
Melanoma metastasizes mostly via the lymphatics. It ﬁ rst metastasizes to 
the regional lymph nodes, where the metastatic cells settle. Subsequently, 
they metastasize systemically after occult growth. Primary tumors can also 
metastasize directly into the circulation, leading to rapid systemic metastasis.
Most patients have no clinical signs of metastatic disease at the time of 
diagnosis. However, approximately 20% of these patients do have occult 
metastases in regional lymph nodes. The optimal treatment of patients with 
cutaneous melanoma in regard to the regional lymph node basin has been one 
of the most important controversies for many years. Until the early nineties, 
there were 2 therapeutic options: elective lymph node dissection, in which 
all regional lymph nodes were removed in every patients after the diagnosis 
of a primary melanoma, or the wait-and-watch approach in which a delayed 
lymph node dissection was performed at the time when clinical (i.e. palpable) 
lymph node metastases occur. Various studies compared elective lymph node 
dissection with the wait-and-watch approach and failed to offer a deﬁ nitive 
optimal approach.29-34 However, investigators of the Intergroup Melanoma Trial 
recently demonstrated a survival beneﬁ t for elective lymph node dissection in 
prospectively stratiﬁ ed subsets of patients.35 The World Health Organization trial 
no. 14 showed that survival was signiﬁ cantly better for patients with resected 
microscopic nodal disease by elective lymph node dissection compared with 
patients who did not undergo elective lymph node dissection and subsequently 
developed gross nodal disease.30 From these latest ﬁ ndings, it seems that lymph 
node dissection might be curative in some patients with nodal metastases.
A major disadvantage of elective lymph node dissection is that the procedure 
is applied to all patients with clinically negative lymph nodes. Therefore, 
the majority of patients without nodal metastases (approximately 80%) are 
subjected to the morbidity of elective lymph node dissection without any 
therapeutic beneﬁ t.36 This morbidity is signiﬁ cant and includes wound infection, 
seroma formation and lymphedema. The ideal situation would be to only 
identify those patients with lymph node metastases for therapeutic lymph node 
dissection. This is possible by removing only the lymph node from the draining 
lymph basin that is most likely to contain metastases, the sentinel lymph node.
The sentinel lymph node concept
The sentinel lymph node concept is based on the theory of an orderly progression 
of tumor cells within the lymphatic system in the initial phase of the metastatic 
process. It assumes that early lymphatic metastases, if present, are always found 
G
EN
ER
A
L 
IN
TR
O
D
U
C
TI
O
N
 A
N
D
 O
U
TL
IN
E 
O
F 
TH
E 
TH
ES
IS
13
ﬁ rst within the ﬁ rst-line tumor draining lymph node, the sentinel lymph node. The 
rationale of the sentinel lymph node concept is based on the assumption that 
if the sentinel lymph node is not involved, we can reasonably presume that the 
remaining lymph nodes of the regional basin are free from metastasis as well.
These principles have been described in the past by scientists like Virchow a 
Brainwaite. In 1960, Gould et al were the ﬁ rst to use the term “sentinel node” in 
a manuscript.37 In patients with parotid cancer the authors described a speciﬁ c 
lymph node that was the ﬁ rst node to bear metastatic cells if lymphatic spread 
had occurred. They suggested that examination of this node could be instrumental 
in deciding to perform a radical neck dissection.
In 1976 Cabanas, a Paraguayan surgeon, reported on a “sentinel lymph node” in 
penile carcinoma.38 Like Gould et al, he suggested that metastatic cells from a 
carcinoma initially drain to this speciﬁ c lymph node, which was almost always 
found in the same anatomical position.
However, it was Morton et al, who took the practice of taking a sentinel lymph 
node biopsy a major step forward in the beginning of the 1990s. In 1992 this 
group published the ﬁ rst results of a study in which the sentinel lymph node 
was identiﬁ ed in 194 melanoma patients using blue dye.36 Others conﬁ rmed the 
accuracy of this procedure in studies in which the sentinel lymph node procedure 
was followed by immediate complete lymph node dissection, so that all lymph 
nodes in the draining lymph node basin could be examined histologically.39,40
Initially, the sentinel lymph node procedure was performed by means of a vital 
blue dye which was intradermally injected around the primary tumor or scar. 
Nowadays, a higher detection rate is reached by means of speciﬁ c radiotracers, 
through pre-operative lymphoscintigraphy and intra-operative detection of the 
sentinel lymph node using a handheld gamma-detection probe.36,41-44 Identiﬁ cation 
of the sentinel lymph node is most accurate when this ‘triple technique’ is used, 
encompassing a pre-operative lymphoscintigraphy, intradermal injection of blue 
dye around the primary melanoma site immediately pre-operatively, and the use 
of a handheld gamma-detection probe intra-operatively.45-47
The prognostic value of the sentinel lymph node status has been shown in several 
large studies.48-55 All these studies report a large difference in the probability 
of ﬁ ve-year survival between patients who are sentinel lymph node negative or 
positive, independently of other prognostic variables. Five-year overall survival 
for sentinel lymph node positive patients is around 55-60%, whereas ﬁ ve-year 
overall survival for sentinel lymph node negative patients is around 90%.
Immune defenses against melanoma metastasis
The sentinel lymph node, not only constitutes the ﬁ rst expected site of micro-
metastasis, but also the ﬁ rst point of contact between tumor-associated antigens 
and the adaptive immune system. Here the tumor-associated antigens will be 
presented to cytotoxic T cells by dendritic cells. (FIGURE 1)
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Dendritic cells are bone marrow-derived antigen-presenting cells that are critical
to the initiation of T cell-mediated immunity.56-59 In melanoma, skin-resident 
myeloid dendritic cells (i.e. the Langerhans cells) take up and transport tumor-
associated antigens to tumor-draining lymph nodes.56,60 In order to subsequently 
activate melanoma-speciﬁ c cytotoxic T cells, the migrated Langerhans cells 
need to become activated (i.e. mature) and express high levels of co-stimulatory 
molecules (CD80, CD83, CD86), as well as appropriate chemokine receptors 
(CCR7) for their migration to the paracortical T cell areas of the tumor-draining 
lymph node.61 (FIGURE 2 and 3)
FIGURE 1
Schematic representation of 1. melanoma tumor antigen capture by dendritic Langerhans 
cells in the skin, at the primary tumor site. After capturing they 2. migrate towards the lymph 
nodes, become activated/mature, and 3. prime and activate tumor-speciﬁ c cytotoxic T cells. 
These expanded cytotoxic effector T cells 4. enter the systemic circulation and migrate towards 
the primary and/or metastatic tumor site(s) where they 5. attack and kill the tumor through 
granzyme-mediated apoptosis induction.
Melanoma is the most immunogenic tumor identiﬁ ed to date; tumor-associated 
antigen-reactive T cells are detectable both in the blood and in tumor-draining 
lymph nodes from melanoma patients, and their frequency can be increased 
by speciﬁ c vaccination.62-65 This intrinsic immunogenicity may make melanoma 
lesions particularly amenable to therapeutic approaches aimed at strengthening 
tumor immune surveillance. High numbers of sufﬁ ciently activated dendritic 
cells in the lymphatic tumor-drainage catchment area are very important in this 
regard. Dendritic cell development and activation can both be frustrated by 
inhibitory factors commonly associated with melanoma.60,66,67 The degree of 
such immunosuppression in tumor-draining lymph nodes is directly related to 
their distance to the primary tumor. In keeping with this, the sentinel lymph node 
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is the preferential site of early metastasis68-70 and shows the most pronounced 
immunological downregulation.71,72 The frequency of paracortical sentinel lymph 
node-dendritic cell is reduced, and most sentinel lymph node-dendritic cells 
lack dendritic morphology and display lower expression levels of costimulatory 
molecules as compared to non-sentinel lymph node-dendritic cells.71,72 Such a 
paralysis of dendritic cells in the ﬁ rst line of immunological defense may well 
facilitate the metastatic spread of melanoma cells to more distal tumor-draining 
lymph nodes.71,73
Granulocyte macrophage-colony stimulating factor is a haematopoietic growth 
factor, but is also the most commonly used cytokine to boost anti-tumor immunity. 
It is known to stimulate dendritic cells at all stages of development, by mobilizing 
dendritic cell precursors to the blood and differentiated dendritic cells to the 
site of administration, by activating them, by stimulating their migration to lymph 
nodes and by endowing them with an increased resistance to apoptosis.74
(FIGURE 3)
FIGURE 2 Differences between immature and mature dendritic cells 
Functional differences between immature and mature dendritic cells. Immature dendritic cells 
(DC) reside in peripheral organs. In this state they express membrane receptors needed for 
antigen capture (e.g. scavenger receptors, Fc-receptors, Toll-like receptors [TLR]) and are 
optimally equipped for antigen uptake and processing. Migration of DC to secondary lymphoid 
organs is accompanied by downregulation of the antigen capture and processing machinery and 
a simultaneous activation of the DC (i.e. maturation), characterized by the upregulation of the T 
cell-stimulatory machinery which includes HLA class I and II molecules, costimulatory molecules 
(e.g. CD40, CD80, CD86), adhesion molecules (e.g. CD54), and cytokines (e.g. IL-12p70, 
IL-18, IL-23). In this state the DC is optimally equipped to prime naive T cells, leading to their 
expansion and transition to the effector state.
Local release of granulocyte macrophage-colony stimulating factor has previously 
been reported to result in enhanced recruitment of activated dendritic cells to 
draining lymph nodes in a murine model.75 All these features make granulocyte 
macrophage-colony stimulating factor a prime candidate to test its modulatory 
effects on sentinel lymph node-dendritic cells in a clinical setting. In a clinical 
trial described in this thesis we tested the inﬂ uence of locally administered 
granulocyte macrophage-colony stimulating factor on immunological functions in 
the sentinel lymph node of Stage 1 melanoma patients. (FIGURE 4)
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FIGURE 3
The role of granulocyte macrophage-colony stimulating factor (GM-CSF) in the in vivo 
differentiation and activation of myeloid dendritic cells (DC). Bone marrow-derived DC 
precursors circulate in peripheral blood and seed peripheral organs as immature DC. Upon 
(cytokine- or microbial agent-mediated) activation, DC migrate to secondary lymphoid as mature 
DC. GM-CSF can mobilize DC precursors from the bone marrow, stimulate their differentiation 
and induce DC maturation. Expression of different costimulatory molecules and chemokine 
receptors for each differentiation/maturation stage is listed. 
FIGURE 4
Flow chart of the treatment and experimental schedule to which the patients in the studies 
described in this thesis were subjected. 
1. During 4 days pre-operatively, they were intradermally injected with either saline or 
granulocyte macrophage-colony stimulating factor. 2. The sentinel lymph node procedure 
consists of the triple technique. Pre-operatively all patients were injected with Technetium 
labeled colloidal albumin and a dynamic and static lymphoscintigraphy was made. Just prior 
to surgery, Patent blue was injected intradermally and during surgery, a handheld gamma 
detection probe was used to locate the sentinel lymph node, together with the blue coloration 
of lymphatics. 3. After removal of the sentinel lymph node, the lymph node was bisected. 
4. Viable cells were collected through scraping the cutting surface with a surgical blade. 5. 
The collected cells were immediately processed for FACS-analyses and T cell expansions for 
functional analyses.
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We hypothesized that local treatment with granulocyte macrophage-colony 
stimulating factor would increase the number and activation state of myeloid 
dendritic cells in the sentinel lymph node. The aim of our study was to overcome 
the immunosuppression in the sentinel lymph node by facilitating the activation 
of tumor-speciﬁ c cytotoxic T cells and ultimately establish protection against 
(micro-) metastasis.
The sentinel lymph node biopsy is a standard procedure in the VU University 
medical center since its introduction in the early 1990s: in our institute it is 
offered to all melanoma patients with a Breslow thickness >0.9 mm.76 In the 
Netherland we were one of the ﬁ rst to publish results of the sentinel lymph 
node procedure in melanoma.41 So far, most publications described clinical and 
technical implications of the sentinel lymph node procedure. This thesis is the 
ﬁ rst to describe the possible application of immunotherapies in the context of the 
sentinel lymph node procedure.
This thesis is divided into two parts. The ﬁ rst part describes the clinical relevance 
of the sentinel lymph node procedure in the management of melanoma 
treatment. The second part describes immunological studies concerning the 
sentinel lymph node in melanoma. (FIGURE 4)
Outline of this thesis
Chapter 2 describes the accuracy of the sentinel lymph node procedure 
and clinical outcome in our institute. Since the introduction of the sentinel 
lymph node procedure in our Institute in 1993 we performed more than 600 
procedures. The study described in this chapter, examined the results of the 
sentinel lymph node procedure in 209 consecutive melanoma patients with a 
follow-up of at least 60 months. The detection rate and false negative rate of the 
sentinel lymph node procedure is described and discussed. Furthermore prognostic 
factors associated with survival are determined using regression models.
Of all patients with metastasis to the sentinel lymph node, 60-80% have 
metastases limited to the sentinel lymph node. Despite this, they all undergo 
additional lymph node dissection, which is associated with great morbidity. In 
Chapter 3, a model is described which might predict the absence of additional 
lymph node metastases. Of all sentinel lymph node positive patients, histological 
slides from the sentinel lymph nodes were re-examined under the microscope. 
Using  a sophisticated morphometry system, the two-dimensional surface area 
of metastasis in the sentinel lymph node was measured and correlated to non-
sentinel lymph node involvement and survival. Using this model, additional lymph 
node dissection might be abandoned in future.
Before we could start immunological studies concerning the sentinel lymph 
node, we had to develop a new technique to collect viable cells from a sentinel 
lymph node without interfering in diagnostic and prognostic procedures. In 
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order to monitor tumor-speciﬁ c cellular immune responses in sentinel lymph 
nodes, obtaining viable cells from these nodes is of particular importance. 
Due to extensive diagnostic procedures, obtaining a piece of sentinel lymph 
node to isolate viable immune cells for functional analyses is often impossible. 
For this reason an alternative method to obtain viable cells from a lymph node 
was investigated and described in Chapter 4. Scraping the cutting surface 
of bisected lymph nodes with a surgical blade (FIGURE 4) was compared with 
dissociation of total lymph node (i.e. the “standard” method to obtain viable 
cells). We were the ﬁ rst to use this method in lymph nodes.
The tumor-induced downregulation of immunological defenses is most pronounced 
in the sentinel lymph node. In the immune response against tumors, dendritic 
cells play a crucial role. A tumor-induced decrease in the frequency and activation 
state of sentinel lymph node-dendritic cells will impair the generation of effective 
antitumor T cell responses and increase the likelihood of metastatic spread. 
In Chapter 5 we describe the effects of intradermal injection of granulocyte 
macrophage-colony stimulating factor around the excision site of Stage 1 primary 
melanoma tumors on the number and activation state of dendritic cells in the 
paracortical areas of the sentinel lymph node. Furthermore, we investigated the 
inﬂ uence of granulocyte macrophage-colony stimulating factor on the binding of 
dendritic cells to T cells. This binding is crucial for the tumor antigen-speciﬁ c 
stimulation of T cells.
As a sequel to Chapter 5, Chapter 6 examines the effect of locally administered 
granulocyte macrophage-colony stimulating factor on the frequency of tumor-
speciﬁ c CD8+ T cells in the sentinel lymph node and blood of Stage 1 
melanoma patients. 
A summary of this thesis as well as a discussion of the importance of our ﬁ ndings 
and future prospects are presented in Chapter 7.   
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Abstract 
Purpose: Although sentinel lymph node status is part of the new American Joint 
Committee on Cancer staging system, there is no ﬁ nal proof that the sentinel 
lymph node procedure in melanoma patients inﬂ uences outcome of disease. 
This study investigated the accuracy of the sentinel lymph node procedure and 
clinical outcome in melanoma patients after at least 60 months of follow-up.   
Patients and Methods: Between 1993 and 1996, 209 patients with stage I/II 
cutaneous melanoma underwent selective sentinel lymph node dissection by 
the triple technique. If the sentinel lymph node contained metastatic disease, a 
completion lymphadenectomy was performed. Survival analyses were performed 
using the Kaplan-Meier approach. Factors associated with survival were 
analyzed using the Cox proportional hazards regression model. 
Results: The success rate was 99.5%. Median follow-up was 72 months. Forty 
patients (19%) had a positive sentinel lymph node. The false negative rate was 
9%. Five-year overall survival was 87% for the entire group and 92% and 67% 
for sentinel lymph node-negative and sentinel lymph node-positive patients 
(P<.0001), respectively. All patients with a positive sentinel lymph node and a 
Breslow thickness <1.00 mm survived, and sentinel lymph node-positive patients 
with a Breslow thickness less than 2.00 mm tend to have a better prognosis 
compared with sentinel lymph node-negative patients with a Breslow thickness 
greater than 2.00 mm. Sentinel lymph node status (P=.002), Breslow thickness 
(P=.002) and lymphatic invasion (P=.0009) were all found to be independent 
prognostic factors for overall survival. 
Conclusion: With a success rate of 99.5% and a false negative rate of 9% 
after long-term follow-up, the triple technique sentinel lymph node procedure 
is a reliable and accurate method. Survival data seem promising, although a 
therapeutic effect is still questionable. As shown in this study, not all sentinel 
lymph node-positive patients have a poor prognosis. 
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Introduction
The optimal treatment of patients with cutaneous melanoma regarding the 
regional lymph node basin has been controversial for many years. Various 
studies compared elective lymph node dissection with the wait-and-watch 
approach and failed to offer a deﬁ nitive optimal approach.1-6 However, 
investigators of the Intergroup Melanoma Trial demonstrated a survival beneﬁ t 
for elective lymph node dissection in prospectively stratiﬁ ed subsets of patients.7
The World Health Organization trial no. 14 showed that survival was signiﬁ cantly 
better for patients with resected microscopic nodal disease by elective lymph 
node dissection compared with patients who did not undergo elective lymph 
node dissection and subsequently developed gross nodal disease.2 It seems that 
lymph node dissection is thus curative in some patients with nodal metastases.
The disadvantage of elective lymph node dissection is that the procedure is 
applied to all patients who have clinically negative lymph nodes. Therefore, 
the majority of patients without nodal metastases (approximately 80%) are 
subjected to the morbidity of elective lymph node dissection without any 
therapeutic beneﬁ t.8 This morbidity is signiﬁ cant and includes wound infection, 
seroma formation and lymphedema. The ideal situation would be to only 
identify those patients with lymph node metastases for therapeutic lymph node 
dissection. This is possible by removing only the lymph node from the draining 
lymph basin that is most likely to contain metastases, the sentinel lymph node.
Lymphatic mapping and selective sentinel lymph node dissection is a minimally 
invasive procedure associated with limited morbidity. Since the introduction of 
the sentinel lymph node procedure in the early 1990s, this procedure is widely 
used in the management of patients with cutaneous melanoma without clinical 
evidence of nodal metastases. The sentinel lymph node concept is based on 
the theory of an orderly progression of tumor cells in the initial phase of the 
metastatic progress within the lymphatic system. It assumes that early lymphatic 
metastases, if present, are always found ﬁ rst within the ﬁ rst tumor-draining 
lymph node, the sentinel lymph node. A tumor-negative sentinel lymph node 
would thus predict the absence of metastatic disease in the rest of the tumor-
draining lymph node basin and negate the necessity of an elective lymph node 
dissection. Several studies have validated this assumption.8-10
However, there is no ﬁ nal proof that sentinel lymph node dissection, with 
selective complete lymph node dissection for a tumor-involved sentinel lymph 
node, improves survival of melanoma patients. So far, the sentinel lymph node 
procedure is mainly used for staging of melanoma patients and to select patients 
for (experimental) adjuvant therapies at an early stage.
Since the introduction of the sentinel lymph node procedure in 1993 in our 
institution, we have performed more than 450 selective sentinel lymph node 
dissections, all according to the same protocol. It is important to know whether 
this procedure is accurate in relation to detecting the proper sentinel lymph node 
and to determine the clinical outcome of this procedure is after long-term follow-up.
The aim of this prospective study was to investigate the accuracy of the sentinel 
lymph node procedure and the clinical outcome of stage I or II melanoma 
patients who underwent selective sentinel lymph node dissection after a 
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follow-up of at least 60 months. Furthermore, factors that have an association 
with survival were analyzed using the Cox proportional hazards regression model.
Patients and methods
Patients
From August 1993 to December 1996, 209 consecutive patients with clinical 
stage I or II cutaneous melanoma as deﬁ ned by the American Joint Committee 
on Cancer and with a Breslow thickness of >0.5 mm underwent sentinel lymph 
node mapping and selective complete lymph node dissection in a prospective 
study.11 The selective sentinel lymph node dissection has become the standard 
procedure in our hospital for cutaneous melanoma and is offered to all patients. 
Patients were informed about the possible alternatives for treating the regional 
lymph nodes. All patients were treated according to the same protocol. Before 
the sentinel lymph node procedure, the pathologic characteristics of the primary 
melanoma were reviewed in our hospital if the patient was referred from another 
institution. Patient characteristics are listed in TABLE 1.
Triple technique
To identify and retrieve the sentinel lymph node, the triple technique was used, 
as described before.12-14 Brieﬂ y, the day before surgery, a dynamic and static 
lymphoscintigraphy was made using 1.0 mCi of technetium-99m-labeled colloidal 
albumin (Nanocoll; Sorin Biomedica, Salugia, Italy). A handheld gamma detection 
probe (C-trak; Care Wise Medical Products, Morgan Hill, CA or CTC-4; 
Radiation Monitoring devices, Watertown, MA) was used to verify the site of 
the sentinel lymph nodes. Shortly before operation, 0.15 to 0.5 mL Patent Blue 
V (Laboratoire Guerbet, Aulnay-sous-Bois, France) was injected intradermally 
next to the initial site of the melanoma. A sterile-packed gamma probe was used 
to localize the site of incision.  The blue dye and gamma probe helped to localize 
the sentinel lymph node(s) during meticulous dissection.
A lymph node was considered a sentinel lymph node during surgery when it 
stained blue, had an in situ radioactivity count of at least 3 times that of the 
background count, or had an ex vivo radioactivity count of at least 10 times 
greater than that of the background count.15,16 Residual lymph nodes were excised 
if they contained radioactivity greater than 10% of the sentinel lymph node.17
Cautious palpation of the lymph node basin was performed to detect enlarged 
or pathologic non-sentinel lymph nodes. Harvested sentinel lymph node(s) were 
step-sectioned (ﬁ ve levels in total, 250 µm between levels) and stained with 
hematoxylin and eosin and immunohistochemical with S100 and HMB45.18 If the 
sentinel lymph node contained metastatic tumor cells, a completion regional 
lymphadenectomy was performed at a later date. From the regional lymph basin 
dissection specimens, all lymph nodes were recovered. From these lymph nodes, 
one section was cut and stained with hematoxylin and eosin.
Follow-up comprised regular outpatient physical examination at 3- to 6-month 
intervals. No patient was lost during follow-up. Median follow-up time was 72 
months (range, 60 to 100 months).
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TABLE 1. Characteristics of the patient population
                      SLN-negative    SLN-positive 
Characteristics      patients  (%)   patients  (%)   patients  (%)
Total           209   (100)  168    (80)#  40    (19)
Gender 
  Male          90     (43)   72    (80)#  17    (19)
  Female         119   (57)   96    (81)  23    (19)
Age (years)
  Median          47
  Range          18-81
Site primary melanoma
  Trunk         83    (40)  66    (79)  17     (21)
  Upper Extremity     24    (11)  18    (75)#  5     (21)
  Lower Extremity     86    (41)  68    (79)  18    (21)
  Head/Neck       16    (8)    16    (100)  0     (0)*
Breslow thickness (mm)
  Median         1.41
  Mean          1.78
Type melanoma
  Superﬁ cial spreading   146   (71)  123   (84)#  22    (15)*
  Nodular        57    (27)  39    (68)  18    (32)*
  Acrolentiginous     3     (1)    3     (100)  0     (0)
  Lentiginous malignant  3     (1)    3     (100)  0     (0)
Clark Level
  II           19    (9)    17    (89)   2     (11)
  III           73    (35)   68    (93)   5     (7)*
  IV           110   (53)  80    (73)#  29    (26)*
  V           7     (3)   3     (43)  4     (57)*
Ulceration
  Absent         174    (83)  143   (82)#  30    (17)
  Present        35    (17)   25    (71)   10    (29)
Lymphatic Invasion
  Absent         193   (92)  159    (82)#  33    (17)
  Present        16     (8)    9     (56)  7     (44)*
Abbreviation: SLN, sentinel lymph node 
* X
2-test: P<0.05 
# Sentinel lymph node status unknown in one male patient; superﬁ cial spreading melanoma on 
the upper extremity, Clark IV, no ulceration and no lymphatic invasion. 
Statistical Analysis 
Standard statistical techniques were used. Categorical variables were compared 
using the X
2-test to compare the result of a speciﬁ c subgroup with that of the 
rest of the patient population. Analysis of disease-free survival and overall 
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survival was performed by the Kaplan-Meier approach, with statistical analysis 
performed using the log-rank test. Univariate and multivariate analyses on the 
basis of Cox’s proportional hazards regression model were used to associate 
covariates to disease-free survival and overall survival. Breslow thickness was 
treated as a continuous variable for both univariate and multivariate analyses. 
P values less than .05 were considered signiﬁ cant. 
All statistical analyses were performed with Statistical Package for the Social 
Sciences software for Windows 98 (SPSS, Chicago, IL). 
Results 
Sentinel lymph node Identiﬁ cation 
In 209 patients, 242 lymph node basins were mapped. Focal accumulation in 
at least one basin was observed in 100% of the cases. In 176 patients (84%) 
lymphatic mapping of one lymph node basin was performed, and 33 patients 
(16%) underwent mapping of two lymph node basins.  
All removed sentinel lymph nodes (n=378; 100%) were hot, and of these, 329 
sentinel lymph nodes (87%) were both hot and blue. Of the 49 sentinel lymph 
nodes, which were only hot, four (8%) contained metastatic disease. In two 
patients this was the only sentinel lymph node to be tumor-positive; the two 
other patients also had a second positive sentinel lymph node, which was both 
hot and blue. 
During surgery, the sentinel lymph node was found high in the left axilla in one 
patient and was not accessible for removal. The decision was made not to 
remove this sentinel lymph node to avoid potential morbidity associated with 
the intervention. This patient had a superﬁ cial spreading melanoma on the left 
forearm with a Breslow thickness of 1.28 mm. He remained disease free after a 
follow-up of 67 months. Therefore, the success rate was 99,5% (208 of 209). 
Sentinel lymph node Status 
In 40 patients (19%), the sentinel lymph node proved to be tumor-positive. The 
sentinel lymph node was tumor-negative in 168 patients (80%). In four patients 
in whom the initially identiﬁ ed sentinel lymph node had been negative, a clinically 
evident positive lymph node developed in the same basin during follow-up. In 
these patients the sentinel lymph node was thus initially false-negative. This yields 
a false-negative rate of 9% (4 of 44) and a failure-rate of 1,9% (4 of 209) (FIGURE 1). 
Three of these patients underwent selective sentinel lymph node dissection 
within 1 year after introduction of the procedure in our hospital. The last patient 
underwent the procedure 3 years after introduction. 
The distribution of positive sentinel lymph nodes according to Breslow thickness 
is shown in TABLE 2. With increasing Breslow thickness, a growing percentage of 
sentinel lymph node-positive patients is revealed. For patients with a Breslow 
thickness between 0,5 and 1,0 mm, 6% of patients had a positive sentinel lymph 
node. This increased to 55% sentinel lymph node positivity in patients with a 
Breslow thickness of greater than 4,0 mm.  
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FIGURE 1. Flowchart of patient outcome 
Flowchart of clinical outcome of 209 stage I/II cutaneous melanoma patients who underwent 
selective sentinel lymph node (SLN) dissection. CLND, completion lymph node dissection; ALN, 
additional lymph nodes. 
TABLE 2. Distribution of patients according to Breslow thickness and positive sentinel 
lymph nodes
                              SLN-positive 
Breslow Thickness (mm)        patients  (%)   patients  (%)
0.5 – 1.0              63     (30)   4     (6)* 
1.01 – 2.0               91     (44)   15     (16)
2.01 – 4.0               44     (21)   15     (34)* 
> 4.0                 11     (5)    6     (55)*
Abbreviation: SLN, sentinel lymph node 
*X
2-test: P<0.05
   
A total of 38 completion lymphadenectomies were performed in 40 patients 
who had at least one positive sentinel lymph node. Two patients refused to 
undergo a completion lymphadenectomy. In 29 of these patients (76%), no 
additional positive lymph nodes were revealed. In the remaining nine completion 
lymphadenectomy specimens, additional positive lymph nodes were found. One 
additional positive lymph node was found in six patients, two additional positive 
lymph nodes were found in two patients, and three additional positive lymph 
nodes were found in one patient. 
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First site of recurrence 
Forty-ﬁ ve patients (22%) developed a recurrence of the disease during 
follow-up (FIGURE 1). The median time until recurrence was 23 months (TABLE 3). 
Seventy-ﬁ ve percent of the relapses occurred within 3 years after the sentinel 
lymph node-procedure, but even after more than 80 months, recurrences 
appeared. A recurrence to the locoregional skin occurred in 53% of these 
patients. Thirty-eight percent of the patients had a systemic recurrence, and 9% 
developed a recurrence in the draining lymph node basin. Of the patients with a 
positive sentinel lymph node, 55% (22 of 40) developed a recurrence: 13 (59%) 
to the locoregional skin and nine (41%) systemic. Of the patients with a negative 
sentinel lymph node, 14% (23 of 168) developed a recurrence: 11 (48%) to the 
locoregional skin, eight (35%) systemic, and four (17%) in the draining lymph 
node basin (TABLE 3 and FIGURE 1). 
TABLE 3. First site of recurrence and death of disease
Characteristics                 patients     (%) 
Total recurrences                 45        (22) 
Median time in months (range)       23 (7-86)
Distribution
  Locoregional skin                24        (53) 
  Systemic                   17        (38)
  Draining LN basin                4        (9)
Recurrences
  SLN-positive   (n=40)            22        (55)
    Locoregional skin              13        (59) 
    Systemic                 9         (41)
 
  SLN-negative    (n=168)           23        (14) 
    Locoregional skin              11        (48) 
    Systemic                 8        (35)
    Draining LN basin              4        (17) 
 
  SLN unknown   (n=1)             0        (0)
Death of Disease
   SLN-positive   (n=40)            15        (38) * 
   SLN-negative   (n=168)           16        (10) 
   SLN unknown  (n=1)             0        (0)
Abbreviations: LN, lymph node; SLN, sentinel lymph node;  
*X
2-test: P<0.05
Disease-Free Survival and Overall Survival 
To date, after a median follow-up of 72 months, 83% (174 of 209) of the patients 
are alive, six of whom have evidence of disease. During follow-up, 31 patients 
(15%) died of disease. Of these patients, 16 had a negative sentinel lymph node 
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(10%; 16 of 168) and 15 had a positive sentinel lymph node (38%; 15 of 40) 
(TABLE 3). Four patients with no recurrence of disease died from another cause 
during follow-up. 
The 5-year disease-free survival and overall survival for the whole group were 
80% and 87%, respectively (FIGURE 2).  
FIGURE 2. Overall survival for all patients (n=209)
 Overall survival for all patients (n=209). Five-year overall survival is 87%.
The 5-year disease-free survival was 88% for patients with a negative 
sentinel lymph node and 50% for patients with a positive sentinel lymph 
node (P<0.0001). Patients with a positive sentinel lymph node had a 5-year 
overall survival of 67%; and those with a negative sentinel lymph node had a 
signiﬁ cantly higher overall survival of 92% (P<0.0001; TABLE 4 and FIGURE 3).  
TABLE 4. Five-year disease-free survival & overall survival according to sentinel 
lymph node status and Breslow thickness
Characteristics          5-Year DFS (%)    5-Year OS (%)
SLN-negative     (n=168)  88*          92* 
SLN-positive     (n=40)   50*          67*
Breslow thickness (mm) 
  0.5 – 1.0      (n=63)   100*         100*
  1.01 – 2.0    (n=91)   85          93*
  2.01 – 4.0    (n=44)   52*          64*
  >4.0       (n=11)   55*          63*
Abbreviations: SLN, sentinel lymph node; DFS, disease-free survival; OS, overall survival 
*X
2-test: P<0.0 
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FIGURE 3. Overall survival according to sentinel lymph node status 
Kaplan-Meier curves for overall survival according to sentinel lymph node (SLN) status. Five-year 
overall survival for SLN-negative and SLN-positive patients are 92% and 67%, respectively. 
(log-rank test; P<0.0001). 
FIGURE 4. Overall survival according to N-stage 
Kaplan-Meier curves for overall survival according to number of metastatic lymph nodes. N0, 
no metastatic lymph nodes; N1, 1 metastatic lymph node; N2/3, 2 to 3/>4 metastatic lymph 
nodes (15 patients, N2; 1 patient, N3). Five-year overall survival are 92%, 79% and 50%, 
respectively. (log-rank test; P<0.0001). 
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FIGURE 4 shows the overall survival according to the number of involved lymph 
nodes. Five-year overall survival was 79% for patients with one involved lymph 
nodes (N1 stage; i.e., the sentinel lymph node) and 50% for patients with 2 to 
3 (N2 stage) or > four (N3 stage; one patient) (P<0.0001); 5-year disease-free 
survival was 62% and 31%, respectively (P<0.0001). All 5-year disease-free 
survival and overall survival rates in relation to other factors are given in TABLE 5.  
TABLE 5. Five-year disease-free survival and overall survival
Characteristic            5-Year DFS (%)   5-Year OS (%)
Total          (n=209)   80         87
N-stage
  N0         (n=168)   88*         92*
  N1         (n=24)    62*         79
  N2/3        (n=16)    31*         50*
Gender
  Male         (n=90)    78          87
  Female        (n=119)   83          88
Age, years 
  <60        (n=166)   83          87
  >60        (n=43)    74          88
Clark level
  II           (n=19)    100*        100
  III          (n=73)    96*         97*
  IV          (n=110)   70*         81*
  V          (n=7)     43*         57
Type Melanoma 
  SSM         (n=146)   88*         93* 
  NOD         (n=57)    61*         74*
  ALM         (n=3)     100        100
  LMM         (n=3)     67          67
Site Primary Melanoma 
  Trunk         (n=83)    83          84
  Upper Extremity    (n=24)     79          83
  Lower Extremity    (n=86)     83          93*
  Head/Neck      (n=16)    63          81
Ulceration
  Absent        (n=174)   87          91
  Present        (n=35)    49*         71*
Lymphatic Invasion
  Absent        (n=193)   86          91
  Present        (n=16)    13*         43* 
Abbreviations: SSM, superﬁ cial spreading melanoma; NOD, nodular melanoma; ALM, 
acrolentiginous melanoma; LMM, lentiginous malignant melanoma; DFS, disease-free 
survival; OS, overall survival  
*X
2-test: P<0.05 
Most remarkable, of the patients with lymphatic invasion, 87% (14 of 16) developed a 
relapse, and 51% of patients with ulceration present in the primary melanoma had a 
recurrence within 5 years after the sentinel lymph node procedure (TABLE 5). Five-year 
overall survival rates for patients with ulceration or lymphatic invasion present in the 
primary tumor were 71% and 43%, respectively (FIGURE 5A and 5B). 
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FIGURE 5. Overall survival according to features of the primary tumor
Kaplan-Meier curves for overall survival according to features of the primary melanoma. 
A. Ulceration (ULC). Five-year overall survival for ulceration absent and present, 91% and 
71%, respectively (log-rank test; P=0.0001). 
B. Lymphatic invasion (LI). Five-year overall survival for lymphatic invasion absent and present, 
91% and 43%, respectively (log-rank test; P<0.0001).
Survival by Breslow thickness 
All patients with a Breslow thickness between 0.5 and 1.0 mm remained alive 
during follow-up. The 5-years overall survival decreased to 63% for patients with 
a Breslow thickness of >4.0 mm (FIGURE 6; TABLE 4).  
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FIGURE 6. Overall survival according to Breslow thickness of the primary tumor
Kaplan-Meier curves for overall survival according to Breslow (Bres) thickness. Five-year overall 
survival for Breslow 0.5 to 1.0, 1.01 to 2.0, 2.01 to 4.0 and >4.0 mm: 100%, 93%, 64% 
and 63%, respectively. (log-rank test: P<0.0001).
The overall survival curves for Breslow thickness according to sentinel lymph 
node status are given in FIGURE 7. Five-year overall survival rates for sentinel 
lymph node-negative patients per Breslow category were as follows: 100% (0.5 
to 1.0 mm), 95% (1.01 to 2.0 mm), 76% (2.01 to 4.0 mm) and 60% (>4.0 mm) 
(P=0.0002). For sentinel lymph node-positive patients, 5-year overall survival 
rates per Breslow category were as follows: 100%, 87%, 40% and 67%, 
respectively (P=0.02). Combination of these two factors, as shown in FIGURE 7, 
gives a helpful tool to estimate survival. Patients with a positive sentinel lymph 
node and a Breslow thickness between 1.01 and 2.0 tend to have a better overall 
survival compared to patients with a negative sentilymph node and a Breslow 
thickness exceeding 2.0 mm (P=0.16).
Univariate and Multivariate regression analysis of disease-free and overall survival
We performed a univariate and a multivariate Cox regression analysis on all 
patients to determine the inﬂ uence of several factors on disease-free survival 
and overall survival (TABLE 6). The model selected for multivariate regression was 
created by the backward stepwise elimination method. After univariate analysis, 
four factors were signiﬁ cantly related to disease-free survival and overall 
survival: Breslow thickness, sentinel lymph node status, ulceration and lymphatic 
invasion. These factors entered the multivariate analyses and all four factors had 
an independent and signiﬁ cantly related to a poorer overall survival included 
increasing tumor thickness (P=0.002), a positive sentinel lymph node (P=0.002) 
and the presence of lymphatic invasion (P=0.0009). Surprisingly, in this study 
ulceration was not an independent factor that correlated with overall survival.
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FIGURE 7. Overall survival according to Breslow thickness for sentinel lymph 
node-negative patients and for sentinel lymph node-positive patients.
Kaplan-Meier curves for overall survival according to Breslow (Bres) thickness and sentinel 
lymph node (SLN) status. 
A. SLN-negative. Five-year overall survival per Breslow category: 100%, 95%, 76% and 
60% respectively. (log-rank test; P=0.0002) 
B. SLN-positive. Five-year overall survival per Breslow category: 100%, 87%, 40% and 67% 
respectively. (log-rank test; P=0.02)
C
H
A
P
TE
R
 2
A
B
40
TABLE 6. Univariate and multiviate Cox regression analysis of disease-free survival 
and overall survival for all patients.
                Disease-Free Survival 
                Univariate  Multivariate 
Prognostic factor        P      HR   95% Cl    P 
Breslow thickness        <0.0001  1.20  1.01-1.41   0.04 
SLN Status           <0.0001  2.45  1.24-4.84   0.01
Ulceration            <0.0001  3.06  1.50-6.26   0.002 
Lymphatic Invasion        <0.0001  12.87  6.09-27.20  <0.0001
                Overall Survival
                Univariate  Multivariate
Prognostic factor        P      HR   95% Cl    P
Breslow thickness        <0.0001  1.30  1.10-1.54   0.002
SLN Status           <0.0001  2.51  1.12-5.59   0.002
Ulceration            0.0002   -    -       NS
Lymphatic Invasion        <0.0001  3.93  1.76-8.78   0.0009
Abbreviations: HR, hazard ratio; Cl, conﬁ dence interval; SLN, sentinel lymph node; NS, 
not signiﬁ cant
Discussion  
We have been performing the triple-technique sentinel lymph node procedure as 
standard care in clinically stage I or II cutaneous melanoma patients for almost 
9 years. The major reason for using this procedure is to stage patients more 
accurately and remove potential micrometastatic disease at an early stage while 
also sparing patients with a negative sentinel lymph node from having to undergo 
a regional lymph node dissection with associated morbidity. After a follow-up 
period of at least 60 months, we can now describe the clinical outcome of these 
patients more accurately. 
Our success rate of 99,5% in retrieving the sentinel lymph node compares 
favorably with other series.19,20 The sentinel lymph node was not removed during 
surgery in only one patient, although in this patient the sentinel lymph node 
could be detected both on the lymphoscintigraphy and with the gamma probe. 
Removing this sentinel lymph node would cause signiﬁ cant additional morbidity, 
and the decision was made to leave the sentinel lymph node in situ.  
The false-negative rate in this study was 9%. Four of 168 patients 
who initially had a negative sentinel lymph node developed a recurrence 
in the same draining lymph node basin. Pathological re-evaluation of the 
sentinel lymph nodes of these patients did not reveal (micro)metastatic 
disease. In two of these four patients another possible reason was found 
to be the cause of the false-negative procedure. In one patient, the initial 
excision of a melanoma on the trunk had been too wide (5 x 9 centimeters). 
This excision may have changed the initial lymphatic draining pattern. In another 
patient, re-evaluation of the lymphoscintigraphy made during the sentinel lymph 
node procedure showed a second lymph vessel that initially was not identiﬁ ed. 
The associated down-stream node was not removed during surgery. 
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There are three major causes of false-negative procedures: pathological failure, 
technical failure and biological failure.21 In the ﬁ rst, a histopatholigic sampling 
error fails to detect micrometastatic disease. Using step sections of the sentinel 
lymph node and immunohistochemistry increases the detection rate of 
(micro)metastases.18 A technical failure can have several causes. First, the 
method used to identify and retrieve the sentinel lymph node is extremely 
important. The combined, three-pronged approach (triple technique) to detect 
the sentinel lymph node improves the success rate and therefore results in fewer 
false-negative procedures. The ﬁ rst two mentioned false-negative procedures 
are results of technical failures; narrow primary excision of the melanoma and 
thorough interpretation of the lymphoscintigraphy are indispensable. The last two 
false-negative procedures are most likely the result of biologic failure. A biologic 
failure occurs when lymphatics are obstructed by melanoma cells, which cause 
a rerouting of the lymph ﬂ ow. As a consequence, the true sentinel lymph node is 
not detected and a non-sentinel lymph node is retrieved. This type of failure is 
hard to deal with and is inevitable. 
Compared to other series in which false-negative rates between 5.5% and 
12% are described after median follow-up periods of 14-35 months, a false 
negative rate of 9% after a median follow-up of 72 months is, in our opinion, 
acceptable.20-24 Nevertheless, some of the false-negative procedures could 
have been prevented. The sentinel lymph node procedure is a technically 
demanding procedure that requires considerable skill and experience not 
only from the operating surgeon but also from the physician performing the 
lymphoscintigraphy and the pathologist evaluating the sentinel lymph node. 
In this study, 22% of the patients developed a recurrence. Of patients with a 
positive sentinel lymph node, 55% relapsed. Recurrence was uncommon after 
a negative selective sentinel lymph node dissection, occurring in only 14% of 
patients in this study after a median follow-up of 72 months. Gershenwald et al21
and Thompson25 described comparable ﬁ gures after a much shorter follow-up 
period. On the other hand, these studies had larger sample sizes compared 
with that of the current study. Before the sentinel lymph node era, the regional 
lymph nodes were the most frequent site of recurrence. The sentinel lymph node 
procedure changed the pattern of recurrence by reducing the number of ﬁ rst 
recurrences within the regional lymph node basin.26 The most important sites 
for recurrences are now locoregional (53%) and systemic (38%). Whether this 
changed pattern of recurrence inﬂ uences survival is still a matter of debate. 
In this series, the 5-year disease-free survival and overall survival were 80% 
and 87%, respectively. Patients with a negative sentinel lymph node have a 
signiﬁ cantly better disease-free survival and overall survival compared to sentinel 
lymph node-positive patients (88% and 92% vs. 50% and 67%, respectively). 
In other series, similar percentages were found.19,27-29 Essner et al compared 
selective sentinel lymph node dissection with elective lymph node dissection 
in a matched-pair analyses.29 Disease-free survival and overall survival were 
identical for both approaches, and they concluded that selective sentinel lymph 
node dissection and elective lymph node dissection seemed to be therapeutically 
equivalent procedures for the management of clinically negative regional lymph 
nodes. They even showed that 5-year overall survival for patients with a positive 
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sentinel lymph node (64%) was higher compared with that of patients with 
tumor-positive nodal dissections after elective lymph node dissection (45%); 
the comparison approached signiﬁ cance (P=0.077). The good survival results 
in our study might be because a substantial number of patients have a tumor 
with a thickness of less than 1.0 mm. Nevertheless, analysis of patients with a 
Breslow thickness of >1.0 mm (n=151; data not shown) showed an almost equal 
and good 5-year overall survival of 83% (89% for patients with a negative 
sentinel lymph node and 64% for those with a positive sentinel lymph node; 
P=0.0004). However, not all patients with a positive sentinel lymph node have a 
poor prognosis. In this study, all patients with a positive sentinel lymph node and 
a Breslow thickness <1.00 mm are alive. As shown in FIGURE 7, the combination 
of these factors provides a tool for predicting outcome. Patients with a positive 
sentinel lymph node and a Breslow thickness between 1.01 and 2.0 mm tend to 
have a better survival compared with patients with a negative sentinel lymph 
node and a Breslow thickness exceeding 2.0 mm. However, the number of 
patients in this study is relatively small for comparison of different subgroups. 
A larger group with even longer follow-up is necessary to conﬁ rm these 
observations. 
Comparable to Dessureault et al30, we found an overall survival for patients with 
a negative sentinel lymph node of 92%. They found a signiﬁ cantly better survival 
compared with patients with negative nodes after elective lymph node dissection 
(77.7%) or observation alone (69.8%) and concluded that selective sentinel 
lymph node dissection might contribute to a survival beneﬁ t in populations of 
patients with melanoma. A possible reason for this better survival after negative 
selective sentinel lymph node dissection compared with negative elective lymph 
node dissection might be the reﬂ ection of the greater accuracy of the sentinel 
lymph node procedure to detect nodal metastases. Selective sentinel lymph 
node dissection misses fewer patients with stage III melanoma than does elective 
lymph node dissection or observation.30 Therefore, the group of patients after 
negative elective lymph node dissection probably contains patients who might 
have been sentinel lymph node-positive after a sentinel lymph node procedure.18
Multivariate analysis of those factors that inﬂ uenced disease-free survival and 
overall survival demonstrated that Breslow thickness, sentinel lymph node status 
and lymphatic invasion were signiﬁ cantly correlated to disease-free survival and 
overall survival. Ulceration was signiﬁ cantly related only to disease-free survival. 
As also described by others, sentinel lymph node status and Breslow thickness 
are strong prognostic factors to determine clinical outcome, especially overall 
survival.14,31-33 The lack of multivariate signiﬁ cance for ulceration as a predictor of 
overall survival is unexplained but may be an artifact of inadequate sample size 
or possibly due to the inﬂ uence of multiple confounding covariables in this model. 
Cascinelli et al33 also found that ulceration was not a signiﬁ cant independant 
prognostic factor. An important ﬁ nding in our study was the signiﬁ cantly strong 
and independent association of lymphatic invasion of the primary melanoma with 
survival. Lymphatic invasion was the strongest prognostic factor for overall survival 
after multivariate analysis (P=0.0009). Borgstein et al34 and Statius Muller et al14
also showed that lymphatic invasion is a very strong and relevant predictor of 
developing recurrence and should be included as a stratiﬁ cation criterion.  
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Trial 14 of the World Health Organization Melanoma Program has indirectly 
outlined the potential beneﬁ t of the sentinel lymph node procedure.2 In that 
study, patients with occult lymph node metastases discovered at elective lymph 
node dissection showed a better survival compared with patients who received 
therapeutic lymph node dissection at the time when clinical nodal involvement 
appeared. Furthermore, data from another recent prospective clinical trial 
suggest that occult lymph node micrometastases are clinically important and 
early therapeutic lymph node dissection may favorably impact survival.1,7 Thus 
selective lymph node dissection is potentially therapeutic for a relatively large 
subset of patients.  
In addition to this possible potential therapeutic effect, lymphatic mapping and 
selective sentinel lymph node dissection have some major advantages. First 
and foremost, the detection of micrometastatic disease using the sentinel lymph 
node procedure allows a more accurate staging. Sentinel lymph node status is 
a signiﬁ cantly strong and independent prognostic factor. Second, the sentinel 
lymph node procedure potentially spares node-negative patients from further 
lymph node dissection associated with signiﬁ cant morbidity. Third, it provides a 
consistent interpretation of clinical trials when true pathological stage is known. 
Fourth, it provides a tool to select patients for adjuvant therapy trials. Fifth, a 
more accurate knowledge of lymphatic drainage patterns is provided by the 
sentinel lymph node procedure. Finally, there is an important psychologic beneﬁ t 
for patients whose sentinel lymph node does not reveal metastases. Although 
survival of patients with a Breslow thickness of less than 1.0 mm is 100% in our 
study, this psychologic beneﬁ t is still a reason to perform a sentinel lymph node 
procedure in these patients, although the application of a sentinel lymph node 
procedure in this group of patients is questionable.35
We conclude that the triple-technique sentinel lymph node procedure, with a 
success rate of 99.5% and a false-negative rate of 9% after a median follow-up 
of 72 months, is an accurate and reliable procedure. A 5-year overall survival 
of 87%, with 92% for patients with a negative sentinel lymph node and 67% 
for patients with a positive sentinel lymph node, is promising. Sentinel lymph 
node status, Breslow thickness and lymphatic invasion are strong predictors 
for survival. Nevertheless, whether the sentinel lymph node procedure indeed 
improves survival is difﬁ cult to conclude from this study, moreover because this 
is a nonrandomized trial with no control arm. It is hoped that the outcome of 
the Multicenter Selective Lymphadenectomy Trial, in which selective complete 
lymph node dissection are compared with observation, will provide conclusive 
evidence of the impact of selective lymph node dissection on overall survival.20
While we await the results of this study, we believe that even if selective sentinel 
lymph node dissection in and of itself does not improve survival, it is of great 
value and should be continued until or unless another less invasive staging test 
with similar predictive value is developed.
Acknowledgements
Supported by a grant from the Fritz Ahlqvist Foundation.
C
H
A
P
TE
R
 2
44
References
 1.  Balch CM, Soong SJ, Bartolucci AA et al. Efﬁ cacy of an elective regional lymph node dissection
  of 1 to 4 mm thick melanomas for patients 60 years of age and younger. 
  Ann Surg 1996; 224(3): 255-63. 
 2.  Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of
   regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma  
  Programme. Lancet 1998; 351(9105): 793-6. 
 3.  Drepper H, Kohler CO, Bastian B et al. Beneﬁ t of elective lymph node dissection in subgroups of  
  melanoma patients. Results of a multicenter study of 3616 patients. Cancer 1993; 72(3): 741-9. 
 4.  Sim FH, Nelson TE, Pritchard DJ. Malignant melanoma: Mayo Clinic experience.
   Mayo Clin Proc 1997; 72(6): 565-9. 
 5.  Veronesi U, Adamus J, Bandiera DC et al. Delayed regional lymph node dissection in stage I  
  melanoma of the skin of the lower extremities. Cancer 1982; 49(11): 2420-30. 
 6.  Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the  
  efﬁ cacy of routine elective lymphadenectomy in management of malignant melanoma. 
  Preliminary results. Cancer 1978; 41(3): 948-56. 
 7.   Balch CM, Soong S, Ross MI et al. Long-term results of a multi-institutional randomized trial  
  comparing prognostic factors and surgical results for intermediate thickness melanomas 
  (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7(2): 87-97. 
 8.  Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for  
  early stage melanoma. Arch Surg 1992; 127(4): 392-9. 
 9.  Reintgen D, Cruse CW, Wells K et al. The orderly progression of melanoma nodal metastases.  
  Ann Surg 1994; 220(6): 759-67. 
 10. Thompson JF, McCarthy WH, Bosch CM et al. Sentinel lymph node status as an indicator of the  
  presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5(4): 255-60. 
 11. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer  
  staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16): 3635-48. 
 12. Statius Muller MG, Borgstein PJ, Pijpers R et al. Reliability of the sentinel node procedure in  
  melanoma patients: analysis of failures after long-term follow-up. 
  Ann Surg Oncol 2000; 7(6): 461-8. 
 13. Veen Hvd, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe-guided sentinel node  
  biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994; 81(12): 1769-70. 
 14. Statius Muller MG, van Leeuwen PAM, de Lange-De Klerk E.S. et al. The sentinel lymph node  
  status is an important factor for predicting clinical outcome in patients with Stage I or II 
  cutaneous melanoma. Cancer 2001; 91(12): 2401-8. 
 15. Albertini JJ, Cruse CW, Rapaport D et al. Intraoperative radio-lympho-scintigraphy improves  
  sentinel lymph node identiﬁ cation for patients with melanoma. Ann Surg 1996; 223(2): 217-24. 
 16. Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN. Gamma-probe-guided lymph node 
  localization in malignant melanoma. Surg Oncol 1993; 2(5): 303-8. 
 17. McMasters KM, Reintgen DS, Ross MI et al. Sentinel lymph node biopsy for melanoma: how  
  many radioactive nodes should be removed? Ann Surg Oncol 2001; 8(3): 192-7. 
 18. van Diest PJ, Peterse HL, Borgstein PJ, Hoekstra O, Meijer CJ. Pathological investigation of  
  sentinel lymph nodes. Eur J Nucl Med 1999; 26(4 Suppl): S43-S49. 
 19. Gershenwald JE, Thompson W, Mansﬁ eld PF et al. Multi-institutional melanoma lymphatic 
  mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II mela 
  noma patients. J Clin Oncol 1999; 17(3): 976-83. 
S
LN
 D
IS
S
EC
TI
O
N
 F
O
R
 S
TA
G
E 
I/I
I M
EL
A
N
O
M
A
45
 20. Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intraoperative lymphatic  
  mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. 
  Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230(4): 453-63. 
 21. Gershenwald JE, Colome MI, Lee JE et al. Patterns of recurrence following a negative sentinel  
  lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16(6): 2253-60. 
 22. Wagner JD, Corbett L, Park HM et al. Sentinel lymph node biopsy for melanoma: experience  
  with 234 consecutive procedures. Plast Reconstr Surg 2000; 105(6): 1956-66. 
 23. Jansen L, Nieweg OE, Peterse JL et al. Reliability of sentinel lymph node biopsy for staging  
  melanoma. Br J Surg 2000; 87(4): 484-9. 
 24. Nguyen CL, McClay EF, Cole DJ et al. Melanoma thickness and histology predict sentinel lymph  
  node status. Am J Surg 2001; 181(1): 8-11. 
 25. Thompson JF. The Sydney Melanoma Unit experience of sentinel lymphadenectomy for 
  melanoma. Ann Surg Oncol 2001; 8(9 Suppl): 44S-7S. 
 26. Statius Muller MG, van Leeuwen PAM, van Diest PJ et al. Pattern and Incidence of First Site  
  Recurrences following Sentinel Node Procedure in Melanoma Patients. 
  World J Surg 2002; 26(12): 1405-11. 
 27. Essner, R., Rose, M., Kojima, M., Huynh, Y., Turner, R. R., and Morton, D. L. Predicting the 
  natural history of melanoma after tumor-negative sentinel lymph node dissection. 
  ASCO, abstract 1397. 2001. Ref Type: Conference Proceeding 
 28. Cascinelli N, Belli F, Santinami M et al. Sentinel lymph node biopsy in cutaneous melanoma: the  
  WHO Melanoma Program experience. Ann Surg Oncol 2000; 7(6): 469-74. 
 29. Essner R, Conforti A, Kelley MC et al. Efﬁ cacy of lymphatic mapping, sentinel lymphadenectomy,  
  and selective complete lymph node dissection as a therapeutic procedure for early- stage 
  melanoma. Ann Surg Oncol 1999; 6(5): 442-9. 
 30. Dessureault S, Soong SJ, Ross MI et al. Improved staging of node-negative patients with 
  intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph  
  node biopsy. Ann Surg Oncol 2001; 8(10): 766-70. 
 31. Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Breslow thickness and clark level  
  in melanoma: support for including level in pathology reports and in American Joint Committee  
  on Cancer Staging. Cancer 2000; 88(3): 589-95. 
 32. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma  
  patients: validation of the American Joint Committee on Cancer melanoma staging system. 
  J Clin Oncol 2001; 19(16): 3622-34. 
 33. Cascinelli N, Clemente C, Bifulco C et al. Do patients with tumor-positive sentinel nodes 
  constitute a homogeneous group? Ann Surg Oncol 2001; 8(9 Suppl): 35S-7S. 
 34. Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma 
  predictable? Ann Surg Oncol 1999; 6(3): 315-21. 
 35. McMasters KM, Reintgen DS, Ross MI et al. Sentinel lymph node biopsy for melanoma: 
  controversy despite widespread agreement. J Clin Oncol 2001; 19(11): 2851-5. 
C
H
A
P
TE
R
 2
46
SENTINEL LYMPH 
NODE TUMOR LOAD: 
AN INDEPENDENT 
PREDICTOR OF 
ADDITIONAL LYMPH 
NODE INVOLVEMENT 
AND SURVIVAL 
IN MELANOMA 
Ronald J.C.L.M. Vuylsteke1, Paul J. Borgstein1, Paul A.M. van Leeuwen1, 
Hester A. Gietema1, Barbara G. Molenkamp1, Markwin G. Statius Muller1, 
Paul J. van Diest2, Joost R.M. van der Sijp1 and Sybren Meijer1
  
Departments of Surgical Oncology1 and Pathology2
VU University Medical Center, Amsterdam, The Netherlands 
Annals of Surgical Oncology 2005; 12(6): 440-448
48
P
R
ED
IC
TI
V
E 
VA
LU
E 
O
F 
S
LN
 T
U
M
O
R
 L
O
A
D
 IN
 M
EL
A
N
O
M
A
49
Synopsis 
Sentinel lymph node metastatic area can be used to predict the absence of 
positive additional lymph nodes. We hypothesize that patients with a low sentinel 
lymph node metastatic area might not beneﬁ t from an additional lymph node 
dissection. 
Abstract  
Background: Even though 60-80% of melanoma patients with a positive 
sentinel lymph node have no positive additional lymph nodes, all these patients 
are subjected to an additional lymph nodes dissection with its associated 
morbidity. The aim of this study was to predict the absence of additional lymph 
node metastases in patients with a positive sentinel lymph node by using features 
of the primary melanoma and sentinel lymph node tumor load.  
Methods: Of 71 sentinel lymph node-positive patients, 52 had metastasis 
limited to the sentinel lymph node (group 1), and 19 had >1 positive additional 
lymph nodes after additional lymph node dissection (group 2). The tumor load 
of the sentinel lymph node was assessed by measuring the total surface area 
by computerized morphometry. Breslow thickness, ulceration and lymphatic 
invasion of the primary tumor, and total sentinel lymph node metastatic area were 
tested as covariates predicting the absence of positive additional lymph nodes.   
Results: The mean sentinel lymph node metastatic area was 1.18 mm2 (group 1) 
and 3.39 mm2 (group 2) (P=0.003) and was the only signiﬁ cant and independent 
factor after multivariate analysis (P=0.02). None of the patients with both a 
Breslow thickness <2.5 mm and a sentinel lymph node metastatic area <0.3 mm2, 
had a positive additional lymph node.   
Conclusions: Sentinel lymph node metastatic area can be used to predict the 
absence of positive additional lymph nodes in melanoma patients. In this study, 
patients with a Breslow thickness <2.5 mm and a sentinel lymph node tumor load 
<0.3 mm2 seemed to have no positive additional lymph nodes and had excellent 
survival. We hypothesize that this subgroup might not beneﬁ t from additional 
lymph node dissection. Prospective larger trials, using this model and between 
additional lymph node dissection and no-additional lymph node dissection, 
should conﬁ rm this hypothesis. 
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Introduction 
Sentinel lymph node biopsy has become the standard procedure in our hospital 
for patients with a primary cutaneous melanoma and no clinically detectable 
regional lymph node metastases. It has been shown to be a reliable method 
with low false-negative rates.1-4 Sentinel lymph node biopsy offers a reliable 
procedure to predict lymphatic tumor spread. Biopsy of the sentinel lymph node 
will allow lymph node metastasis (clinically occult or microscopic metastasis) to 
be identiﬁ ed at a very early stage of development and will spare approximately 
80% of patients who have a negative sentinel lymph node a superﬂ uous elective 
lymph node dissection.2,5-7 Because only a few lymph nodes have to be screened 
by the pathologist, this can be done with more attention, thus resulting in a 
higher sensitivity for ﬁ nding metastatic cells.8
The concept of the sentinel lymph node procedure is based on the theory of an 
orderly progression of the metastatic process within the lymphatic system.9 The 
sentinel lymph node has a barrier function for disseminating tumor cells and an 
effective ﬁ ltering capacity.10  When the sentinel lymph node is tumor-negative, 
there should conceptually be no second-echelon metastasis, and an additional 
lymph node dissection can be omitted.7,11 When metastatic tumor cells are 
detected in the sentinel lymph node, there is a fair chance that there are further 
second-echelon metastases, and an additional lymph node dissection follows as 
a rule to achieve local control.  
However, only 20 to 33 % of the patients who have undergone an additional 
lymph node dissection after a positive sentinel lymph node have additional 
tumor-involved lymph nodes in the dissected draining lymph node basin.5,6,12,13
The current accurate methods for detecting small groups of metastatic cells 
in the sentinel lymph node upstage many patients who have no tumor spread 
beyond the sentinel lymph node and might not need an additional lymph node 
dissection. A method to predict the absence of tumor spread beyond the sentinel 
lymph node would spare this group of patients unnecessary additional lymph 
node dissection and its associated morbidity.  
Although it was mentioned that patients with tumor-positive sentinel lymph nodes 
could be divided into several subgroups, most studies published so far have not 
found any factor to be signiﬁ cant in predicting the chance for positive additional 
lymph nodes in patients with positive sentinel lymph nodes.12,14-16 Combinations 
of Breslow thickness of the primary tumor, volume of tumor involvement in the 
sentinel lymph node, and reduced density of interdigitating dendritic cells in the 
sentinel lymph node (as an index of nodal immune downregulation) have been 
mentioned as powerful predictors of non-sentinel lymph node tumor-status and 
clinical outcome in some publications.13,17-20
The aim of this study was to analyze the sentinel lymph node metastatic area 
in combination with primary tumor parameters as predictors of metastatic 
involvement of additional lymph nodes. With these variables, a simple model is 
created to predict the absence of lymphatic tumor spread beyond the sentinel 
lymph node(s). Eventually, this might obviate the need of an additional lymph 
node dissection for a subset of sentinel lymph node positive patients.  
P
R
ED
IC
TI
V
E 
VA
LU
E 
O
F 
S
LN
 T
U
M
O
R
 L
O
A
D
 IN
 M
EL
A
N
O
M
A
51
Materials and methods 
Patients 
From August 1993 to September 2001, a total of 454 consecutive patients with 
a clinical stage I or II cutaneous melanoma, as deﬁ ned by the American Joint 
Committee on Cancer, underwent sentinel lymph node biopsy in a prospective 
study.21 All patients were treated according to the same protocol; no alterations 
where introduced during the study. Breslow thickness, Clark level of invasion, 
presence of lymphatic invasion and ulceration of the primary melanoma were 
determined, or reevaluated if a patient was referred from another hospital. 
Sentinel lymph nodes were successfully detected and removed in 447 patients 
(98%) from a total of 531 regional lymph node basins. The sentinel lymph node 
was not found in three patients. In four patients the sentinel lymph node was 
left in situ to avoid potential morbidity associated with the intervention: three 
patients had their sentinel lymph node situated in the parotid gland, and in one 
patient the sentinel lymph node was situated deep in the axilla.  
The group consisted of 245 females and 209 males with a median age of 49 
years (range, 6-84 years). The mean Breslow thickness was 1.79 mm (median, 
1.37 mm; range, 0.50-9.00 mm). From this group, the patients with a positive 
sentinel lymph node were selected and ﬁ nally divided into a group without 
additional lymph node involvement (group 1) and a group with involvement of 
additional lymph nodes (group 2).   
Triple technique 
To determine lymphatic drainage patterns, all patients underwent dynamic and 
static lymphoscintigraphy before surgery. 99mTechnetium-labeled colloidal albumin 
(Nanocoll; Sorin Biomedica, Saluggia, Italy) with a particle size of 30 to 80 nm 
was used as tracer and was given through two to four intradermal injections 
with 10 MBq in 0.15 mL per injection as described by van der Veen et al.22
These injections were given just adjacent to the scar of the excision biopsy. 
Immediately after the injections, dynamic lymphoscintigraphy was started: 20 
images of 60 seconds each. Static lymphoscintigraphy (300 seconds per image) 
was made 2 to 18 hours after the injection to check whether initial accumulations 
had retained the tracer. A handheld gamma-detection probe (C-trak [Care Wise 
Medical Products, Morgan Hill, CA] or CTC-4 [Radiation Monitoring Devices, 
Watertown, MA]) with settings of 120 keV (lower threshold) and 160 keV (upper 
threshold) was used to verify the side of the sentinel lymph nodes. All sites were 
marked on the skin with indelible ink. Surgery was performed 2 to 24 hours after 
injection of the tracer.  
Shortly before the operation, 0.15 to 0.5 ml Patent Blue V (Laboratoire Guerbet, 
Aulnay-sous-Bois, France) was injected intradermally next to the initial side of 
the melanoma. A sterile-packed gamma probe was used to localize the site of 
the incision. The blue dye and gamma probe helped in localizing the sentinel 
lymph node(s) during meticulous dissection. These nodes were subsequently 
excised. A lymph node was considered a sentinel lymph node during surgery 
when it stained blue, had an in situ radioactivity count of at least 3 times that of 
the background, or had an ex vivo radioactivity count of at least 10 times greater 
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than that of the background. To establish that all hot nodes had been removed, 
residual activity in the basin was checked with the gamma probe after removal of 
the sentinel lymph node(s). Residual lymph nodes were excised if they contained 
radioactivity > 10% of the sentinel lymph node. Cautious palpation of the lymph 
node basin was performed to detect enlarged or pathologic non-sentinel lymph 
nodes. When indicated, a wide local excision of the primary scar was performed 
after the sentinel lymph node procedure.  
Pathologic examination 
After the sentinel lymph node procedure, harvested sentinel lymph node(s) 
were ﬁ xed in neutral buffered formaldehyde, lamellated according to size, and 
completely embedded in parafﬁ n. Sentinel lymph nodes smaller than 0.5 cm 
were processed and parafﬁ n-embedded intact. Those between 0.5 and 1.0 
were halved, and sentinel lymph nodes larger than 1.0 cm were lamellated into 
pieces of approximately 0.5 cm in size. One initial 4-µm-thick haematoxylin and 
eosin-stained section was made per block. When negative, four additional step 
ribbons were cut at 250-µm intervals. Of each ribbon, one section was stained 
with haematoxylin and eosin, and two were used for S-100 and HMB-45 immuno-
histochemistry as described previously.8
The sentinel lymph node metastatic area was determined by using an interactive 
video morphometry system (Q-prodit; Leica, Cambridge, UK). In every sentinel 
lymph node found to contain metastatic tumor cells, the conﬁ guration of the 
metastatic cells, the number of foci, and their distribution within the lymph 
node were examined. The sentinel lymph node section containing the largest 
visible amount of metastatic tumor cells was selected. The surface areas of 
the individual tumor deposits in this single section were measured, and the 
sentinel lymph node metastatic area was calculated by summing up these areas. 
In case of two positive sentinel lymph nodes, the one with the largest tumor 
load was used. The sentinel lymph node metastatic areas were measured by 
two independent observers, of which one observer measured the areas twice 
with an interval of approximately 8 weeks. The intraobserver and interobserver 
reproducibility was good, with Spearman’s correlation coefﬁ cients of 0.99 and 
0.98, respectively. 
At a later date, an additional regional lymphadenectomy was performed, when 
the sentinel lymph node(s) contained metastatic tumor cells, if the patient 
agreed. From the dissected draining lymph node basin, all lymph nodes were 
recovered. The lymph nodes were lamellated and embedded as described 
previously. From each block, one section was cut and stained with haematoxylin 
and eosin.  
Patients with a negative sentinel lymph node were followed up only. Follow-up 
comprised regular outpatient physical examination at 3- to 6-month intervals. 
Relevant diagnostic investigations occurred only when indicated. Median 
follow-up was 64 months (range, 3-124). 
Statistical analysis 
Statistical analysis was performed with SPSS for Windows 98 (SPSS Inc., 
Chicago, IL). Categorical variables were analyzed by using the X
2-test. 
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Non-parametric data were analyzed using the Mann-Whitney U-test. Pearson‘s 
correlation analysis was performed for Breslow thickness and area of metastasis 
in the sentinel lymph node. All relevant variables that were associated with the 
presence of positive additional lymph nodes by univariate regression analysis 
were included in a multivariate logistic regression analysis: Breslow thickness, 
sentinel lymph node metastatic area, and presence of ulceration and lymphatic 
invasion in the primary tumor. Analysis of disease-free and overall survival was 
performed by the Kaplan-Meier approach, and differences between curves were 
analyzed with the log-rank test. Multivariate survival analysis was done with Cox 
regression. P values <0.05 were considered signiﬁ cant. 
TABLE 1. Characteristics of the patients with removed positive sentinel lymph nodes 
Characteristics             patients  (%)
Total                  79
Gender
  Female               38    (48)
  Male                41    (52)
Age (years)
  Median        45
  Range         18-79
Breslow thickness (mm)#
  Mean         2.86
  Median        2.30
  Range         0.69-9.00
 
  0.5-1.0 mm             9     (11)
  1.01-2.0 mm            26     (33)
  2.01-4.0 mm            27    (34)
  >4.0 mm              17    (22)
Type melanoma
  Superﬁ cial spreading          46    (58)
  Nodular               32    (41)
  Lentiginous malignant         1     (1)
Site primary melanoma
  Trunk                39    (49)
  Upper extremities           11    (14)
  Lower extremities           28    (36)
  Head & neck             1     (1)
Ulceration
  Present               21    (27)
  Absent                58    (73)
Lymphatic invasion
  Present               10     (13)
  Absent                69    (87)
Clark level of invasion
  II                   3     (4)
  III                  16    (20)
  IV                  52    (66)
  V                   5     (6)
  Unknown               3     (4)
# None of the melanomas in these patients had signs of regression  
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Results 
Sentinel lymph node Identiﬁ cation  
Eighty patients (18%) had a tumor-positive sentinel lymph node. The sentinel 
lymph node of one patient was located in the parotid gland. Fine-needle 
aspiration biopsy showed the sentinel lymph node to contain metastatic 
cells. She was not subjected to a complete triple-technique sentinel lymph 
node procedure but underwent an additional lymph node dissection after this 
ﬁ ne-needle biopsy. Of the remaining 79 patients, ultimately 71 were subject of 
the study.  
The mean Breslow thickness of the primary tumor was 2.86 mm (median, 2.30 
mm; range, 0.69-9.00 mm). The remaining patient and tumor characteristics are 
displayed in TABLE 1. 
One hundred forty-three sentinel lymph nodes were detected in 93 regional 
lymph node basins (1.5 sentinel lymph nodes per basin). Sixty-seven patients 
had 1 tumor-draining basin, 11 had 2, and 1 patient had 4. The mean number of 
sentinel lymph nodes per patient was 1.8.  
A total of 872 (median, 11.5 per patient) additional lymph nodes were removed 
by additional lymph node dissection in 74 patients, and 5 patients refused to 
undergo additional lymph node dissection for personal reasons. These 5 patients 
are all alive after a median follow-up of 59 months. Of these 74 patients, the 
sentinel lymph nodes of 55 (74%) patients were the only lymph nodes to contain 
melanoma, whereas 19 (26%) patients had non-sentinel lymph nodes involved: 
10 (53%) patients had 1 non-sentinel lymph node involved, 4 (21%) had 2 
non-sentinel lymph nodes involved, and 5 (26%) patients had >3 non-sentinel 
lymph nodes involved. 
TABLE 2. Comparison of cutaneous melanoma patients (n=71) with metastasis only in 
the sentinel lymph node (group 1) and patients with additional positive regional lymph 
nodes (group 2).
 
                 Only SLN involved   Additional LN
                 (Group 1)        (Group 2)
                 patients  (%)     patients  (%)   P value
Total               52     (73)    19    (27)    
Breslow thickness (mean; mm)      2.90         3.18     NS
Unfavorable prognostic factors
#    16     (31)    9     (47)   0.19
†
 Ulceration            13      (25)      7     (37)
 Lymphatic invasion         5     (10)    5     (26)
SLN metastatic area (mean; mm2)     1.18                  3.39      0.003*
Recurrence            20      (38)      13     (68)  0.03
†
 Locoregional cutaneous
•       11     (21)    8     (42)
 Distant              9     (17)    5     (26)        
       
Abbreviations: SLN, sentinel lymph node; LN, lymph node; NS, not signiﬁ cant 
# Ulceration and/or lymphatic invasion of primary melanoma 
† Chi-square test 
* Mann-Whitney U-test   
• Locoregional cutaneous includes satellite and intransit metastases
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Area of tumor involvement in sentinel lymph nodes 
The slides of three patients were not available for measuring the area of 
metastasis in the sentinel lymph node, so the characteristics of 71 patients were 
left for measuring the area of tumor involvement in the sentinel lymph node and 
for statistical analysis.  
Within the sentinel lymph nodes, the morphological distribution of metastatic 
tumor cells varied from tiny clusters of melanoma cells lying in the subcapsular 
sinus to extensive inﬁ ltration of the entire lymph node, replacing nearly all of 
the normal lymphoid tissue. The total surface area of the tumor foci within a 
lymph node appeared to correlate to their morphological distribution: very small 
deposits were always found in the subcapsular or marginal sinuses, whereas 
larger masses tended to involve the adjacent parenchyma or even extended 
beyond the outer nodal limits. The 71 patients were divided into two subgroups: 
group 1 encompassed those in whom only the sentinel lymph node(s) contained 
metastases (52 patients), whereas those with positive additional lymph nodes 
were assigned to group 2 (19 patients). The characteristics of the two groups are 
shown in TABLE 2.
FIGURE 1 
Sentinel lymph node (SLN) metastatic area of cutaneous melanoma patients with only sentinel 
lymph node involvement (group 1; 52 patients) compared with patients with positive additional 
lymph nodes (group 2; 19 patients). Horizontal bars represent the mean sentinel lymph node 
metastatic area in both groups: 1.18 mm2 for group 1 and 3.39 mm2 for group 2 (P=0.003)
 
In individual sentinel lymph nodes, the metastatic area ranged from 0.003 to 
13.96 mm2, with a mean of 1.77 mm2. The mean sentinel lymph node metastatic 
area was 1.18 mm2 for group 1 and 3.39 mm2 for group 2 (P=0.003; TABLE 2). 
Actual values of the sentinel lymph node metastatic area of each patient are 
shown in FIGURE 1. There was a positive correlation between Breslow thickness 
and total metastatic surface area (correlation coefﬁ cient, 0.334; P=0.004; FIGURE 2).  
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FIGURE 2  
Scatter plot of total sentinel lymph node (SLN) metastatic area and Breslow thickness for a group 
of cutaneous melanoma patients with (19 patients; circles) or without (52 patients; squares) 
additional lymph node metastases. No positive additional lymph nodes were found in patients with 
both an arbitrarily taken Breslow thickness of the primary tumor <2.5 mm and sentinel lymph node 
metastatic area <0.3 mm2. Pearson’s correlation coefﬁ cient was 0.334 (P=0.004).
 
In patients with a sentinel lymph node metastatic area <0.03 mm2 (10 patients), 
no positive additional lymph nodes were found. However, when only patients 
with a Breslow thickness <2.5 mm were considered, the threshold for the 
presence of positive additional lymph nodes increased to an area of 0.3 mm2. 
There was a signiﬁ cant correlation between sentinel lymph node metastatic 
area and Breslow thickness (Pearson’s correlation coefﬁ cient, 0.334; P=0.004; 
FIGURE 2). In other words, no positive additional lymph nodes were found in patients
with both an arbitrarily taken Breslow thickness of the primary tumor <2.5 mm 
and a sentinel lymph node metastatic area <0.3 mm2. In logistic regression, the 
sentinel lymph node metastatic area was the only independent factor that was 
signiﬁ cant (P=0.02) in predicting the presence of positive additional lymph 
nodes (TABLE 3). 
TABLE 3. Multivariate predictive value (logistic regression) of several factors for the 
presence of additional positive lymph nodes in sentinel lymph node-positive cutaneous 
melanoma patients (n=71)
Prognostic factor       RR    95% CI    P value
Breslow thickness >2.5 mm    0.64   0.18-2.32   0.50
Ulceration present        1.67  0.45-6.15   0.44
Lymphatic invasion present    3.18  0.70-14.43  0.13
SLN metastatic area >0.3 mm2
  
5.92  1.41-24.86  0.02
Abbreviations: SLN, sentinel lymph node; RR, Risk ratio; CI, conﬁ dence interval
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Recurrent disease 
Recurrent disease was seen in 33 (46%) of the 71 patients during follow-up 
(TABLE 2). Twenty (38%) patients in group 1 had a recurrence, whereas 13 (68%) 
in group 2 had a recurrence (P=0.03). Locoregional cutaneous metastasis was 
the ﬁ rst recurrence to develop in 19 patients (11 in group 1 and 8 in group 2), 
whereas 14 patients (9 in group 1 and 5 in group 2) developed distant metastases 
as the ﬁ rst site of recurrence. None of the patients had a recurrence in the 
draining lymph node basin. 
Disease-free survival and overall survival 
Patients were divided into three subgroups. Subgroup A comprised patients 
with a Breslow thickness <2.5 mm, a sentinel lymph node tumor load <0.3 mm2, 
and no positive additional lymph nodes (n=21), subgroup B comprised all other 
patients without positive additional lymph nodes (Breslow thickness >2.5 mm, 
sentinel lymph node metastatic area >0.3 mm2, or both; n=31), and subgroup C 
encompassed patients with positive additional lymph nodes (n=19). Subgroup A 
had a signiﬁ cantly better disease-free survival (P<0.0001) and overall survival 
(P<0.0001) compared with the rest of the patients (FIGURES 3 and 4, respectively). 
Five-year disease-free survival was 87% ± 8.6% (± standard error of the mean 
(SEM)) for subgroup A, 52% ± 10.4% for subgroup B, and 18% ± 10.9% for 
subgroup C. Five-year overall survival was 94% ± 5.4%, 56% ± 10.7%, and 
30% ± 12.1%, respectively. 
FIGURE 3 
Disease-free survival curves for cutaneous melanoma patients with a Breslow thickness <2.5 
mm, a sentinel lymph node metastatic area <0.3 mm2, and no positive additional lymph 
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nodes (group A); patients with a Breslow thickness >2.5 mm and/or a sentinel lymph node 
metastatic area >0.3 mm2 and no positive additional lymph nodes (group B); and patients with 
positive additional lymph nodes (group C; P<0.0001).
FIGURE 4 
Overall survival curves for cutaneous melanoma patients with a Breslow thickness <2.5 mm, 
a sentinel lymph node metastatic area <0.3 mm2, and no positive additional lymph nodes 
(group A); patients with a Breslow thickness >2.5 mm and/or a sentinel lymph node metastatic 
area >0.3 mm2 and no positive additional lymph nodes (group B); and patients with positive 
additional lymph nodes (group C; P<0.0001). 
TABLE 4. Multivariate Cox regression analysis of disease-free survival and overall 
survival for all sentinel lymph node-positive cutaneous melanoma patients.
             Disease-Free Survival     Overall Survival
Prognostic factor      HR   95% CI   P value   HR   95% CI   P value
Breslow thickness >2.5 mm  0.94  0.41–2.14  0.89   0.94  0.35–2.56  0.91
Ulceration present      2.05  0.92–4.53  0.08    1.32  0.52–3.40 0.56
Lymphatic invasion present  2.99  1.24–7.24  0.02    1.66  0.57–4.86  0.36
SLN metastatic area >0.3 mm2 3.36  1.39–8.10  0.007   4.09  1.35–12.4  0 0.01
Abbreviations: SLN, sentinel lymph node; HR, Hazard ratio; CI, conﬁ dence interval  
We performed a multivariate Cox regression analysis on all patients to determine
the inﬂ uence of several factors on disease-free survival and overall survival 
(TABLE 4). The factors that were independently related to a poorer disease-free
survival included the presence of lymphatic invasion in the primary tumor 
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(P=0.02) and a sentinel lymph node metastatic area >0.3 mm2 (P=0.007).  A 
sentinel lymph node metastatic area of >0.3 mm2 was the only independent 
factor correlated to a worse overall survival (P=0.01). 
Discussion 
The sentinel lymph node procedure has become common in cutaneous 
melanoma. Patients with a negative sentinel lymph node are spared an 
additional lymph node dissection and are followed up during frequent visits at 
the outpatient department. The applied triple-technique procedure has been 
shown to be reliable, with a relatively low false-negative rate.1-4 If the sentinel 
lymph node contains metastatic melanoma cells, an additional lymph node 
dissection follows at a later date. However, approximately two thirds of the 
patients with a positive sentinel lymph node have metastases limited to the 
sentinel lymph node.5,6,12,13 The signiﬁ cant associated morbidity of an additional 
lymph node dissection (paresthesiasis, wound infection, seroma formation, and 
lymphedema) without proven better long-term survival makes it worthwhile to 
try to develop a staging model to predict which group of patients with a positive 
sentinel lymph node have additional lymph node involvement and might beneﬁ t 
from an additional lymph node dissection and which group of patients might be 
saved from this additional operation.   
The development of immunohistochemistry with S-100, HMB-45, and Melan-A 
antibodies has made it possible to detect smaller (and, thereby, probably 
earlier) metastatic cells, but it upstages many patients who will not beneﬁ t from 
an additional lymph node dissection and necessitates the development of an 
additional staging system. 
Varying degrees of nodal involvement in lymphatic spread has long been 
recognized, but the clinical signiﬁ cance of occult metastases, especially micro-
metastases (so far arbitrarily deﬁ ned as metastases with a diameter <2 mm), 
continues to be a subject of debate. The clinical implications of micrometastases 
are not completely elucidated, and their biologic behavior is not yet clear.23,24 It 
is possible that there is a critical mass of cancer cells that confers prognostic 
implications.18,19,23
The lymphatic spread of melanoma cells follows an orderly progression via the 
sentinel lymph node to non-sentinel lymph nodes in the same draining lymph 
node basin. In the sentinel lymph node, too, tumor cells are thought to follow 
an orderly progression, arriving in the subcapsular sinuses through an afferent 
capsular lymph vessel. Later, there is subcapsular outgrowth of malignant cells 
in the marginal sinuses and into the immediately adjacent cortical parenchyma. 
Finally, these cells extend to the deeper zones of the lymph node parenchyma, 
frequently following the medullary sinuses to efferent lymphatic vessels, and 
may ultimately penetrate the capsule.17 At present there is no staging system 
that considers the volume of tumor found in the lymph nodes; they are simply 
considered to be positive or negative.21 The distribution of the melanoma cells 
in the sentinel lymph node was, in combination with the Breslow thickness of 
the primary tumor, mentioned as a signiﬁ cant predictive factor for the chance of 
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non-sentinel lymph node involvement.17,20 This supports the use of a classiﬁ cation 
system of the metastatic spread in the sentinel lymph node according to the size 
and distribution of the metastatic cells in the sentinel lymph node, because a 
signiﬁ cant number of lymph node-positive patients have metastases limited to 
the sentinel lymph node(s).  
For breast carcinoma, it has been suggested that a combination of tumor size 
and the size of the metastasis in the sentinel lymph node is predictive for the 
chance of non-sentinel lymph node involvement.25,26 In a small melanoma study, 
Cochran et al.18 tried to improve the predictive accuracy with morphological 
techniques to determine the tumor load. Outcome was most accurately 
predicted to be favorable when fewer than four lymph nodes were involved and 
the total tumor diameter was <15% of the total nodal diameter. 
By following a line of reasoning similar to that of Breslow when he devised his 
micrometer-based thickness measurement as a surrogate for primary tumor 
volume, we decided to assess the total surface area of tumor deposits in the 
sentinel lymph node by morphometry as a measure for sentinel lymph node 
tumor load. Because microscopic metastatic cells seldom appear as round foci 
but are often clustered along the subcapsular sinus, this method provides a more 
accurate assessment of tumor load than tumor diameter does. 
In this study, the sentinel lymph node metastatic area was the only independent 
predictor of positive additional lymph nodes. Irrespective of Breslow thickness, 
patients with a sentinel lymph node metastatic area <0.03 mm2 never had 
positive additional lymph nodes. Nevertheless, there was a signiﬁ cant correlation 
between Breslow thickness and sentinel lymph node metastatic area.  In patients 
with a Breslow thickness <2.5 mm, the sentinel lymph node metastatic area 
threshold below which additional positive lymph nodes were never found was 
even 0.3 mm2. These patients had an excellent 5-year disease free and overall 
survival (83% and 94%, respectively), comparable to those of patients with 
a negative sentinel lymph node.27 Starz et al.17 used a comparable method 
to determine the tumor burden in the sentinel lymph node. They used the S 
classiﬁ cation, which is based on the maximum depth of invasion of metastatic 
cells in the sentinel lymph node; S0 represents no metastatic involvement of the 
sentinel lymph node, and SIII represents a metastatic invasion of the SLN >1 mm. 
The predictive value of their S classiﬁ cation seems to be similar to the sentinel 
lymph node metastatic area described in this study; it is a strong predictor of 
additional lymph node involvement and survival.28 Cochran et al.20 described 
similar results regarding the relative area of tumor in the sentinel lymph node.  
In this study, the sentinel lymph node metastatic area was independently related 
to a poorer disease-free survival and was the only factor independently related to 
a worse overall survival. The fact that sentinel lymph node metastatic area was 
the only factor signiﬁ cantly related to a worse overall survival might be explained 
by the fact that the median follow-up in this present study was relatively short. 
The additional lymph nodes in this study were examined with routine histological 
techniques (haematoxylin and eosin). Additional lymph node involvement was 
present in 27% of these patients. These data seem comparable to the data of 
other studies that analyzed additional lymph nodes using the same technique as 
for sentinel lymph nodes and found  additional lymph node involvement in 28% 
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and 21%, respectively.17,20 Whether analyzing the additional lymph nodes with the 
same technique as used for sentinel lymph node would increase the percentage 
of additional lymph node involvement is not known. 
In conclusion, the total sentinel lymph node metastatic area may, in combination 
with the Breslow thickness of the primary tumor, be used to predict the absence 
of positive additional lymph nodes and survival. The combination of these factors 
makes it possible to formulate a staging model, so that superselective lymph 
node dissection becomes feasible. Such a micro-staging system not only will 
avoid unnecessary morbidity, but also shows that patients with a positive sentinel 
lymph node are a heterogeneous group. This study shows that patients with a 
Breslow thickness <2.5 mm and a sentinel lymph node metastatic area <0.3 mm2
might not beneﬁ t from an additional lymph node dissection. We hypothesize 
that an additional lymph node dissection might be omitted in these patients. 
Nevertheless, to answer these questions, a prospective trial in which sentinel 
lymph node-positive patients are randomized between additional lymph node dis-
section and no additional lymph node dissection, has to be performed.29,30
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Abstract 
Immune responses against tumor antigens will initially occur in the ﬁ rst 
tumor-draining lymph node, the sentinel lymph node. Because of extensive 
diagnostic procedures, obtaining a piece of sentinel lymph node to isolate viable 
immune cells for functional analyses is often impossible. For this reason an 
alternative method to obtain viable cells from a lymph node was investigated, 
i.e., scraping lymph nodes with a surgical blade, and compared with dissociation 
of total lymph nodes. 
Tumor-draining lymph nodes were retrieved from ﬁ ve oncological patients. 
The collected dendritic cells and T cells were phenotypically and functionally 
characterized by ﬂ ow cytometry and antigen-speciﬁ c interferon-c release in an 
ELISPOT assay. Results were compared between the two isolation methods. 
Viabilities and phenotypic characteristics of the collected cells were entirely 
comparable for both methods. T cell functionality was also comparable between 
both methods, with equal T cell expansion factors and similar frequencies of 
cytotoxic T cells speciﬁ cally recognizing the M1 matrix protein of Inﬂ uenza 
haemophilus or the tumor antigen Her-2/neu.  
In conclusion, scraping lymph nodes to obtain cells for analysis of immune 
functions in lymph nodes is feasible and presents a good alternative to dissociation 
of lymph nodes. Scraping may even be applied to small lymph nodes that a 
pathologist will submit entirely for histological examination and may thus prove 
useful in the monitoring of immune responses in sentinel lymph nodes. 
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Introduction 
Since the early 1990s a simple method has become available to detect and 
retrieve the ﬁ rst tumor-draining lymph node, the so-called sentinel lymph node. 
This is done with a radioactive tracer and blue dye that are both injected around 
the tumor.1,2 During surgery, guided by the blue staining of the draining tissues, 
the radioactivity and the preoperatively made lymphoscintigraphy, the sentinel 
lymph node is removed and examined meticulously by the pathologist. Sections 
are cut and stained by haematoxylin and eosin and for speciﬁ c tumor markers. If 
the sections from the center of the sentinel lymph node are tumor-negative, other 
sections at intervals of 250 µm are cut and stained.3 Because of this extensive 
diagnostic processing, it is near impossible to obtain a fresh piece of the sentinel 
lymph node from which viable cells can be isolated. 
Nevertheless, for immunological research, fresh sentinel lymph node material is 
important, because in these nodes the immune defense to tumor cells is initiated. 
The sentinel lymph node plays an important role in the interaction between 
a developing tumor and the host immune defense, sustaining the initiation and 
possibly even the maintenance of tumor immunity.4,5 In these processes, dendritic 
cells play a very important role. They are uniquely equipped to activate naive T 
lymphocytes.6-9 To monitor tumor-speciﬁ c cellular immune responses in tumor-
draining lymph nodes, speciﬁ cally the sentinel lymph nodes, obtaining viable 
cells from these nodes is of particular importance. For this reason we evaluated 
an alternative method in a relatively small pilot-study to determine whether 
sufﬁ cient numbers of viable cells could be obtained from lymph nodes for in 
vitro phenotypic and functional analyses so as not to interfere with diagnostic 
procedures.  
Dendritic cells constitute an exceedingly small subpopulation of cells in 
lymph nodes (<1%), and are therefore difﬁ cult to accurately characterize 
and quantitate.10-12 Usually, lymph nodes are mechanically or enzymatically 
dissociated to obtain viable cells.13-17 According to Monfalcone and colleagues10, 
enzymatic dissociation of lymph nodes is preferred above the mechanical 
dissociation technique. Dissociating the lymph nodes enzymatically resulted in 
a large increase in cell yield, as well as in an increased cell viability. Especially 
relatively large and fragile cells, such as dendritic cells, are shown in higher 
quantities by the use of the enzymatic dissociation technique.  
Scraping fresh tissue with a surgical blade is often used in intra-operative 
settings, usually from tumors, to obtain cytological preparations for diagnostic 
procedures. This method is rapid, easy and reliable.18-20 It is mainly used to 
detect malignant cells, but to our knowledge its usefulness for phenotypic and 
functional analysis of dendritic cells and T cells has not yet been evaluated. 
Because of the growing need for reliable immunological monitoring in sentinel 
lymph nodes, we decided to evaluate the usefulness of this scraping method to 
sample the immunological status in lymph nodes, focusing on dendritic cells and 
T cells. We show that sampling a small piece of lymph node by scraping is a 
reliable alternative to total dissociation of the lymph node for immunomonitoring 
purposes. 
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Materials and Methods
Culture and dissociation media 
Unless otherwise stated, all cultures were maintained in complete medium (CM) 
comprising Iscove’s modiﬁ ed Dulbecco’s medium (IMDM) supplemented with 
25 mmol/L Hepes buffer (BioWhittaker, Verviers, Belgium) with 10% fetal calf 
serum, 50 IU/mL penicillin-streptomycin, 1.6 mmol/L L-glutamine, and 0.05 
mmol/L 2-b-mercaptoethanol. For dissociation DNase/collagenase medium 
comprising RPMI 1640 (BioWhittaker) with 0.14% collagenase A (Boehringer 
Mannheim, Mannheim, Germany), 0.1% DNase I (Boehringer Mannheim), and 
5% fetal calf serum was used. 
Patients and lymph node processing
From ﬁ ve oncological patients (TABLE 1) who underwent an elective lymph node 
dissection, one lymph node from the dissection specimen was used for this study 
according to institutional policies regarding the use of discarded tissue. Before 
surgery 40 to 50 ml of blood was drawn from each patient. Peripheral blood 
mononuclear cells were isolated from heparinized blood by density gradient 
centrifugation using Lymphoprep (Nycomed Pharma AS, Asker, Norway). Cells 
were washed twice with sterile phosphate-buffered saline with 0.1% bovine 
serum albumin and cryopreserved at –196°C in fetal calf serum containing 12.5% 
dimethyl sulfoxide. 
TABLE 1. Patient characteristics, location, and size of the removed lymph nodes (LN) 
Patient     Type of Malignancy     Location LN   Size LN (mm)
1       Pancreatic carcinoma    Mesenterium   18 x 14 x 5
2       Colon carcinoma      Mesenterium   4 x 4 x 3
3       Breast cancer        Axilla       5 x 4 x 4
4       Melanoma         Groin      8 x 5 x 5
5       Melanoma         Axilla       18 x 8 x 5  
All lymph nodes were tumor-draining lymph nodes, but not unequivocally 
identiﬁ ed as the sentinel lymph node. Directly after removal the lymph node 
were collected in ice-cold CM. Further processing took place on a petri dish 
containing 1 to 2 ml of CM on ice in a sterile environment.  
First, fat was trimmed from the lymph node, after which it was bisected 
crosswise. From one cutting surface, imprint cytological specimens were made 
by dabbing the surface on an uncoated glass slide. The other cutting surface of 
the lymph node was scraped 10 times with a surgical scalpel blade (size no.22; 
Swann Morton Ltd., Shefﬁ eld, England) while holding the lymph node with a 
forceps. With the sharp, round edge of the blade cells were scraped off the 
surface of the lymph node. The blade was rinsed in DNase/collagenase medium. 
The remains of the lymph node were cut into 2-mm3 pieces with a surgical 
scalpel followed by enzymatic digestion in DNase/collagenase. The specimens 
obtained by scraping and dissociation were collected in 15 to 30 ml of DNase/
collagenase medium and kept in a waterbath at 37°C for 45 minutes and were 
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stirred meanwhile. After 45 minutes the cells were washed twice with 10 ml of 
CM and counted using a cytometer and Trypan-blue exclusion to determine yield 
and viability of the cells obtained by each of the isolation methods. 
Immunocytochemical staining of imprint specimens
Imprints from the cutting surfaces were made and air-dried overnight and ﬁ xed 
in acetone for 10 minutes. They were stained immunocytochemically using a 
biotin-streptavidin staining technique as described previously.21 Monoclonal 
antibodies (mAbs) recognizing CD1a, CD86 (both from Becton Dickinson, 
Mountain View, CA) and CD83 (Immunotech, Marseilles, France) were used 
at dilutions of 1:50, 1:10 and 1:10 respectively.  
Flow cytometry 
Freshly isolated lymph node cells were directly stained with antibodies and 
analyzed by ﬂ ow cytometry to establish their phenotypic characteristics. 
Single-color and dual-color analyses of cell surface markers were performed 
using combinations of mAbs labeled with either phycoerythrin or ﬂ uorescein 
isothiocyanate. Commercially available mAbs recognizing CD1a, CD4, CD8 
and CD86 (all from Becton Dickinson), and CD40 and CD83 (both from 
Immunotech) were used. The numbers of lymph node cells analyzed were 50 
to 100,000 events per measurement. 
T cell expansion
After scraping or dissociation, T cells from the lymph node cells were expanded.  
Cells were incubated for 1 hour on ice with 2 µg of aCD3 per 1 x 106 cells and 
0.4 µg of aCD28 per 1 x 106 cells (kindly provided by Dr. René van Lier, CLB, 
Amsterdam, The Netherlands) in 100 to 200 µl of CM with 5% fetal calf serum. 
After incubation the cells were placed on 24-well plates, coated with afﬁ nity-
puriﬁ ed goat-a-mouse immunoglobulin (1:100; Dako, Glostrup, Denmark), in a 
concentration of 1 x 106 cells/ml/well for 1 hour at 4°C. The cells were cultured 
for 48 hours in a humidiﬁ ed 5% CO2 incubator at 37°C. After 48 hours the 
cells were resuspended and each well was divided over four new uncoated 
wells, 250 µL per well. To each new well 750 µl of CM, containing interleukin-2 
(CLB, Amsterdam, The Netherlands) at a concentration of 14 IU/ml, was added 
resulting in an end-concentration of >10 IU interleukin-2 per ml. The cells were 
cultured at 37°C in a humidiﬁ ed 5% CO2 incubator for another 5 days. After 5 
days the cells were harvested and counted. The described cycle was repeated 
once. After the second cycle the cells were harvested, counted, frozen, and 
stored for functional analysis at a later date. Expansion factors were determined. 
Monocyte-derived Dendritic Cell Culture
For functional analyses of expanded lymph node T cells, monocyte-derived 
dendritic cells were used as stimulator cells. The monocyte-derived dendritic 
cells were generated according to previously described methods.22 Brieﬂ y, 
plastic-adherent peripheral blood mononuclear cells were cultured for 7 days 
at a cell density of 3 to 5 x106 peripheral blood mononuclear cells per ml of 
CM, containing 100 ng/ml granulocyte-macrophage colony-stimulating factor 
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(GM-CSF) and 1000 IU/ml of interleukin-4. A typical phenotype (CD1a+/CD14-) 
and morphology was achieved. 
Adenovirus infection of Monocyte-derived Dendritic Cells 
After collection, the monocyte-derived dendritic cells were transfected with 
adenovirus encoding the M1 matrix protein of Inﬂ uenza haemophilus (Adv-ﬂ u) 
(kindly provided by Dr C Rickards and Dr GW Wilkinson, University of Wales, 
Cardiff, UK) or adenovirus-green ﬂ uorescent protein (Adv-GFP) as a negative 
control. Transduction was CD40-targeted using a bispeciﬁ c antibody conjugate 
as previously described by Tillman and colleagues.23 Transduction of the 
monocyte-derived dendritic cells took place at a multiplicity of infection (MOI) of 
100. The next day monocyte-derived dendritic cells were washed and seeded in 
pre-coated ELISPOT plates. 
Peptide loading of T2 cells 
For those patients who were HLA-A2-positive, T2 cells loaded with HLA-A2-
restricted ﬂ u peptide (containing the M1-derived HLA-A2 binding epitope amino 
acids 58 to 66) or the HLA-A2-restricted HER-2/neu peptides (KIFGSLAFL and 
IISAVVGIL) were used as stimulator cells as well. As a control E7 peptide was 
used. T2 cells were pulsed overnight in serum-free CM with ß-microglobulin 
(5 µg/ml) and E7 peptide (50 µg/ml), ﬂ u-peptide (50 µg/ml), or HER-2/neu
peptide (50 µg/ml) at 37°C in a humidiﬁ ed 5% CO2 incubator. The next day, 
cells were harvested and seeded in pre-coated ELISPOT plates.  
Antigen-speciﬁ c Interferon-c production by memory CTLs 
To analyze the expanded CD8+ T cells functionally, the interferon (IFN)-c
ELISPOT assay was used.24-26 As effector cells, expanded aCD3/aCD28-
stimulated CD8+ T cells from the lymph node, obtained through dissociation or 
scraping, were used. Isolation of the expanded CD8+ lymph node lymphocytes 
was performed by using the untouched CD8+ mini MACS selection kit, 
according to the manufacturer’s instructions (Miltenyi Biotec, Bergisch 
Gladbach, Germany). After separation, cells were washed and resuspended in 
CM and added directly to the transduced monocyte-derived dendritic cells or 
loaded T2 cells. 
The IFN-c ELISPOT assay was performed as described previously.27 Plates 
were seeded with 100 µl of CM per well containing 5,000 stimulator-cells 
(monocyte-derived dendritic cells or T2 cells) and 25,000 or 12,500 effector-
cells (CD8+ T cells), resulting in E/S ratios of 5:1 and 2.5:1, respectively. Each 
sample was tested in duplicate at each of the E/S ratios. Spots were counted by 
2 independent observers using a microscope. To calculate the number of CD8+ 
T cells speciﬁ cally responding to inﬂ uenza, the mean numbers of spots induced 
by Adv-GFP-transfected monocyte-derived dendritic cells or E7 peptide-
loaded T2 cells alone were subtracted from the mean spot numbers induced by 
Adv-ﬂ u-transfected monocyte-derived dendritic cells, ﬂ u peptide, or HER-2/neu
peptide-loaded T2 cells. The speciﬁ c response is expressed as the number of 
speciﬁ c spots per 1,000,000 effector cells (i.e., the number of inﬂ uenza-speciﬁ c 
or HER-2/neu-speciﬁ c CD8+ T cells per 1,000,000 CD8+ T cells). 
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HER-2/neu-HLA-A2-tetramer-binding analysis 
Expanded and separated CD8+ T cells were stained with HLA-A2-restricted 
tetramers containing the HER-2/neu peptides KIFGSLAFL or IISAVVGIL. 
Phycoerythrin-conjugated HLA-A*0201 tetramer reagents were generated as 
described previously.28,29 Expanded and puriﬁ ed CD8+ T cells from peripheral 
blood lymphocytes (PBL) and obtained through dissociation and scraping were 
stained with the phycoerythrin-labeled tetramers (20 µg/ml); incubation for 5 
minutes in CM at 37°C in a humidiﬁ ed 5% CO2 incubator, after which the cells 
were washed and kept at 4°C. The cells were analyzed by ﬂ ow cytometry. The 
number of CD8+ T cells analyzed were at least 250,000 events per measurement. 
Statistical Analysis 
Data sets were compared nonparametrically using the paired Wilcoxon signed 
rank test. Correlation between CD4:CD8 ratios was determined using the non-
parametrical Spearman test. P<0.05 was considered signiﬁ cant.  
Results 
Yield and Viability of collected lymph node cells
Dissociation yielded an average of 53.0 x106 (range, 7.0 x106 to 1.9 x108) cells. 
The mean yield of cells after scraping of the lymph node was 8.2 x106 (range, 
2.8 x106 to 20 x106) cells. Mean viability of the cells collected by scraping was 
91% (range, 86% to 96%); mean viability of cells obtained by dissociation was 
85% (range, 79% to 92%). 
Phenotypic analysis of Dendritic Cells 
Fluorescence-activated cell sorting (FACS) analyses were performed to 
determine the numbers, phenotypic characteristics, and activation state of lymph 
node dendritic cells. The membrane marker CD83 was used to detect mature 
dendritic cells in the lymph node. CD1a and CD86 were used as additional 
dendritic cell and activation markers. A typical FACS analysis of lymph node 
dendritic cells in a representative patient is shown in FIGURE 1A. In all but one 
patient (patient 4), the observed dendritic cell frequencies were lower among 
lymph node cells obtained through scraping compared to the lymph node cells 
obtained after dissociation. However, the paired nonparametrical Wilcoxon test 
revealed no signiﬁ cant differences between the two methods (FIGURE 1B). All 
CD83+ cells were positive for CD86 as well. In two patients (patients 1 and 2) no 
CD1a-positive cells were detectable. The lymph nodes from these two patients 
were located in the mesenterium, whereas the lymph nodes from the other three 
patients were skin-draining lymph nodes (TABLE 1).  
The marker expression levels of the dendritic cell markers CD83, CD1a and 
CD86 were comparable between both methods. (P=0.686, P=0.138, and 
P=0.500) (FIGURE 1B).  
The FACS-results were consistent with the immunocytochemical imprints 
made from the tested lymph nodes. Staining for CD1a, CD83 and CD86 
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showed numerous strongly positive cells with typical dendritic cell morphology 
(FIGURE 1C). Imprints made from the mesenteric lymph nodes in patients 1 and 2, 
showed no CD1a-positive cells. 
FIGURE 1A 
FACS analyses of lymph node cells obtained though scraping the cutting surface of tumor-
draining lymph nodes with a surgical scalpel in a representative patient (patient 3). CD83/iso, 
CD83/CD1a and CD83/CD86 staining of axillary lymph node cells.
FIGURE 1B 
FACS analysis data for lymph node dendritic cells (LNDC) per patient. Lymph node dendritic 
cell frequencies are expressed as the percentage of total lymph node cells and lymph node 
dendritic cell marker expression levels are expressed as mean ﬂ uorescence (MF; logarithmic 
scale) for the dissociation method and the scraping method. The mean percentages are the 
percentages of the total number of counted lymph node cells. Mean dendritic cell frequencies 
for CD83+, CD83+/CD1a+ and CD83+/CD86+ obtained with the dissociation method were 
0.51% (range, 0.33% to 0.85%), 0.28% (range, 0.01% to 0.75%), and 0.55% (range, 
0.17% to 1.31%), respectively. With the scraping method these frequencies were 0.42% 
(range, 0.05% to 0.74%), 0.25% (range, 0.01% to 0.73%), and 0.44% (range, 0.15% 
to 0.93%), respectively. The mean expression levels of the dendritic cell markers CD83, 
CD1a* and CD86* for the dissociation and scraping method were 77 versus 77, 1365 versus 
1706, and 163 versus 128, respectively. Paired Wilcoxon signed ranks test used between 
methods revealed no signiﬁ cant differences. *, Double positive for CD83.
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FIGURE 1C 
Immunocytochemical stainings for the dendritic cell markers CD1a, CD83 and CD86 on 
imprint specimens of an axillary lymph node from a breast cancer patient (patient 3). Original 
magniﬁ cation 400x.
Phenotypic analysis of T cells
The CD4 or CD8 phenotype of lymph node T cells was determined by ﬂ ow 
cytometry. T cells were expressed as CD4:CD8 ratios for each method. CD4:
CD8 ratios of collected T cells varied between patients, but within patients 
there was a signiﬁ cant correlation (correlation coefﬁ cient, 0.94) between CD4:
CD8 ratios found immediately after dissociation or scraping. (P=0.037, FIGURE 2). 
Mean percentages of CD4+ T cells obtained through dissociation or scraping 
were 32.82% (range, 28.12 to 38.63%) and 36.67% (range, 25.95 to 50.55%) 
(P=0.345), respectively. For CD8+ T cells, these mean percentages were 9.86% 
(range, 6.18 to 12.46%) and 9.55% (range, 5.06 to 11.62%) (P=0.500), respectively. 
T cell Functional analysis
To obtain sufﬁ cient numbers of CD8+ T cells for functional analyses, lymph node 
T cells were nonspeciﬁ cally stimulated and expanded. T cell expansion factors 
after aCD3/aCD28 stimulation were similar for the dissociation method and 
the scraping method, 52.7 (range, 6.3 to 97.9) and 51.2 (range, 6.2 to 102.0) 
(P=0.786), respectively. 
  
After expansion functional analyses of separated and puriﬁ ed CD8+ T cells 
were done. As model antigen, the M1 matrix protein of Inﬂ uenza haemophilus
(Adv-ﬂ u) and an M1-derived HLA-A2-binding epitope amino acids 58 to 66 (ﬂ u 
peptide), were used. Flu-speciﬁ c CD8+ T cell frequencies were detected using 
Adv-ﬂ u-transduced monocyte-derived dendritic cells or ﬂ u peptide-loaded T2 
cells, without previous in vitro restimulation. 
Although differences existed between all patients in the frequency of detectable 
IFN-c-secreting inﬂ uenza-speciﬁ c CD8+ T cells using the Adv-ﬂ u-transduced 
monocyte-derived dendritic cells, in individual patients the frequency of 
inﬂ uenza-speciﬁ c CD8+ T cells (i.e., the difference between the spots induced 
by Adv-ﬂ u-transduced monocyte-derived dendritic cells and the number of spots 
induced by GFP-transduced monocyte-derived dendritic cells) among CTL 
obtained by dissociation or scraping were comparable (P=0.786, FIGURE 3A).
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FIGURE 2 
Correlation of CD4:CD8 ratios among T cells isolated from lymph nodes by dissociation or 
scraping. Spearman’s nonparametric correlation test; correlation coefﬁ cient of 0.94, P=0.037. 
FIGURE 3A 
Speciﬁ c frequencies of inﬂ uenza M1 matrix protein-speciﬁ c CD8+ T cells. Adenovirus M1-
transduced monocyte-derived dendritic cells were used as stimulator cells (paired Wilcoxon 
signed ranks test between methods, P=0.786). All assays were done in duplicate, except for 
patient 1. (  , Dissociation;   , Scrape).
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In contrast, using the ﬂ u peptide-loaded T2 cells in the HLA-A2-positive patients 
2 to 5, some minor discrepancies were found in frequencies of epitope-speciﬁ c T 
cells obtained by dissociation or through scraping (for patient 3 and 5, FIGURE 3B). 
In general, frequencies of CD8+ T cells speciﬁ cally recognizing the HLA-A2-binding 
ﬂ u-epitope were lower as compared to CTL responding to the entire M1 sequence. 
FIGURE 3B 
Speciﬁ c frequencies of inﬂ uenza M1 matrix protein-speciﬁ c CD8+ T cells. Speciﬁ c frequencies 
of inﬂ uenza peptide (M1-derived HLA-A2-binding epitope amino acids 58 to 66)-speciﬁ c CD8+ 
T cells, in HLA-A2-positive patients (patient 2 to 5). T2 cells loaded with ﬂ u peptide were used 
as stimulator cells (paired Wilcoxon signed ranks test between methods, P=0.715). All assays 
were done in duplicate. Number of inﬂ uenza-speciﬁ c spots (i.e., inﬂ uenza-speciﬁ c CD8+ T cells) 
per 1,000,000 expanded lymph node CD8+ T cells are shown (  , Dissociation;   , Scrape).
  
Analyses of HER-2/neu-speciﬁ c CTL in an HLA-A2-positive patient with HER-2/
neu-positive primary breast cancer 
One of the tested patients (patient 3) was found to be HLA-A2-positive and to 
carry a HER-2/neu-positive breast tumor. This offered the possibility to test the 
utility of both isolation methods to detect tumor-speciﬁ c CTL, using HER-2/neu
as model tumor antigen. Higher detectable frequencies of IISAVVGIL-speciﬁ c 
CD8+ T cells were found with both isolation methods by tetramer binding in 
phenotypic analyses, compared to KIFGSLAFL-speciﬁ c CD8+ T cells (FIGURE 4A). 
  
This was in accordance with the results found by the ELISPOT assay in the 
functional analyses (FIGURE 4B).
In comparison, in the expanded PBL very low frequencies of IISAVVGIL-speciﬁ c 
CD8+ T cells were found, consistent with the idea that immunological responses 
against tumor antigens will preferentially occur in tumor-draining lymph nodes 
(FIGURE 4A).
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FIGURE 4A 
FACS analyses with HER-2/neu tetramers for the epitopes KIFGSLAFL and IISAVVGIL of isolated 
CD8+ T cells derived from PBL, dissociated lymph node, and scraped lymph node material from 
an HLA-A2-positive patient (patient 3) with proven HER-2/neu-positive breast cancer.
FIGURE 4B
IFN-c ELISPOT data from the same patient: T2 cells were used as stimulator cells, loaded with 
HER-2/neu epitopes KIFGSLAFL and IISAVVGIL. Responder cells were CD8+ T cells from 
dissociated or scraped lymph node material (  , Dissociation;   , Scrape). Speciﬁ c frequency 
determined at an effector/stimulator ratio of 1.25:1 (10,000 loaded T2 cells). Each sample 
was tested in duplicate.
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Discussion 
In this study we have shown that isolation of viable cells from a lymph node 
by scraping with a surgical scalpel to sample local immunological responses 
is a very suitable alternative for dissociation of lymph nodes, which can be 
considered the gold standard to isolate viable lymph node cells. 
Dendritic cells and T cells in tumor-draining lymph nodes are crucial in the 
immune response against tumor antigens. In the ﬁ rst-line tumor-draining lymph 
node, i.e., sentinel lymph node, the ﬁ rst immunological response against tumor 
antigens will occur.6,8,9 Immune functions in tumor-draining lymph nodes are 
often strikingly down-regulated.30-32 Monitoring and making an inventory of 
immune responses in sentinel lymph nodes is thus of particular importance. For 
this, isolation of viable dendritic cells and T cells from the sentinel lymph node is 
important to test the functional status of these immune effector cells.  
Viable lymph node cells are usually obtained through dissociation of the lymph 
node. Because of extensive diagnostic processing of sentinel lymph nodes, 
obtaining even a small piece of these nodes for dissociation is impossible.3 For 
this reason, we compared this dissociation method with an alternative method in 
which cells were obtained through scraping of lymph nodes. These two methods 
were previously compared for tumor tissue.33 Torres and colleagues33 compared 
dissociation of breast adenocarcinoma with scraping of the tumor and concluded 
that the methods were comparable.  
As was to be expected, the absolute cell yield was higher after enzymatic 
dissociation of the entire lymph node, but the cell yield from scraping a cutting 
surface of the lymph node was well above the number of cells considered 
adequate for ﬂ owcytometric analyses and T cell expansion. A cell yield in the 
range of 1.5 x 106 to 2.5 x 106 was sufﬁ cient for the analyses described in this 
study, which were realized for all the patients studied. Viability of lymph node 
cells obtained through scraping was at least as high and often higher than that of 
cells obtained through dissociation. Although the number of cells obtained after 
scraping seemed to be rather high in relation to the total yield after dissociation, 
in our experience dissociation is a relatively inefﬁ cient method resulting in an 
underrepresentation of the total number of cells actually present in a lymph 
node. Moreover, the total volume of tissue collected by scraping is negligible in 
comparison to the total volume of the lymph node and interferes in no way with 
standard histopathological diagnostic procedures. 
Most importantly, no phenotypic or functional skewing through scraping was 
observed as compared to dissociation. In phenotypic analyses, although in lower 
amounts, we were able to detect dendritic cells after scraping in relatively similar 
quantities as after dissociation. A possible reason for detecting slightly less 
dendritic cells after scraping could be the fact that dendritic cells are large, fragile 
cells that can easily be damaged using mechanical processing.10 Dendritic cell 
marker expression levels were comparable between both methods, suggesting 
that no maturation of dendritic cells occurred because of mechanical manipulation 
associated with the scraping method.  
To assess morphological aspects of dendritic cells, imprint cytology of lymph 
nodes proved to be very suitable. Cells with morphological dendritic cell 
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characteristics stained positive for CD1a, CD83 and CD86 in imprints, thus 
conﬁ rming our FACS data to be dendritic cell speciﬁ c. Interestingly, dendritic cells 
obtained from mesenteric lymph nodes (patients 1 and 2) did not stain positive 
for CD1a. Takahashi and colleagues12,34 also reported that CD1a+ dendritic cells 
are present in superﬁ cial lymph nodes, but not in deeply located lymph nodes, 
suggesting that dendritic cells in mesenteric lymph nodes are derived from CD1a- 
dendritic cell precursors, of which the nature and origin remains unclear.  
T cells were obtained by both isolation methods in equal quantities. There was 
a near exact correlation between CD4:CD8 ratios of T cells obtained through 
dissociation and scraping. In the antigen-speciﬁ c functional analyses of CD8+ 
T cells with transduced monocyte-derived dendritic cells, we used the entire 
sequence of the inﬂ uenza antigen, with all possible epitopes, to stimulate the 
CTLs. In these analyses, the frequencies of IFN-c producing ﬂ u-speciﬁ c CD8+ 
T cells were equal for both isolation methods. Using T2 cells loaded with ﬂ u 
peptides gave slightly different results between the two isolation methods in 2 
patients. A possible explanation for this may be that in the scraping method only 
one speciﬁ c level of the lymph node is sampled, whereas in the dissociation 
method the whole lymph node or a larger part of the lymph node is sampled. It is 
conceivable that at the speciﬁ c level of sampling through scraping, a T cell clone 
with particular epitope recognition is located, in which case a relatively larger 
number of CD8+ T cells speciﬁ cally recognizing this epitope will be detected after 
scraping, compared to the dissociation method, or vice versa.  
Furthermore, this study demonstrated the feasibility of detecting low frequent 
tumor-speciﬁ c CD8+ T cells in expanded T cells obtained through scraping lymph 
nodes. The frequencies of Her-2/neu-speciﬁ c CD8+ T cells detected after scraping 
were comparable with those obtained through dissociation. This was conﬁ rmed 
using two different detection methods: MHC-I-binding tetramers and the IFN-c
ELISPOT assay. Signiﬁ cantly lower frequencies of Her-2/neu-speciﬁ c CD8+ T 
cells were detected in corresponding PBL samples. This is consistent with the 
idea that immunological responses against tumor antigens will preferentially occur 
in tumor-draining lymph nodes.25  
Scraping lymph nodes has several advantages over total dissociation of the 
specimens, in that the lymph node is not consumed in the dissociation process 
and can be further processed for routine histological examination. It might 
also be applied in vaccination studies or studies in which patients are treated 
with immunostimulating adjuvants (e.g., granulocyte-macrophage colony-
stimulating factor), to monitor T cell responses in local lymph nodes. Furthermore, 
scraping is faster and more convenient than dissociation of lymph nodes. However, 
it should always be performed by or in coordination with the pathologist so that 
deﬁ nitive histological examination of these lymph nodes is not compromised. 
In conclusion, scraping lymph nodes to obtain cells for functional and phenotypic 
analysis to determine the immunological responses in lymph nodes is feasible and 
seems to be comparable with cells obtained through dissociation of lymph nodes. 
Scraping may therefore be the solution to collect viable lymph node cells from 
tumor-draining lymph nodes and speciﬁ cally sentinel lymph nodes for phenotypic 
and functional analysis without compromising the diagnostic examination of these 
lymph nodes by pathologists.  
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Abstract 
The initial tumor-draining lymph node, the sentinel lymph node, not only 
constitutes the ﬁ rst expected site of micrometastasis, but also the ﬁ rst point of 
contact between tumor-associated antigens and the adaptive immune system. 
A tumor-induced decrease in the frequency and activation state of sentinel 
lymph node dendritic cells will impair the generation of effective antitumor 
T cell responses and increase the likelihood of metastatic spread. Here, we 
demonstrate that intradermal administration of granulocyte macrophage-
colony stimulating factor around the excision site of stage I primary melanoma 
tumors increases the number and activation state of dendritic cells in the 
paracortical areas of the sentinel lymph node and enhances their binding to 
T cells. We conclude that local treatment of melanoma patients with granulocyte-
macrophage colony-stimulating factor, before surgery, conditions the sentinel 
lymph node microenvironment to enhance mature dendritic cell recruitment 
and hypothesize that this may be more conducive to the generation of T cell-
mediated antitumor immunity. 
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Introduction 
Dendritic cells are bone marrow-derived antigen-presenting cells that are 
critical to the initiation of T cell-mediated immunity. In melanoma, skin-resident 
myeloid dendritic cells (i.e., the Langerhans Cells) take up and transport tumor-
associated antigens to tumor-draining lymph nodes.1,2 In order to subsequently 
activate melanoma-speciﬁ c T cells, the migrated Langerhans cells need to 
become activated (i.e., mature) and express high levels of co-stimulatory 
molecules, as well as appropriate chemokine receptors for their migration to 
the paracortical T cell areas of the tumor-draining lymph node.3 Melanoma 
is the most immunogenic tumor identiﬁ ed to date; tumor-associated antigen-
reactive T cells are detectable both in the blood and in tumor-draining lymph 
nodes from melanoma patients, and their frequency can be increased by 
speciﬁ c vaccination.4-6 This intrinsic immunogenicity may make melanoma 
lesions particularly amenable to therapeutic approaches aimed at strengthen-
ing tumor immune surveillance. High numbers of sufﬁ ciently activated dendritic 
cells in the lymphatic tumor-drainage catchment area are very important in this 
regard. Dendritic cell development and activation can both be frustrated by 
inhibitory factors commonly associated with melanoma.1,7,8 The degree of such 
immunosuppression in tumor-draining lymph nodes is directly related to their 
distance to the primary tumor. Indeed, the ﬁ rst lymph node to directly drain the 
primary tumor, the so-called sentinel lymph node, is the preferential site of early 
metastasis9-11 and shows the most pronounced immunological downregulation.12,13
The frequency of paracortical sentinel lymph node-dendritic cell is reduced, and 
most sentinel lymph node-dendritic cell lack dendritic morphology and display 
lower expression levels of costimulatory molecules as compared to non-sentinel 
lymph node-dendritic cell.12,13 Such a paralysis of dendritic cells in the ﬁ rst line 
of immunological defense may well facilitate the metastatic spread of melanoma 
cells to more distal tumor-draining lymph nodes.12,14 Local release of granulocyte 
macrophage-colony stimulating factor (GM-CSF) has previously been reported 
to result in enhanced recruitment of activated dendritic cells to draining lymph 
nodes in a murine model.15 Here, we demonstrate that intradermal injection of 
GM-CSF around the excision site of primary melanoma tumors increases the 
number and activation state of dendritic cells in the paracortical areas of the 
sentinel lymph node. A concomitant increase in dendritic cell-T cell clustering is 
indicative of intensiﬁ ed immune surveillance. These observations lend support 
to peri-operative local administration of GM-CSF as a valuable immunoadjuvant 
option in the treatment of early-stage melanoma.  
Materials and Methods 
Patients 
In this single-blinded Phase II study, twelve patients with stage I melanoma 
according to criteria of the American Joint Committee on Cancer (all patients 
with Breslow thickness <1.5 mm, aged 18-70 years), who were scheduled 
to undergo a sentinel lymph node procedure, were assigned randomly to 
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preoperative local administration of either recombinant human GM-CSF or 
saline. Patients who had undergone previous immunotherapy or chemotherapy 
were excluded as well as patients receiving immunosuppressive medication or 
suffering from any autoimmune disorder. The study was approved by the medical 
ethical committee of the VU University Medical Center and written informed 
consent was obtained from each patient before treatment. Patient characteristics 
are listed in TABLE 1. 
TABLE 1. Patient and SLN characteristics in the GM-CSF and saline control groups 
                   GM-CSF    Control     P value
Sex (M:F)              4:2       3:3       NS
Age (mean ±sd)            56 ±11     57 ±15     NS
Breslow thickness (mm; mean ±sd)    1.04 ±0.33   0.84 ±0.27   NS
Volumea SLN (mm3; mean ±sd)      1668 ±296   759 ±146    <0.05
Yield scraping (x106; mean ±sd)     69.6 ±23.8   20.4 ±5.69   NS
Positive SLN             0        0        NS 
aVolume: height x width x length 
Abbreviations: SLN, sentinel lymph node; NS, not signiﬁ cant; SD, standard deviation 
Triple-technique Sentinel Lymph Node procedure and GM-CSF administration  
On day 0, patients underwent a triple-technique sentinel lymph node procedure 
as described previously.11,16 In short, a lymphoscintigraphy was performed at 
least four hours prior to surgery to determine the lymphatic drainage pattern in 
a dynamic fashion. Just prior to surgery a blue inert dye was injected adjacent 
to the site of the primary melanoma excision. During surgery, guided by the blue 
staining of the draining lymphoid tissues and a hand-held gamma probe, the 
sentinel lymph node was positively identiﬁ ed, removed and, after isolation of 
viable sentinel lymph node cells, examined meticulously by the pathologist.17
Both patient groups received four daily intradermal injections directly adjacent 
to the scar of the primary melanoma excision, from day –3 until day 0 just prior 
to surgery, with either 3 µg per kg body-weight recombinant human GM-CSF 
(Leucomax, Schering Plough, Maarssen, the Netherlands), dissolved in 1.0 mL 
saline, or 1.0 mL plain saline. 
Isolation of viable Sentinel Lymph Node cells 
Immediately after removal, sentinel lymph nodes were collected in sterile 
ice-cold complete medium, comprising Iscove’s modiﬁ ed Dulbecco’s medium 
supplemented with 25 mmol/L HEPES buffer (BioWhittaker/CAMBREX, 
Verviers, Belgium) with 10% FCS, 50 IU/mL penicillin-streptomycin, 1.6 
mmol/L L-glutamine, and 0.05 mmol/L b-mercaptoethanol. Before routine 
histopathological examination of the sentinel lymph node, viable cells were 
isolated using a previously described cytological scraping method.18 In short, 
after measuring the size of the sentinel lymph node, it was bisected crosswise 
with a surgical scalpel and the cutting surface of the sentinel lymph node 
was scraped 10 times with a surgical blade (size no.22; Swann Morton Ltd., 
Shefﬁ eld, United Kingdom). Sentinel lymph node cells were rinsed from the 
blade with medium containing 0.1% DNAse I, 0.14% Collagenase A (Boehringer 
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Mannheim, Mannheim, Germany), and 5% FCS, incubated for 45 minutes at 
37°C, and subsequently placed in PBS with 5 mmol/L EDTA for 10 minutes on 
ice. Finally, the sentinel lymph node cells were washed twice in complete me-
dium, counted, and further processed.
Flowcytometry
Freshly isolated sentinel lymph node cells were directly stained with antibodies 
labeled with either phycoerythrin or ﬂ uorescein isothiocyanate, and analyzed by 
ﬂ owcytometry at 100,000 events per measurement, as previously described.18
Monoclonal antibodies against CD1a, CD14, CD86 (Pharmingen, San Diego, CA), 
CD40, and CD83 (Immunotech, Marseille, France) were used.
Immunocytochemistry
Cytospin preparations were acetone-ﬁ xed and stained immunocytochemically 
as described previously.18 Monoclonal antibodies against CD1a, CD3, CD14, 
CD86 (Becton Dickinson, San Jose, CA), CD40, CD83 (Immunotech, Marseille, 
France) and S100 (DAKO A/S, Glostrup, Denmark) were used. 
The number of positively stained dendritic cells and the number of T cells 
clustered per dendritic cell were determined with an interactive video 
morphometry system (Q-PRODIT, Leica, Cambridge, United Kingdom). The 
outer border of each cytospot was demarcated at a 100-fold magniﬁ cation, 
and 40 ﬁ elds of vision were randomly selected in an automated manner for 
subsequent evaluation.19 The total number of CD3+ T cells was counted in these 
40 ﬁ elds of vision and used to correct for cell density of the cytospots of each 
patient. In each ﬁ eld of vision, the number of dendritic cells was counted on 
the basis of positive staining of speciﬁ c markers and dendritic cell morphology. 
Furthermore, numbers of T cells directly clustered to the dendritic cells were 
counted. Results are listed as total number of dendritic cells, normalized per 600 
CD3+ T cells (i.e., the mean number of T cells detected per 40 ﬁ elds of vision), 
and a mean number of T cells clustered per dendritic cell.
Immunohistochemistry
Parafﬁ n sections were mounted on Superfrost Plus glass slides and dried 
overnight at 37°C. After deparafﬁ nation, the tissue sections were hydrated 
through decreasing (v/v) percentages of etomidate, and endogenous peroxidase 
was blocked with 0,1% hydrogen peroxide in methanol. Tissue sections were 
pre-treated with 10 mmol/L citrate (pH 6) in an autoclave for 21 minutes at 121°C 
[for CD14 (1:25), CD83 (1:25) and an isotype-matched control antibody] or in a 
microwave at 100°C for 10 minutes [CD1a (1:25) and CD68 (1:400; DAKO A/S)]. 
All antibodies (except CD68) were applied and incubated at room temperature 
for one hour. Detection and visualization were performed with the DAKO 
Chemmate Envision detection kit (DAKO A/S) according to manufacturers’ 
instructions. For the CD68 antibody, an automated immunostainer (Ventana, 
Tuscon, AZ) was used for all incubation, detection and visualization steps 
according to the manufacturers’ instructions. Sections were counterstained with 
haematoxylin, dehydrated, and mounted. Tonsillar tissue sections were used as 
positive control samples.  
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Statistical analysis 
Differences between patient study groups were analyzed using the two-sample 
Mann-Whitney U test and considered signiﬁ cant when P<0.05.
Results
Clinical observations
No signiﬁ cant differences in patient characteristics were observed between the 
two study groups (TABLE 1). Administration of recombinant human GM-CSF was 
well tolerated by all patients. Apart from minor musculoskeletal pain, mild fever, 
and general tiredness after the ﬁ rst injection in some patients, no signiﬁ cant side 
effects or skin abnormalities were observed. The sentinel lymph node contained 
no metastatic tumor cell deposits in any of the patients after routine pathological 
examination. The sentinel lymph nodes in the GM-CSF group were signiﬁ cantly 
larger in volume as compared to the control group (TABLE 1).
FIGURE 1 
Colocalization of CD1a- and CD83-
positive dendritic cells and of CD68 
and CD14 positive macrophages in 
sentinel lymph nodes. Positive cells in 
sentinel lymph node parafﬁ n sections 
are stained brown. 
A) CD1a- and CD83-positive cells 
are colocalized in the paracortical 
areas (top panels, magniﬁ cation 
25x) and have an irregular dendritic 
cell-like morphology (bottom panels, 
magniﬁ cation 400x). Representative 
data are shown from a patient who 
had received intradermal saline 
placebo injections.
B) CD68- and CD14-positive 
cells are both found in the 
(subcapsular) sinuses (top panels, 
magniﬁ cation 25x) and display a 
rounded macrophage-like morphology 
(bottom panels, magniﬁ cation 400x). 
Representative data are shown from a 
patient who had received intradermal 
GM-CSF injections.
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Also, higher sentinel lymph node cell yields were obtained after scraping the 
cutting surface of the sentinel lymph node from GM-CSF-administered patients, 
although this did not reach signiﬁ cance in comparison to the control group. 
Distribution and morphology of Sentinel Lymph Node-Dendritic Cells in situ
Immunohistochemical staining for the dendritic cell markers CD1a and CD83 
revealed colocalization of both markers in the paracortical regions (i.e., T cell 
areas) of the sentinel lymph node (FIGURE 1A). CD1a+ and CD83+ sentinel lymph 
node cells had a distinct irregular dendritic cell morphology (FIGURE 1A). In 
contrast to CD1a+ and CD83+ dendritic cells, cells positive for the monocyte/ 
macrophage markers CD14 and CD68 are preferentially colocalized in the 
marginal sinuses of the sentinel lymph node and displayed a more rounded 
macrophage-like morphology (FIGURE 1B). In none of the GM-CSF-administered 
patients, hyperplasia of lymphoid follicles or paracortical areas was observed, 
nor did the distribution patterns of the CD1a+/CD83+ dendritic cells or the 
CD14+/CD68+ macrophages inside the sentinel lymph node differ between the 
GM-CSF and the control group (data not shown).   
Increased frequency and activation state of Sentinel Lymph Node-Dendritic Cells 
upon intradermal administration of GM-CSF
Flowcytometric analysis showed a signiﬁ cantly increased frequency of CD1a+ 
sentinel lymph node-dendritic cells to be associated with GM-CSF adminis-
tration, while no such association was apparent for the frequency of CD14+ 
monocytes/ macrophages (FIGURE 2A). Mean percentages of CD1a+ sentinel 
lymph node-dendritic cells were 0.68% (range 0.31 to 1.03%) and 0.15% (range 
0.02 to 0.35%) for the GM-CSF and the control group, respectively (P<0.05). 
Of note, no CD1a/CD14 double-positive cells were detected, indicating that 
these markers deﬁ ned two distinct myeloid populations in the sentinel lymph 
node, i.e., CD1a+ dendritic cells and CD14+ macrophages. These data clearly 
demonstrate a speciﬁ c stimulatory effect of local GM-CSF on the migration and 
recruitment of dendritic cells to the draining lymph nodes. The CD1a+ sentinel 
lymph node-dendritic cells were selectively gated and analyzed for expression 
levels of dendritic cell activation markers (FIGURE 2B). Expression levels of the 
maturation marker CD83 and of the costimulatory markers CD86 and CD40 
were all signiﬁ cantly increased in the GM-CSF group as compared to the control 
group (FIGURE 2C), demonstrating an enhanced activation state of the sentinel lymph 
node-dendritic cell.  
Of note, neither in the GM-CSF-administered patients nor in the patients 
receiving saline injections, could any CD1a+/CD83- sentinel lymph node-
dendritic cell be detected, indicating the absence of immature Langerhans cells 
in the sentinel lymph node. Immunocytochemical analysis was in agreement 
with the ﬂ owcytometric data, showing signiﬁ cant and comparable increases in 
the frequency of CD1a+ sentinel lymph node-dendritic cells after intradermal 
recombinant human GM-CSF administration: from on average one dendritic 
cell per 600 CD3+ T cells in the control group (equaling about 0.15%) to 6 to 10 
DC per 600 T cells (1-1.5%) in the GM-CSF group (P<0.05, FIGURE 3A). Similar 
LO
C
A
L 
G
M
-C
S
F 
A
D
M
IN
IS
TR
AT
IO
N
 A
C
TI
VA
TE
S
 S
LN
-D
C
93
and signiﬁ cant increases were observed for the dendritic cell activation markers 
CD83, CD86, CD40, and S100 (all at P<0.05), but not for the macrophage/ 
monocyte marker CD14 (FIGURE 3A). Equal counts for CD1a and the dendritic cell 
activation markers reﬂ ect the mature state of the CD1a+ sentinel lymph node-
dendritic cells. 
FIGURE 2 
Flowcytometric analysis reveals increased frequencies and activation state of CD1a+ dendritic 
cells in melanoma sentinel lymph nodes upon local GM-CSF administration. A) Percentages 
of CD1a+ and CD14+ cells in sentinel lymph node single-cell suspensions in patients who 
received four consecutive daily intradermal injections of GM-CSF (GM-CSF) or of saline 
placebo (saline control). Horizontal bars represent mean percentages. B) CD1a+ sentinel lymph 
node-dendritic cells were gated [see dot plot scatter diagrams (CD1a/iso)] and analyzed for the 
expression of maturation markers (see the corresponding histograms for isotype control, CD83, 
CD86 and CD40). Expression of the indicated markers is listed as mean ﬂ uorescence (MFL). 
Data are shown from two representative patients, one receiving saline injections (control) and 
one receiving GM-CSF. C) MFL intensities obtained with isotype control monoclonal antibodies 
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or with monoclonal antibodies against CD83, CD86, or CD40, on CD1a+ sentinel lymph 
node-dendritic cells in patients receiving injections with saline placebo (control, n=6) or with 
GM-CSF (GM-CSF, n=6). Error bars represent SEM. All signiﬁ cant differences (P<0.05) are 
indicated by asterisks.
FIGURE 3 
Increased frequencies of mature dendritic cells in melanoma sentinel lymph nodes and increased 
T cell/sentinel lymph node-dendritic cell clustering upon local GM-CSF administration. 
A) Immunocytochemical analysis revealed higher numbers of mature sentinel lymph node-
dendritic cells in patients receiving GM-CSF (n=6) than in patients receiving saline (i.e. 
control, n=6), as judged by the number of dendritic cells positive for CD1a and positive for 
the maturation markers CD83, CD86, CD40, and S100. CD14+ macrophages were not 
signiﬁ cantly increased. Counts are based on the evaluation of 40 (100x) ﬁ elds of vision and 
corrected for the cell density of the cytospot by normalization in relation to the number of T cells 
in 40 ﬁ elds of vision (quantiﬁ ed by CD3 staining); expressed as number of dendritic cells per 
600 T cells. B) Clustering of T cells to S100+ sentinel lymph node-dendritic cells (magniﬁ ca-
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tion 400x). Results are shown for a representative control and GM-CSF-treated patient. C) 
Mean number of T cells clustered per dendritic cell or macrophage by staining of CD1a and 
the activation markers CD83, CD86, CD40, and S100, or the monocyte/macrophage marker 
CD14 and based on the evaluation of 40 (100x) ﬁ elds of vision. Error bars represent SEM. 
Asterisks denote signiﬁ cant differences between the saline control the GM-CSF treated patient 
groups (P<0.05).
On the sentinel lymph node cytospots clear sentinel lymph node-dendritic 
cell/T cell clusters (determined on the basis of CD3 positivity; data not shown) 
were observed in the samples from the patients that had received intradermal 
recombinant human GM-CSF (FIGURE 3B). Quantitation showed signiﬁ cantly 
higher numbers (four on average) of T cells in direct contact to sentinel lymph 
node-dendritic cells in GM-CSF-administered patients than in patients that had 
received intradermal saline injections (one T cell per sentinel lymph node-dendritic 
cell on average; FIGURE 3C). Again, this T cell clustering effect was found to be 
dendritic cell speciﬁ c because the numbers of T cells in direct contact to CD14+ 
macrophages was not increased by GM-CSF administration (FIGURE 3C). 
Discussion 
In this randomized trial, we have shown that short-term local administration of 
GM-CSF signiﬁ cantly increases the number and activation state of dendritic 
cells in the sentinel lymph nodes of stage I cutaneous melanomas. Although 
the study of non-sentinel lymph nodes in these patients would have provided 
valuable information on the speciﬁ city of the observed effects for sentinel lymph 
nodes, we were bound by restrictions from the local ethical committee and could 
not perform these comparative studies.  Previous reports, however, clearly 
demonstrated a preferential decrease in sentinel lymph node-dendritic cell 
frequency and maturation state as early as stage I of melanoma development.12,13
The fact that these inhibitory effects on dendritic cell activation and migration 
to the tumor-draining lymph node are directly related to the proximity of the 
primary tumor indicates the causative agents to be tumor-derived. Data from 
earlier studies suggest that IL-10 and gangliosides may be good candidates in 
this regard.7,8 Clearly, the crippling of dendritic cell functions in the principal 
nodes involved in immune surveillance will frustrate speciﬁ c T cell activation and 
likely increase the chance of tumor immune escape and metastasis.  
GM-CSF has powerful stimulatory in vivo effects on dendritic cell recruitment, 
activation, and survival.20 This makes it a prime candidate to test its modulatory 
effects on sentinel lymph node-dendritic cell numbers and on their activation 
state in a clinical setting. Evidence that systemic and long-term GM-CSF 
administration can increase tumor-draining lymph node-dendritic cell 
frequencies and improve clinical outcome was recently reported by us in patients 
with locally advanced breast cancer.21 Here, we demonstrate that in a relatively 
short period (four injections in four days) and in a localized fashion (intradermal 
injections around the tumor excision scar), the frequency of sentinel lymph node-
dendritic cells can be quadrupled and their phenotypic maturation state increased 
(as determined by a quantitative ﬂ ow cytometric method). This indicates 
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the applicability of GM-CSF administration in the treatment of early-stage 
melanoma. Previous reports of suppressed sentinel lymph node-dendritic cells 
in stage I melanoma12,13 suggest that this GM-CSF-induced upregulation of both 
sentinel lymph node-dendritic cell frequency and maturation state signiﬁ es a 
restoration of dendritic cell functions to more normal levels. Increased numbers 
of CD83+ dendritic cells inﬁ ltrating the paracortical areas of the sentinel lymph 
node upon GM-CSF administration indicate an enhanced migration of mature 
dendritic cells to the sentinel lymph node T cell zones, which has previously 
been reported to be CCR7 mediated.22,23 Interestingly, no CD1a+/CD83- 
immature dendritic cells were present in the single-cell suspensions of either the 
GM-CSF- or the saline-treated sentinel lymph node. In keeping with this, similar 
in situ densities and anatomic distributions were observed for both CD1a+ and 
CD83+ sentinel lymph node-dendritic cells by immunohistochemistry in both 
study groups. These ﬁ ndings seem to argue against the migration of immature 
CD83- dendritic cells to lymph nodes where they might effect T cell tolerance 
under steady-state and tumor conditions.24 Nevertheless, the GM-CSF-induced 
upregulation of the costimulatory molecules CD40 and CD86 described here is 
consistent with suboptimal sentinel lymph node-dendritic cell maturation in stage 
I melanoma patients.12,13
A previous study of dendritic cell-T cell interactions in intact lymph nodes has 
revealed protracted periods of binding between dendritic cells and T cells 
upon antigen recognition.25 Our ﬁ nding of a signiﬁ cant increase in the numbers 
of T cells bound to the sentinel lymph node-dendritic cells upon GM-CSF 
administration may well be a reﬂ ection of this phenomenon, as protracted 
binding of T cells to dendritic cells will increase the likelihood of ﬁ nding 
T cell-dendritic cell clusters at a given time. Thus, local peritumoral GM-CSF 
administration might lead to enhanced tumor-associated antigen presenta-
tion and T cell recruitment and activation in the sentinel lymph node. Indeed, 
our observation of GM-CSF-induced increases in sentinel lymph node size 
and cell numbers may also result from this enhanced T cell attraction and 
retention by activated sentinel lymph node-dendritic cells. In keeping with this, 
we have found evidence for speciﬁ c recruitment of tumor-speciﬁ c cytotoxic T 
lymphocytes (CTLs) to sentinel lymph nodes (Vuylsteke et al., manuscript in 
preparation). Peritumoral treatment with GM-CSF may be expected to facilitate 
the activation of tumor speciﬁ c CTLs, which was recently suggested to offer 
protection from the outgrowth of micrometastases.22 Nevertheless, the ﬁ nding 
of GM-CSF-induced increased numbers of tumor speciﬁ c-CTLs and a possible 
diminished outgrowth of micrometastases in the sentinel lymph node has yet to 
conﬁ rm this hypothesis. To this end, we are planning a larger prospective study, 
which should include patients with melanomas between 1 and 4 mm of Breslow 
thickness, who are not eligible for adjuvant therapy but who are at risk for occult 
nodal metastasis.16 Particularly these patients may beneﬁ t from local GM-CSF 
treatment because nodal metastases, despite offering a ready source of tumor-
associated antigens, may be expected to interfere with dendritic cell maturation 
and migration to the sentinel lymph node 26 and to thus interfere with proper 
anti-tumor CTL activation. GM-CSF may counteract these detrimental effects 
and prevent further metastatic spread and outgrowth. 
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Abstract
Purpose: Impaired immune functions in the sentinel lymph node (SLN) 
may facilitate early metastatic events during melanoma development. Local 
potentation of tumor-speciﬁ c T cell reactivity may be a valuable adjuvant 
treatment option.  
Experimental Design: We examined the effect of locally administered 
granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency 
of tumor-speciﬁ c CD8+ T cells in the SLN and blood of stage I melanoma. 
Twelve patients were randomly assigned to preoperative local administration of 
either recombinant human GM-CSF or NaCl 0.9%. CD8+ T cells from SLN and 
peripheral blood were tested for reactivity in an IFNc ELISPOT assay against 
the full-length MART-1 antigen and a number of HLA-A1, HLA-A2, and HLA-A3-
restricted epitopes derived from a range of melanoma-associated antigens.  
Results: Melanoma-speciﬁ c CD8+ T cell response rates in the SLN were one 
of six for the control group and four of six for the GM-CSF-administered group. 
Only one patient had detectable tumor-speciﬁ c CD8+ T cells in the blood, but 
at lower frequencies than in the SLN. All patients with detectable tumor-speciﬁ c 
CD8+ T cells had a percentage of CD1a+ SLN-dendritic cells (DC) above the 
median (i.e., 0.33%). This association between above median CD1a+ SLN-DC 
frequencies and tumor antigen-speciﬁ c CD8+ T cell reactivity was signiﬁ cant in a 
two-sided Fisher’s Exact Test (P=0.015). 
Conclusions: Locally primed anti tumor T cell responses in the SLN are 
detectable as early as stage I of melanoma development and may be enhanced 
by GM-CSF-induced increases in SLN-DC frequencies.   
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Introduction 
Melanoma is the most immunogenic tumor identiﬁ ed to date, and as such, 
it is a prime candidate for the implementation of novel immunotherapeutic 
approaches. In vivo primed T cells reactive to a wide range of melanoma-speciﬁ c 
tumor-associated antigens are detectable in tumors, in tumor-draining lymph 
nodes, and in the blood of patients with melanoma, and most importantly, their 
frequency can be increased by tumor-associated antigen-speciﬁ c vaccination.1-8
T cell inﬁ ltration of melanoma tumor ﬁ elds has been identiﬁ ed as an important 
prognostic factor.9 Indeed, we recently found that in patients with late stage 
melanoma, tumor-speciﬁ c tumor-inﬁ ltrating CD8+ T cells may afford a survival 
advantage, whereas circulating tumor-speciﬁ c CD8+ T cells do not.7,10 These 
ﬁ ndings offer a clear indication of the ability of effector T cells to control 
melanoma development locally.  
For the generation of an effective anti melanoma T cell response, high numbers 
of sufﬁ ciently activated myeloid dendritic cells (MDC) are essential.11 MDC take 
up antigens from the tumor tissue environment, and after sufﬁ cient activation, 
transport these to draining lymph nodes for presentation and activation of 
speciﬁ c T cells. Unfortunately, immune effector functions in tumor-conditioned 
microenvironments are often disturbed, resulting in tolerance rather than 
immune activation. Speciﬁ cally, MDC differentiation and activation can both be 
frustrated by melanoma-derived suppressive factors (e.g., interleukin-10 and 
gangliosides).12-15 The ﬁ rst lymph node to directly drain the primary tumor, the 
so-called sentinel lymph node (SLN), is the preferred site of early metastasis 16-18
and takes the brunt of the tumor-induced immunosuppression.15 In early stages 
of melanoma development, SLNs show signs of profound MDC suppression, 
both in terms of numbers and of phenotypic activation.19,20 This will likely cripple 
speciﬁ c T cell activation, increasing the chances of tumor immune escape and 
metastatic spread.20,21  
We recently reported on the dendritic cell (DC)-modulatory effects of 
intradermal injections of granulocyte macrophage-colony stimulating factor 
(GM-CSF) around the excision site of stage I melanoma tumors, resulting in 
signiﬁ cantly increased numbers and activation state of MDC in the paracortical 
T cell areas of the SLN.22 In view of the critical role of MDC in the initiation of T 
cell-mediated immunity, we hypothesized that potentiated MDC functions in the 
GM-CSF-administered group might be reﬂ ected in a higher number of tumor-
speciﬁ c CD8+ T cells in the SLN. This hypothesis is indeed supported by our 
ﬁ nding that local priming of melanoma-speciﬁ c CD8+ T cells, as early as stage 
I of melanoma development, is associated with a high MDC content of the SLN, 
as observed in patients receiving locally administered GM-CSF. We conclude 
that local GM-CSF administration may offer a valuable adjuvant therapy option 
for early-stage melanoma patients, aimed at the control of early metastatic events. 
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Materials and Methods  
Patients and GM-CSF administration
Twelve patients with stage I melanoma according to criteria of the American 
Joint Committee on Cancer (AJCC), scheduled to undergo a SLN procedure 
were assigned randomly to preoperative local administration of either 
recombinant human GM-CSF or NaCl 0.9% 22. All patients qualiﬁ ed for a SLN 
procedure, with Breslow thickness >1mm or with Breslow thickness < 1mm, but 
with Clark level >IV, regression, ulceration, or other high-risk factors.23 Patients 
who had undergone previous immunotherapy or chemotherapy were excluded, 
as well as patients using immunosuppressive medication, or suffering from any 
autoimmune disorder. The study was approved by the medical ethical committee 
of the VU University Medical Center and written informed consent was obtained 
from each patient before treatment. Patient characteristics are listed in TABLE 1. 
Both patient groups received daily intradermal injections, with either 3 µg 
per kg body weight rhGM-CSF (Leucomax; Schering Plough, Maarssen, the 
Netherlands), dissolved in 1.0 mL NaCl 0.9%, or 1.0 mL plain NaCl 0.9%. These 
injections were given directly adjacent to the scar of the primary melanoma 
excision, from day -3 until day 0 (just prior to surgery). 
TABLE 1. Patient and SLN characteristics
                      GM-CSF   Control    P value  
Sex (M/F)                 4/2      3/3      0.575*  
Age (mean ± SD)              56 ±11    57 ±15    0.747*  
Breslow thickness (mm, mean ± SD)      1.04 ±0.33  0.84 ±0.27   0.262*  
Positive SLN                 0       0       1.000*  
Time from primary excision to SLN (day, mean ± SD)   49 ±32    66 ±50    0.470*  
HLA-A1                  2 of 6     1 of 6     1.000** 
HLA-A2                  3 of 6     1 of 6     0.545** 
HLA-A3                  0 of 6     3 of 6     0.182**
*Two-sample Mann-Whitney U test. 
**Two-tailed Fisher’s exact test. 
           
Triple-technique SLN procedure and isolation of viable SLN cells
On day 0, patients underwent a triple-technique SLN procedure as described 
previously.24,25 In short, the day before surgery patients underwent a dynamic 
and static lymphoscintigraphy to determine the lymphatic drainage pattern. Just 
prior to surgery, a blue inert dye was injected adjacent to the site of the primary 
melanoma excision. During surgery, guided by the blue staining of the drain-
ing tissues, the radioactivity and the preoperatively made lymphoscintigraphy, 
SLNs were removed. Immediately after removal the SLN was collected in sterile 
ice-cold complete medium, comprising of Iscove’s modiﬁ ed Dulbecco’s medium 
supplemented with 25 mmol/L Hepes buffer (BioWhittaker, Verviers, Belgium), 
50 IU/mL penicillin-streptomycin, 1.6 mmol/L L-glutamine, and 0.05 mmol/L b-
mercaptoethanol, supplemented with 10% FCS. Before routine histopathological 
examination of the SLN, viable cells were isolated using a previously described 
cytologic scraping method.26 In short, after measuring the size of the SLN, it was 
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bisected crosswise and the cutting surface of the SLN was scraped 10 times 
with a surgical blade (size no. 22; Swann Morton Ltd. England). SLN cells were 
rinsed from the blade with Iscove’s modiﬁ ed Dulbecco’s medium containing 
0.1% DNase I, 0.14% collagenase A (Boehringer, Mannheim, Germany), and 
5% FCS, incubated for 45 minutes at 37°C, and subsequently in PBS with 5 
mmol/L EDTA for 10 minutes on ice. Finally, the SLN cells were washed twice in 
complete medium, counted, and further processed. After isolation of viable SLN 
cells, the bisected SLN was examined by the pathologist according to routine 
diagnostic procedures.27
Isolation of peripheral blood mononuclear cells and ﬂ ow cytometry  
On day 0, before surgery, 40 to 50 mL of blood was drawn from each patient. 
Peripheral bloos mononuclear cells (PBMC) were isolated from heparinized 
blood by density gradient centrifugation using Lymphoprep (Nycomed Pharma 
AS, Oslo, Norway). Cells were washed twice with sterile PBS with 0.1% bovine 
serum albumin. To determine the patients’ HLA-A1, HLA-A2, or HLA-A3 status, 
PBMC were stained with monoclonal antibodies, BB7.2 and MA 2.1 (HLA-A2), 
GAP A3 (HLA-A3), (American Tissue Culture Collection, Rockville, MD), and 
A1/A36 (HLA-A1, One Lambda, Canuga Park, CA), whereas CD4/CD8 status 
was checked with directly labeled anti-CD4 and anti-CD8 (BD, San Jose, 
CA). Freshly isolated SLN cells were directly stained with PE-labeled CD1a 
(PharMingen, San Diego, CA) and FITC-labeled CD83 (Immunotech, Marseille, 
France) antibodies and analyzed by ﬂ ow cytometry at 100,000 events per 
measurement, as previously described.26
T cell expansion
To obtain sufﬁ cient cells for functional analysis, and for the sake of uniformity, 
T cells from both the SLN and PBMC were expanded as described previously.26
Cells were incubated for 1 hour on ice with 2 µg anti-CD3 and 0.4 µg anti-CD28 
per 1 x 106 cells (kindly provided by Dr. René van Lier, CLB, Amsterdam, the 
Netherlands) in 100 to 200 µL complete medium with 5% FCS. After incubation 
and washing, the cells were placed on 24-well plates, coated with afﬁ nity-
puriﬁ ed goat anti-mouse immunoglobulin (1:100; Dako, Glostrup, Denmark) 
in complete medium with 10% human pooled serum (CLB) at a concentra-
tion of 1 x 106 cells/mL/well for 1 hour at 4°C. The cells were cultured for 48 
hours, in a humidiﬁ ed 5% CO2 incubator at 37°C. After 48 hours the cells were 
resuspended and the contents of each well was divided over four new uncoated 
wells at a volume of 250 µL per well. To each new well 750 µL fresh culture me-
dium was added and rhIL-2 (CLB, Amsterdam, the Netherlands) to a ﬁ nal con-
centration of 10 IU/ml. The cells were cultured for another ﬁ ve days, after which 
they were harvested and counted. This expansion cycle was repeated at least 
once more or until sufﬁ cient numbers were obtained: T cells from four patients in 
the control group and ﬁ ve patients in the GM-CSF administered group under-
went two expansion cycles, one patient each from the control and the GM-CSF-
administered group underwent three expansion cycles, whereas one patient in the 
control group underwent four expansion cycles. Finally, the expanded T cells were 
harvested, counted, frozen, and stored for functional analysis at a later date.  
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Culture and adenovirus infection of monocyte-derived dendritic cells 
Monocyte-derived dendritic cells (MoDC) were generated according to previously 
described methods.28 Plastic-adherent monocytes from 3 to 5 x106 PBMC 
per mL CM were cultured for 7 days in complete medium with 10% FCS in 
the presence of 100 ng/mL GM-CSF (Schering Plough) and 1000 IU/mL 
interleukin-4 (CLB). The DC phenotype (CD1a+/CD14-) was conﬁ rmed by ﬂ ow 
cytometry as described.29 For each patient, autologous MoDC were infected 
with E1-deleted adenoviral (type 5) vectors encoding the melanoma-associated 
Mart-1 protein (Ad-Mart-1) or (as a negative control) green ﬂ uorescent protein 
(Ad-GFP); (both kindly provided by Dr D.T. Curiel, University of Alabama, 
Birmingham, AL). MoDC were infected at a multiplicity of infection of 100, in 
a CD40-targeted fashion, using a bispeciﬁ c antibody conjugate, as previously 
described by Tillman et al.29 The day following infection, MoDC were washed 
and further used in a CD8+ T cell activation assay.  
Peptide loading of MoDC and T2 stimulator cells
A panel of HLA-A1, HLA-A2, or HLA-A3-binding peptides, derived from various 
melanoma-associated tumor antigens and containing previously described CD8+ 
T cell epitopes (TABLE 2), was used for CD8+ T cell reactivity testing. Peptide-
loaded T2 cells were employed as stimulator cells in ELISPOT readouts for 
HLA-A2+ patients. Additional inclusion of patients with HLA-A1+ and HLA-A3+ 
necessitated the use of immature autologous MoDC for this purpose as HLA-A1- 
or HLA-A3-transduced T2 cell lines were not available to us at that time. T2 cells 
or MoDC were loaded overnight in serum-free medium with b2-microglobulin 
(5µg/mL, Sigma, St. Louis, MO) and melanoma-associated or control peptides 
(50 µg/mL) at 37°C in a humidiﬁ ed 5% CO2 incubator. For A2- and A3-binding 
melanoma CD8+ T cell peptides, A2- and A3-binding control peptides were 
used, derived from the human papillomavirus type-16 E7 and Bcr-abl protein 
sequences, respectively. As no appropriate control peptide was available for 
A1-binding melanoma peptides, unloaded MoDC were used as negative control 
stimulators. After overnight pulsing, stimulator cells were washed, counted and 
used for CD8+ T cell activation testing.  
TABLE 2. Peptides used for CD8+ T cell IFNc ELISPOT analysis 
Binding to    CD8+ T cell epitope and tumor antigen origin
HLA-A1      Tyrosinase 145-156
         Tyrosinase 243-251
HLA-A2     Mart-1 26-35
         Tyrosinase 369-377
         gp-100 154-162
         Mage-A3
         NY-ESO 157-165
HLA-A3      Mage-A1 96-104
         gp-100 17-25 
  
C
H
A
P
TE
R
 6
108
Melanoma-speciﬁ c ex vivo CD8+ T cell activation and IFNc ELISPOT analysis 
To functionally test the expanded CD8+ T cells for melanoma-speciﬁ c reactivity, 
an IFNc ELISPOT assay was done.30,31 As effector cells, anti-CD3/anti-CD28-
stimulated and expanded CD8+ T cells from the SLN and PBMC were used. 
CD8+ T cells were isolated from the expanded T cell population using the 
untouched CD8+ mini-MACS selection kit, according to the manufacturer’s 
instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). After isolation, 
CD8+ T cells were washed and resuspended in complete medium with 10% 
FCS and added directly to the transduced or peptide-loaded MoDC or T2 
stimulator cells in anti-IFNc precoated Multiscreen 96-well ﬁ ltration plates 
(Millipore, Molsheim, France). Plates were seeded with 10,000 stimulator 
(S)-cells (MoDC or T2 cells) per well and 100,000 or 50,000 effector (E) 
CD8+ T cells, resulting in E/S ratios of 10:1 and 5:1, respectively. Assays with 
Adenoviral-transduced MoDC were tested in quadruplicate. All other assays 
were tested in quadruplicate where possible, but at least in duplicate at each 
of the E/S ratios. After overnight incubation (18 hours), the cells were ﬂ icked 
off and an ELISPOT assay was done as previously described 32, using a 
commercially available anti-IFNc monoclonal antibody pair (Mabtech, Nacka, 
Sweden). After development of the plates, spots were counted by an automated 
ELISPOT reader (AID Diagnostika, Strassberg, Germany). CD8+ T cell 
ELISPOT activity was expressed either as the number of spots per well or as 
the number of speciﬁ c effector CD8+ T cells per 1x106 CD8+ T cells (obtained 
by subtracting frequencies of spot-forming CD8+ T cells in control conditions 
from the spot-forming CD8+ T cell frequencies in the test conditions, based 
on results from the highest E/S ratio, 10:1). ELISPOT CD8+ T cell responses 
were considered positive when (a) the number of spots in the test condition 
was signiﬁ cantly higher than the number of spots in the control condition in an 
unpaired two-sided Student’s t test (P<0.05), comparing values obtained from 
both of the tested E/S ratios and recalculating the number of spots per 100,000 
CD8+ T cells, (b) the mean number of spots for both E/S ratios of the test 
condition exceeded the number of spots for the corresponding E/S ratios of the 
control condition by at least 2-fold, and (c) the absolute difference in number of 
spots between the test and control condition in the highest E/S ratio (10:1) was 
at least ﬁ ve. 
HLA-A2-tetramer binding analysis
In all HLA-A2+ patients (n=4), expanded T cells were stained with HLA-A2/
peptide tetramers, comprising the same HLA-A2-binding melanoma-associated 
peptides that were used in the ELISPOT analysis (TABLE 2). APC-conjugated 
HLA-A*0201 tetramers were generated as described previously.7,33,34 Expanded 
T cells from PBMC and SLN (consisting of only T cells, as checked by ﬂ ow 
cytometric analysis with a cocktail of lineage-speciﬁ c monoclonal antibodies 
against CD14, CD15, CD16, CD56 and CD19; BD Biosciences, San Jose, CA) 
were stained with the APC-labeled tetramers (40 µg/mL) by incubation for 15 
minutes in CM at 37°C in a humidiﬁ ed 5% CO2 atmosphere, after which, the 
cells were washed and kept at 4°C. The cells were subsequently analyzed by 
ﬂ ow cytometry, double-staining (after tetramer binding) for CD8 (PE-labeled, 
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BD Biosciences) and gating out dead cells by propidium iodide uptake. The total 
number of analyzed T cells was at least 1,000,000 events per measurement, as a 
detection limit of 0.01% of CD8+ T cells was assumed. 
Statistical analysis
Differences in patient characteristics between test groups were analyzed using 
the two-sample Mann-Whitney U test and in HLA-status and T cell response rates 
using the Fisher’s Exact test. Differences were considered signiﬁ cant when P<0.05. 
Results 
Patients
There were no signiﬁ cant differences in patient characteristics between the GM-
CSF and the control group (TABLE 1). Intradermal administration of GM-CSF was 
well tolerated and none of the SLN showed metastatic tumor cells on routine 
histopathological testing. HLA typing was done using ﬂ ow cytometry, and in both 
treatment groups two patients were negative for either HLA-A1, HLA-A2, or HLA-
A3, which made them ineligible for IFNc ELISPOT testing and HLA-tetramer 
staining for melanoma-speciﬁ c epitopes restricted by these HLA types. 
FIGURE 1. 
CD8+ T cell responses against full-length Mart-1 were tested in a 1-day IFNc ELISPOT analysis 
in SLN and PB from patients with stage I melanoma receiving intradermally injected NaCl 
0.9% (no GM-CSF) or GM-CSF (+GM-CSF). Elispot reactivity is expressed as the number of 
spots per 100,000 CD8+ effector T cells. For each patient, autologous MoDC were infected 
with an adenoviral type 5 vector encoding melanoma associated full-length Mart-1 (Ad-Mart-
1; closed columns) or with an adenovirus encoding green ﬂ uorescent protein (Ad-GFP; negative 
control; open columns), and used to stimulate expanded and isolated CD8+ T cells. Two GM-CSF-
administered patients (patient 8 and 11) showed a positive Mart-1-speciﬁ c CD8+ T cell response 
in the SLN [speciﬁ c CD8+ T cell frequencies (per 1x106 total CD8+ T cells) are listed].
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FIGURE 2.
Melanoma-speciﬁ c CD8+ T cells from patients with stage I melanoma recognize HLA-A1- and 
HLA-A2-binding epitopes from multiple melanoma-associated antigens; responses are more 
prominent in the SLN than in PB. A, IFNc Elispot reactivity is expressed as the number of spots 
per 100,000 CD8+ effector T cells. CD8+ T cell responses against peptides derived from 
various melanoma-associated antigens were tested in a 1-day ELISPOT analysis in SLN and PB. 
Melanoma-speciﬁ c and control peptides were loaded onto autologous MoDC (in case of HLA-A1 
or HLA-A3 positivity) or T2 cells (in case of HLA-A2 positivity), which were used to stimulate 
expanded and isolated CD8+ T cells. Data are only shown from positively responding patients; 
patient number, treatment allocation, and HLA-status are indicated. Positive responses (against 
the listed epitopes) are denoted by the calculated speciﬁ c CD8+ T cell frequencies (per 1x106 
total CD8+ T cells). B, in HLA-A2+ patients, expanded T cells from sentinel lymph nodes (SLN) 
were stained with HLA-A2/peptide tetramers, comprising the same HLA-A2-binding melanoma-
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associated peptides that were previously tested in the ELISPOT analysis. Cells were analyzed 
by ﬂ ow cytometry after double staining for CD8 and HLA-A2 tetramers; results are shown for 
patient 9, who previously did not respond in the IFNc ELISPOT assay to any of the indicated 
epitopes from Mart-1, tyrosinase, GP100, MAGE-A3, and NY-ESO and for patient 12, who 
previously responded to the epitopes derived from Mart-1, tyrosinase, GP100, and NY-ESO 
(A). Tetramer-binding CD8+ T cell frequencies (per 1x106 total CD8+ T cells; detection limit 
at 100) are listed (ND, not detectable). C, for all three positively responding HLA-A2+ patients 
melanoma-speciﬁ c CD8+ T cell reactivity determined by IFNc ELISPOT-assay (open columns) 
could be conﬁ rmed by HLA-A2-tetramer binding analysis (closed columns), although not for all 
tested epitopes. Nor were the calculated frequencies of speciﬁ c CD8+ T cells (per 1x106 total 
CD8+ T cells) always equivalent between both methods (ND, not detectable).
CD8+ T cell reactivity in the SLN and peripheral blood
T cell responses against Mart-1 and the tested melanoma peptides (TABLE 2)
were evaluated by IFNc ELISPOT assay. So as not to interfere with routine 
diagnostic procedures and to ensure sufﬁ cient numbers of T cells for functional 
analyses, T cells were nonspeciﬁ cally expanded by anti-CD3 and anti-CD28 
stimulation, after which untouched CD8+ T cells were isolated by negative 
selection, using a magnetic bead cocktail, and tested overnight.26 The number 
of required expansion rounds for sufﬁ cient yields of CD8+ T cells was not 
signiﬁ cantly different between the control and the GM-CSF-administrated 
group. Also, the mean preexpansion and postexpansion CD4/CD8 ratios were 
equivalent for the control group (preexpansion CD4/CD8 ratio, 7.33 ± 3.94; 
postexpansion CD4/CD8 ratio, 17.0 ± 14.3) and the GM-CSF-administered group 
(preexpansion CD4/CD8 ratio, 8.03 ± 4.67; postexpansion CD4/CD8 ratio, 16.2 
± 14.5). CD8+ T cell responses against Mart-1 were evaluated independently of 
HLA status for all patients, using autologous MoDC infected with an adenoviral 
vector encoding full-length Mart-1. Two GM-CSF-administered patients, but 
none of the NaCl 0.9%-administered patients, showed a positive Mart-1-speciﬁ c 
SLN CD8+ T cell response (FIGURE 1). This was not signiﬁ cant in a two-sided 
Fisher’s exact test (P=0.227). 
CD8+ T cell reactivity against deﬁ ned melanoma epitopes was tested in the 
HLA-A1, HLA-A2, or HLA-A3-positive patients and the obtained response rates 
in the SLN were one of four for the control group and three of four for the 
GM-CSF-administered group. Results for the positively responding patients, 
including the calculated speciﬁ c CD8+ T cell frequencies, are shown in FIGURE 2A. 
One GM-CSF-administered patient (patient 8) showed a T cell response against 
both full-length Mart-1 and melanoma peptides (including the HLA-A2-restricted 
peptide Mart-1 26-35; FIGURE 2A). Overall SLN CD8+ T cell response rates, to 
either full-length Mart-1 or the melanoma-associated peptides  were one of 
six for the control group and four of six for the GM-CSF-administered group 
(TABLE 3A). Higher melanoma-specific CD8+ T cell reactivity was consistently 
found in the SLN than in peripheral blood (PB). Only one patient (patient 6) 
showed any speciﬁ c CD8+ T cell reactivity in the peripheral blood (FIGURE 2A).   
For all HLA-A2 positive patients (n=4), HLA-A2-tetramer binding analysis was 
also performed. Cells were analyzed by ﬂ ow cytometry after double staining for 
CD8 and HLA-A2 tetramers [show-cased in FIGURE 2B for patients 9 (a negative 
responder in the ELISPOT assay) and patient 12 (a positive responder)]. 
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A detection limit of 0.01% was assumed and HLA-A2 tetramer+ populations 
exceeding this percentage of the total tested CD8+ T cell population were 
considered to signal positive reactivity against a given epitope. Even though 
the detected frequencies were not always equivalent, melanoma-speciﬁ c 
CD8+ T cell reactivity as determined by IFNc ELISPOT assay, could generally 
be conﬁ rmed for all three positively responding HLA-A2+ patients by HLA-
A2-tetramer binding analysis (FIGURE 2C). Of the 17 peptide tests carried out 
between the four HLA-A2+ donors, CD8+ T cell reactivity was found both with 
ELISPOT and by tetramer-binding in seven tests, no reactivity was found with 
either method in eight tests, whereas ELISPOT reactivity was found which could 
not be conﬁ rmed by tetramer binding in two instances (overall concordance 
between tests, 88%).   
FIGURE 3.
High SLN-MDC frequencies correlate to melanoma-speciﬁ c CD8+ T cell reactivity. The GM-
CSF (+)treated and NaCl 0.9% (–) treated patients are indicated (patient numbers listed) in 
relation to CD8+ T cell reactivity (+, positive ELISPOT response against at least one of the 
tested tumor antigen epitopes) and the frequency (% of total SLN leukocytes) of CD1a+ SLN-MDC.
CD1a+ SLN-MDC content in relation to melanoma-speciﬁ c CD8+ T cell reactivity
Previously, we found a signiﬁ cant increase in the frequency of mature CD1a+ CD
SLN-MDC after GM-CSF administration.22 Mean percentages of SLN-MDC 
were 0.68% in the GM-CSF group and 0.15% in the control group (P=0.006). 
When patients were classiﬁ ed according to the percentage of CD1a+ SLN-MDC, 
an association with positive melanoma antigen-speciﬁ c CD8+ T cell reactivity 
became apparent (FIGURE 3). Melanoma-speciﬁ c CD8+ T cell reactivity was 
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found in ﬁ ve of six patients with a percentage of SLN-MDC above the median 
(i.e., 0.33% SLN-MDC-based on all 12 tested patients), whereas no reactivity 
was detected in any of the patients with a percentage of SLN-MDC below the 
median (TABLE 3B). This T cell reactivity was signiﬁ cant in a two-sided Fisher’s 
exact test (P=0.015). 
TABLE 3. CD8+ T cell reactivity rates in SLN and PB of the patients tested for stage I 
melanoma.
A) NaCl 0.9 % or GM-CSF-administration   Control        GM-CSF
                      SLN   PB    SLN    PB
Ad-Mart-1                 0 of 6   0 of 6   2 of 6   0 of 6  
CD8+ T cel peptides             1 of 4   1 of 4   3 of 4   0 of 4 
Overall CD8+ T cell reactivity         1 of 6   1 of 6    4 of 6   0 of 6
B) CD1a+ SLN-DC content          <0.33% SLN-DC*   >0.33% SLN-DC
                      SLN   PB    SLN   PB
Ad-Mart-1                 0 of 6   0 of 6   2 of 6   0 of 6  
CD8+ T cel peptides             0 of 3   0 of 3   4 of 5   1 of 5  
Overall CD8+ T cell reactivity         0 of 6**  0 of 6   5 of 6   1 of 6
*SLN-DC rate: percentage CD1a+ cells of total SLN cell population; overall median SLN-DC 
rate=0.33%
**Signiﬁ cantly lower than the corresponding SLN CD8+ T cell reactivity rate in the “>0.33% 
SLN-DC” group (5 of 6) in a two-sided Fisher’s exact test (P=0.015)
Discussion
Cutaneous melanoma is the most aggressive type of skin cancer, for which 
complete surgical excision at an early stage remains the only curative 
treatment option. Adjuvant therapy options are limited and show no survival 
beneﬁ ts. Naturally occurring melanoma-speciﬁ c T cell responses have mostly 
been described in patients with advanced-stage melanoma, but are already 
detectable in the early stages of melanoma development.35 This underlines the 
immunogenicity of this particular tumor type and raises the possibility to boost 
these early immune responses by novel immunotherapeutic approaches in order 
to curb early metastatic events. Unfortunately, melanoma-inﬁ ltrating T cells and 
T cells in melanoma SLN have often been described to be in a state of tolerance 
due to tumor-induced immune suppression.5,36 This is effected both indirectly 
at the level of DC and their interactions with T cells, and directly on the T cells 
themselves.37,38 As shown in adoptive transfer studies, this state of functional 
tolerance is reversible in vitro and after activation and expansion, tumor-derived 
T cells can mediate signiﬁ cant tumor regression in patients with refractory 
melanoma.39-41 DC-based vaccination studies in advanced-stage melanoma have 
also resulted in long-lasting anti-melanoma T cell responses but generally with 
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limited clinical effects.35,42 The ability to generate or boost melanoma-speciﬁ c 
T cell responses in vivo and at earlier, more localized stages of melanoma 
development, might have clinical beneﬁ t through the clearance of early occurring 
micrometastases.  
Lymphatic mapping and selective SLN excision in patients with melanoma is 
a minimally invasive procedure, which allows for the identiﬁ cation of patients 
at-risk for lymph node metastasis who should undergo a full therapeutic 
tumor-draining lymph node dissection. Recent studies have conﬁ rmed the 
SLN procedure to be safe and offers a possible survival beneﬁ t.23,24,43 Routine 
application of this procedure in patients with early stage melanoma presents 
a unique translational setting to study adjuvant therapies in vivo aimed at 
potentiation of immune reactivity within the SLN. We therefore set up a small-
scale clinical trial to investigate the effects of GM-CSF, injected around the scar 
of the previously removed primary melanoma, on the SLN immune status.  
We hypothesized that a superior activation state of MDC in the melanoma SLN 
would be effected through the local administration of GM-CSF, and that such a 
microenvironment would be more conducive to the generation of T cell-mediated 
anti-tumor immunity.44,45 We previously reported a signiﬁ cant increase in the 
number, maturation, and activation state of CD1a+ SLN-MDC after local GM-
CSF treatment.22  We also found a signiﬁ cant increase in the numbers of T cells 
bound to the SLN-DC upon GM-CSF administration and concluded that this 
might well be a reﬂ ection of protracted periods of binding between DC and T 
cells upon speciﬁ c antigen recognition. In keeping with this, we now report that 
melanoma-speciﬁ c CD8+ T cell response rates were higher in the GM-CSF-
administered patients and correlated with CD1a+ SLN-MDC content. Moreover, 
a more robust melanoma-speciﬁ c CD8+ T cell reactivity was observed in the 
SLN of the stage I melanoma patients compared with the peripheral blood.   
To investigate melanoma-speciﬁ c CD8+ T cell response rates in the SLN, 
viable T cells were obtained by scraping the cutting surface of bisected SLN. 
Previous validation of this technique showed that the viabilities and phenotypic 
characteristics of SLN cells obtained by scraping were entirely comparable to 
SLN cells obtained by dissociation of the total lymph node.26,46 T cell function-
ality was also comparable between both methods, with equal T cell expansion 
factors and similar frequencies of CD8+ T cells speciﬁ cally recognizing the M1 
matrix protein of Inﬂ uenza haemophilus or the tumor antigen Her-2/neu.26  
To facilitate standardized functional testing of tumor-speciﬁ c CD8+ T cells 
from all SLN samples, polyclonal T cell expansion was required. The employed 
polyclonal expansion method was previously shown to efﬁ ciently induce the 
proliferation of tumor-speciﬁ c T cells from tumor-draining lymph nodes, while 
maintaining speciﬁ city at the clonal level, even after 3 months of culture.47,48  
The number of HLA-A2-positive patients was more prevalent in the GM-CSF 
cohort, with three HLA-A2-positive patients in the GM-CSF- and only one in the 
saline-administered patient group. As this was a relatively small study, it was 
important to, as much as possible, avoid any bias in the T cell readouts that 
might result from this imbalance in HLA-A2 status between the two test groups. 
We therefore also included HLA-A1 and HLA-A3 binding melanoma antigen-
derived epitopes in our panel to enable us to also test HLA-A1+ and HLA-A3+ 
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patients. This resulted in a more balanced distribution with four evaluable patients 
in both test groups. Although more evaluable peptides were available for HLA-
A2 (TABLE 1), the number of peptides tested per patient was not solely dictated 
by HLA status but by the number CD8+ T cells that were isolated upon T cell 
expansion as well. Overall, the total number of ELISPOT assays per group was 
balanced with 16 peptides tested in four GM-CSF-administered patients and 
13 peptides tested in four saline-administered patients. Of note, in a separate 
study carried out subsequent to this trial, we have tested six HLA-A2+ stage-I/II 
melanoma patients that were similarly administered saline, and none of these 
displayed any reactivity against the same panel of tested peptides used in this 
study. This supports our assumption that the under-representation of HLA-A2+ 
patients in the saline control group of this study is not related to the lack of 
detection of tumor-speciﬁ c CTL reactivity in this group. Moreover, as a measure 
of CTL reactivity independent of HLA status, we also included full-length MART-1 
in our assays.  
The higher melanoma-speciﬁ c CD8+ T cell reactivity rate found in the SLN 
compared with the peripheral blood is consistent with the literature 1,49, and 
indicative of local priming. No external source of antigen was provided in the 
currently applied intradermal GM-CSF administration scheme. This suggests 
that the detected CD8+ T cells were primed against endogenous tumor-derived 
antigen sources, despite the fact that at the time of GM-CSF administration, no 
discernable tumor load remained in these patients. Interestingly in this context, 
recent studies from the Boon-Coulie laboratory showed that even in the case 
of melanoma antigen-speciﬁ c vaccination, reinvigorated preexistent antitumor 
CTLs, rather than newly primed antivaccine CTLs, were likely responsible 
for subsequent antitumor effects.8,50 By way of explanation, they suggested 
that a temporary break of tumor-induced immunosuppression because of 
vaccination (possibly due to immunoactivating signals from the newly primed 
antivaccine CTL) might reactivate previously primed antitumor CTL and 
set into motion an antitumor response. A similar effect may be achieved by 
breaking immunosuppression with DC-activating agents such as GM-CSF. Our 
observation of an association between GM-CSF administration, high MDC 
frequencies, and increased antimelanoma CD8+ T cell frequencies certainly 
seems in line with this notion. The fact that we did not add an external tumor 
antigen source for new T cells to be primed against, suggests that either 
sufﬁ cient tumor-derived antigen traces lingered in the SLN (possibly in the 
context of residing macrophages or DC) to stimulate the melanoma antigen-
reactive CD8+ T cells or that previous activation of antitumor CD8+ T cells had 
already induced a shift in the T cell repertoire resulting in increased anti-tumor 
T cell frequencies in the SLN, which may have been further reinforced by the 
general immunostimulation provided by GM-CSF. Importantly, no relationship 
between T cell reactivity rates and the length of interval between primary 
melanoma excision and the SLN procedure was found: in three of six patients 
with a below median interval and in two of six patients with an above median 
interval, melanoma-speciﬁ c CD8+ T cells were detected. In line with this, the 
interval length between the responding and non-responding patients did not 
differ signicantly either (64 ± 46 versus 49 ± 35 days, respectively; P=0.371 in the 
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Mann-Whitney U test). Thus, the difference in T cell reactivity rates observed 
between the two test groups was not  attributable to a possible difference in the 
retention of melanoma-derived antigens due to  testing at varying time points 
subsequent to the removal of the primary tumor (i.e., the melanoma antigen 
source). 
Although this is a small study and these data await conﬁ rmation in a larger trial, 
they are nevertheless important in that they show that (a) anti-tumor CD8+ T 
cells can already be primed in vivo in the earliest stages of melanoma devel-
opment at a relatively low Breslow thickness and that (b) these CD8+ T cell 
responses seem to be enhanced by immunostimulatory agents such as GM-CSF. 
In future studies, we aim to also include patients with higher Breslow thickness, 
who are at greater risk for SLN metastasis. SLN metastases in these patients 
will increase the risk of immune suppression and further metastatic spread, 
but will also provide a ready source of tumor antigens for immune priming or 
boosting. Local GM-CSF administration in these patients will not only allow the 
further study of such processes as reversal of immune suppression and tumor-
speciﬁ c T cell priming, but also of any clinical beneﬁ t in terms of (disease-free) 
survival.     
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Summary 
Cutaneous melanoma is the most aggressive type of skin cancer, for which 
complete surgical excision at an early stage remains the only curative treatment 
option. One of the most powerful prognostic factors for survival in melanoma 
patients is the presence of (micro)metastatic disease in the regional lymph 
nodes. The optimal surgical management of clinically occult lymph node 
metastases has been a debate for many years. There are two treatment options; 
elective lymph node dissection and the so-called “wait-and-watch” approach. 
Disadvantage of the elective lymph node dissection is its invasiveness; 80% of 
patients with no sign of metastatic disease are subjected to an operation which is 
associated with great morbidity.  
A good compromise would be the removal of only the lymph node which directly 
drains the tumor, the sentinel lymph node. The sentinel lymph node concept 
is based on the concept of orderly progression of metastatic cells within the 
lymphatic system. It assumes that early lymphatic metastases, if present, are 
always found ﬁ rst within the ﬁ rst tumor draining lymph node, the sentinel lymph 
node. A tumor negative sentinel lymph node would thus predict the absence of 
metastatic disease in the rest of the tumor draining lymph node basin and negate 
the necessity of an elective lymph node dissection.  
Since the introduction of the sentinel lymph node procedure in 1993 in the VU 
University Medical Center, we performed more than 600 procedures. The data 
of all these patients are kept up to date in a large database. Due to accurate work 
of research fellows and medical students almost no patient is lost to follow up.  
In this thesis we described the clinical and technical aspects of the sentinel 
lymph node procedure in cutaneous melanoma. Furthermore, we developed 
a model to predict non-sentinel lymph node involvement. All these studies are 
based on patient information from the aforementioned database. 
Besides these studies on the clinical aspects of the sentinel lymph node 
procedure, we started an immunological research line. We investigated whether 
immunological suppression, as present in the sentinel lymph node, could be 
overcome by treatment of melanoma patients with agents which stimulate 
immunological defenses. These immunological studies are described in the last 
part of this thesis. 
In Chapter 2, the accuracy of the sentinel lymph node procedure and the 
clinical outcome of melanoma patients, who underwent selective sentinel lymph 
node dissection, after a follow-up of at least 60 months were investigated. 
Furthermore, factors associated with survival were described. The success 
rate of the sentinel lymph node procedure in this series was 99,5%; in only 1 
patient did we not remove the sentinel lymph node during surgery, although 
the sentinel lymph node was detected both by lymphoscintigraphy and with the 
gamma-detection probe. It was located in the parotid gland, and removing this 
lymph node would have been associated with a very great risk of morbidity. We 
therefore decided not to remove this sentinel lymph node.  
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Forty patients (19 %) had a positive sentinel lymph node. The false negative rate 
in this study was 9%: four of 168 patients who initially had a negative sentinel 
lymph node developed a recurrence in the same draining lymph node basin. 
We showed that patients with a negative sentinel lymph node had a signiﬁ cantly 
better survival compared to sentinel lymph node positive patients. Five-year 
disease-free survival was 88% vs. 50%, respectively. Overall survival rates 
were 92 % vs. 67 %, respectively. We found that not all patients with a positive 
sentinel lymph node have a poor prognosis. In this study all patients with a 
positive sentinel lymph node and a Breslow thickness <1.00 mm are alive to date. 
Combining these two factors provides a tool to predict outcome. Multivariate 
analysis of those factors related to disease-free survival and overall survival 
demonstrated that Breslow thickness, sentinel lymph node status, and lymphatic 
invasion were signiﬁ cantly and independently correlated to disease-free survival 
and overall survival.  
Of melanoma patients with a positive sentinel lymph node, 60-80% have no 
positive additional lymph nodes. Yet, they are all subjected to an additional 
lymph node dissection with associated morbidity. In Chapter 3, we have 
created a model in an attempt to predict the absence of additional lymph node 
metastases in patients with a positive sentinel lymph node. For this, we used 
features of the primary melanoma and sentinel lymph node tumor load. Tumor 
load of the sentinel lymph node was assessed by measuring the total surface 
area of metastasis in the sentinel lymph node by computerized morphometry.  
We analyzed 71 sentinel lymph node positive patients, of which 52 had 
metastases limited to the sentinel lymph node, and of which 19 had one or more 
positive additional lymph nodes. Mean sentinel lymph node metastatic area 
was 1.18 mm2 and 3.39 mm2 (P=0.003) in these groups, respectively, and was 
the only signiﬁ cant and independent factor after multivariate analysis to predict 
additional lymph node involvement (P=0.02). None of the patients with both a 
Breslow thickness <2.5 mm and sentinel lymph node metastatic area <0.3 mm2, 
had positive additional lymph nodes. These patients had an excellent survival, 
comparable to sentinel lymph node negative patients. 
Using this model, we can now divide sentinel lymph node positive patients 
in subgroups, some of which do not beneﬁ t from an additional lymph node 
dissection because they are not likely to have additional lymph node involvement. 
In these patients additional lymph node dissection may be omitted. Larger 
randomized conﬁ rmatory studies are needed to establish the need for an 
additional lymph node dissection in subgroups of sentinel lymph node 
positive patients.  
To study functional immunological processes in lymph nodes, viable cells are 
required. Normally, a piece of lymph node is dissociated to obtain these vi-
able cells. Due to extensive diagnostic procedures, obtaining a piece of sen-
tinel lymph node to isolate viable immune cells is often impossible. For this 
reason, in Chapter 4, an alternative method to obtain viable cells from a 
lymph node was investigated, i.e., scraping the cutting surface of a bisected 
lymph node with a surgical blade, and compared with dissociation of the total 
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lymph node. From 5 oncological patients tumor-draining lymph nodes were 
retrieved. The collected dendritic cells and T cells were phenotypically and 
functionally characterized using FACS analyses and IFN-c ELISPOT-assays. 
Viabilities, frequencies and phenotypic characteristics of the collected cells 
were entirely comparable for both methods. The mean yield of cells after 
scraping of the lymph node was 8.2 x106 (range 2.8 x106 – 20 x106) cells; more 
than enough to do multiple immunological analyses. Mean viability of these 
cells was 91% (range 86% - 96%). Around 0.5% of viable lymph node cells 
with both isolation methods consisted of CD1a+ dendritic cells. T cells were 
obtained by both isolation methods in equal quantities. There was a near exact 
correlation between CD4/CD8-ratios of T cells obtained through dissociation 
and scraping. T cell functionality was also comparable between both methods, 
with equal T cell expansion factors and similar frequencies of cytotoxic T cells 
speciﬁ cally recognizing the M1 matrix protein of Inﬂ uenza Haemophilus or the 
tumor antigen Her-2/neu. Scraping lymph nodes to obtain cells for analysis of 
immune functions in lymph nodes is feasible and presents a very good alternative 
to dissociation of lymph nodes. This technique is ideal for immunological tests in 
sentinel lymph nodes. It does not disturb or interfere with pathological examination 
of the sentinel lymph node. We used this technique in all further immunological 
studies of the sentinel lymph node. 
The last 2 chapters describe the results of a clinical pilot study we performed. To 
overcome the immunological suppression in the sentinel lymph node, melanoma 
patients were treated locally with granulocyte macrophage-colony stimulating 
factor. Twelve Stage 1 melanoma patients were intradermally injected with either 
granulocyte macrophage-colony stimulating factor or saline at the primary tumor 
site during 4 days prior to sentinel lymph node dissection. After undergoing a 
sentinel lymph node procedure, sentinel lymph node cells were isolated using the 
scraping method described in Chapter 4.  
In Chapter 5, we report the effects of granulocyte macrophage-colony 
stimulating factor treatment on the myeloid dendritic cell population in the 
sentinel lymph node. Intradermal administration of granulocyte macrophage-
colony stimulating factor around the excision site of stage I primary melanoma 
tumors increased the number and activation state of dendritic cells in the 
paracortical areas of the sentinel lymph node and enhanced their binding to T 
cells. Mean percentages of mature CD1a+ sentinel lymph node-dendritic cells 
were 0.68% (range 0.31 to 1.03%) and 0.15% (range 0.02 to 0.35%) for the 
granulocyte macrophage-colony stimulating factor–administered group and the 
saline-administered control group, respectively (P<0.05). 
The effect of granulocyte macrophage-colony stimulating factor on tumor 
antigen-speciﬁ c T cell responses is described in Chapter 6. CD8+ T cells from 
sentinel lymph nodes and peripheral blood were tested for reactivity in an IFN-c
ELISPOT-assay against the full-length MART-1 antigen and a number of HLA-
A1/-A2/-A3-restricted epitopes derived from a range of melanoma-associated 
antigens. Melanoma-speciﬁ c CD8+ T cell response rates in the sentinel 
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lymph node were 1/6 for the saline control group and 4/6 for the granulocyte 
macrophage-colony stimulating factor-administered group. Only one patient had 
detectable tumor-speciﬁ c CD8+ T cells in the blood, but at lower frequencies 
than in the sentinel lymph node. Melanoma-speciﬁ c CD8+ T cell reactivity, as 
determined by IFN-c ELISPOT-assay, could generally be conﬁ rmed by HLA-
A2-tetramer binding analysis. All patients with detectable tumor-speciﬁ c CD8+ 
T cells had a percentage of CD1a+ sentinel lymph node-dendritic cells above 
median (i.e. 0.33%). This suggests that increasing dendritic cell frequency in the 
sentinel lymph node by granulocyte macrophage-colony stimulating factor, leads 
to the priming of more melanoma-speciﬁ c effector T cells. 
Conclusions
The actual therapeutic beneﬁ t of the sentinel lymph node procedure is yet to be 
determined. It is still under discussion whether examination of the sentinel lymph 
node with selective lymphadenectomy in clinically node-negative patients and 
adjuvant medical treatment only in sentinel lymph node-positive patients is more 
effective than clinical follow-up with therapeutic dissection at the clinical onset 
of nodal disease. Some data suggest that early removal of positive lymph nodes 
may improve survival.1,2 The Intergroup Trial suggested that the beneﬁ t of elective 
lymph node dissection may be meaningful in patients whose tumors are non-
ulcerated, with extremity primaries, with a Breslow thickness from 1 to 2 mm, 
and who are less than 60 years of age.3,4 
Sentinel lymph node biopsy represents a minimally invasive procedure for 
identifying patients who have subclinical stage III disease, with a high risk of 
developing occult distant metastases. Current clinical trials attempt to determine 
the efﬁ cacy of selective lymph node dissection guided by sentinel lymph node 
mapping. In 2006 the ﬁ nal results of the Multicenter Selective Lymphadenectomy 
Trial are expected. This trial compares selective sentinel lymph node dissection 
and selective complete lymph node dissection with observation. This study 
should conﬁ rm any therapeutic beneﬁ t of the sentinel lymph node procedure in 
melanoma. Interim analysis data presented at the International Sentinel Lymph 
Node congress in Los Angeles in 2004 suggested that the sentinel lymph node 
procedure might show a small survival beneﬁ t, compared to the observation arm. 
So far, only results from this trial concerning the accuracy of the sentinel lymph 
node procedure and its morbidity are reported.5
The sentinel lymph node procedure has some major advantages. First and 
foremost, the detection of micrometastatic disease using the sentinel lymph 
node procedure allows a more accurate staging. Sentinel lymph node status is 
a strong and a signiﬁ cant independent prognostic factor. Second, the sentinel 
lymph node procedure potentially spares node-negative patients further lymph 
node dissection which is associated with signiﬁ cant morbidity. Third, it enables 
a consistent interpretation of clinical trials through the provision of the true 
pathological stage. Fourth, a more accurate knowledge of lymphatic drainage 
patterns is provided by the sentinel lymph node procedure. Fifth, there is a very 
important psychological beneﬁ t for patients whose sentinel lymph node does 
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not reveal metastases. And ﬁ nally, it gives a tool to select patients for adjuvant 
therapy trials. For these reasons, in our view, sentinel lymph node biopsy should 
always be performed in melanoma patients. 
As shown in several studies, immunological responses against tumor antigens 
will initially occur in the sentinel lymph node.6-11 Sentinel lymph nodes are 
immunologically suppressed and as a result are vulnerable to metastatic 
colonization.12-17 As shown in this thesis, local treatment with granulocyte 
macrophage-colony stimulating factor might overcome this immunosuppression. 
Conclusions we can draw from the research described in this thesis:
• The triple technique sentinel lymph node procedure is an accurate and 
reliable procedure.  
• Selective lymph node dissection is potentially therapeutic for a relatively 
large subset of patients.  
• Even if selective sentinel lymph node dissection in and of itself does not 
improve survival, it is of great value and should be continued until another 
less invasive staging test with similar predictive value is developed. It’s one 
of the most powerful prognostic factors.  
• Patients with a positive sentinel lymph node are a heterogeneous group; not 
all sentinel lymph node-positive patients have a poor prognosis. 
• Sentinel lymph node metastatic surface area can be used to predict the 
absence of additional positive lymph nodes in melanoma patients. 
• Based on sentinel lymph node metastatic surface area and Breslow 
thickness, subgroups of patients with a positive sentinel lymph node can be 
identiﬁ ed who will not signiﬁ cantly beneﬁ t from an additional lymph node 
dissection. 
• Scraping the cutting surface of bisected lymph nodes with a surgical 
blade, to obtain viable cells for analysis of immune functions, is feasible and 
presents a good alternative to dissociation of lymph nodes; scraping may thus 
prove useful in the monitoring of immune responses in sentinel lymph nodes 
without compromising the diagnostic examination of these lymph nodes by 
the pathologist. 
• Local treatment of melanoma patients with granulocyte macrophage-
colony stimulating factor, before surgery, conditions the sentinel lymph node 
microenvironment to enhance mature dendritic cell recruitment; this may be 
more conducive to the generation of T cell-mediated antitumor immunity with 
potential therapeutic beneﬁ t. 
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• Melanoma-speciﬁ c cytotoxic T cell frequencies are higher in the sentinel 
lymph node than in peripheral blood. This is a proof for local priming of 
tumor-speciﬁ c cytotoxic T cells in the sentinel lymph node. 
• Locally primed anti-tumor T cell responses in the sentinel lymph node 
are detectable as early as Stage I of melanoma development and can be 
enhanced by granulocyte macrophage-colony stimulating factor-induced 
increases in sentinel lymph node-dendritic cell frequencies.  
Future Prospects
Recently, recurrences after sentinel lymph node biopsy have been heavily debat-
ed. Some groups suggest that the sentinel lymph node procedure increases the 
risk of local and in-transit metastases in melanoma and should be abandoned.18-21
We, together with others, disagree with this conclusion, as careful examination 
of the evidence does not support it.22-24 Groups of patients are not compared 
correctly, or the data of compared groups are incompatible. Patients who had 
undergone a wide local excision only were compared either with the sentinel 
lymph node negative patients, or with the sentinel lymph node positive patients. 
Since the sentinel lymph node status of the patients who had undergone a wide 
local excision only is unknown, this group of patients is merely comparable to 
the total sentinel lymph node biopsy group. Furthermore, some trials concerning 
wide local excision only, excluded patients with a Breslow thickness exceeding 
2 mm, whereas these trials were compared to trials concerning sentinel lymph 
node biopsy in which also patients were included with Breslow thicknesses of 2 
mm or more. Since Breslow thickness is a strong independent prognostic factor 
this makes the data incompatible. The phase III Multicenter Selective Lymphad-
enectomy Trial will deﬁ nitively settle the issue; until then, use of sentinel lymph 
node procedure, the most accurate staging procedure for early-stage melanoma, 
should continue. 
Sentinel lymph node-positive patients are a heterogeneous group.  As we 
also have shown, not all these patients have additional positive lymph node 
involvement.25-29 We therefore do not believe that all sentinel lymph node-positive 
patients should undergo an additional lymph node dissection with associated 
morbidity. We showed that not all sentinel lymph node-positive patients have a 
poor prognosis.30,31 Some subgroups have an excellent survival of around 100%. 
Perhaps this is because they did all undergo an additional lymph node dissection 
which might have been therapeutic? This is not supported by our unpublished 
data concerning 5 patients who had a micrometastasis in the sentinel lymph 
node and who on their own accord decided not to undergo an additional lymph 
node dissection. They are all alive to date, with no signs of recurrent disease.  
Using models to predict additional lymph node involvement could select 
subpopulations to undergo an additional lymph node dissection or not.30,32-35
To settle these issues, future prospective studies in which sentinel lymph node 
positive patients are randomized between additional lymph node dissection and 
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no additional lymph node dissection, need to be performed. For this reason, a 
sequel to the Multicenter Selective Lymphadenectomy Trial, i.e. MSLT 2, has 
started. In this study sentinel lymph node-positive patients are stratiﬁ ed and 
randomized between additional lymph node dissection and observation.12
Another motivation not to perform additional lymph node dissection in all 
sentinel lymph node positive patients, is an immunological one. Tumor-draining 
lymph nodes, particularly the sentinel lymph node, are the ﬁ rst place where 
the immunological defense against malignant cells takes place. As discussed, 
the sentinel lymph node, and the second and third echelon lymph nodes, show 
signs of immunosuppression. Why remove all lymph nodes, when the chances 
of additional lymph node involvement is that low? We may utilize these lymph 
nodes through adjuvant immunotherapy to generate immunity to tumors and 
prevent metastatic spread. The sentinel lymph node procedure provides an 
unique setting in which to study novel immunotherapy approaches in early stage 
melanoma patients as described in this thesis. 
Many clinical immunological studies are being performed in melanoma patients. 
Most of them are done in Stage 4 melanoma patients, with little clinical 
response. Ideally, immunotherapy should be applied in early stage melanoma. 
The immunological defense in these patients is less disrupted compared to 
Stage 4 patients, and immunotherapy might give better clinical results in these 
patients. We have been able to stimulate immunological responses in the sentinel 
lymph node of Stage 1 melanoma patients through intradermal granulocyte 
macrophage-colony stimulating factor administration. Whether this has clinical 
implications, needs to be studied in future prospective clinical trials.  
What is the state of immunosuppression in case of a metastasis in the sentinel 
lymph nodes? Are there other immunologically stimulatory agents beside 
granulocyte macrophage-colony stimulating factor that we can use? We hope to 
answer these, and other questions in future trials.  
As a sequel to the trial described in this thesis, a larger prospective randomized 
trial has been performed in the VU University Medical Center. Inclusion has 
ended and the results are analyzed at this moment. In this trial, clinical Stage 1 
and 2 melanoma patients have been treated with either saline or CpG, another 
immuno-stimulating agent. CpG possibly activates effector T cells through 
plasmacytoid rather than myeloid dendritic cells. Extensive immunological 
analyses have been performed on the sentinel lymph nodes of patients from this 
trial. These series also included patients with metastases in the sentinel lymph 
node. We expect to ﬁ nd a more pronounced immunological downregulation in 
these patients compared to sentinel lymph node negative patients. 
Sentinel lymph node biopsy is a procedure, the use of which is justiﬁ ed by its 
usefulness in staging and determining prognosis. Furthermore, it is a unique 
tool to study immunological functions and adjuvant immunotherapy options in 
the battle against malignancy. We have to await imminent results from ongoing 
prospective trials to once and for all establish its actual therapeutic beneﬁ t. 
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Samenvatting 
Het melanoom van de huid is één van de meest agressieve vormen van 
huidkanker. De enige curatieve behandelingsoptie is volledige chirurgische 
verwijdering. Een zeer belangrijke prognostische factor gerelateerd aan 
overleving, is de aanwezigheid van (micro)metastasen in de regionale 
lymfeklieren. De meest optimale chirurgische behandeling voor klinisch 
occulte lymfekliermetastasen is al vele jaren onderwerp van discussie. Er 
zijn 2 behandelopties; electieve lymfeklierdissectie en observatie. Electieve 
lymfeklierdissectie is de verwijdering van alle regionale lymfeklieren in een 
vroeg stadium. Bij observatie worden de regionale lymfeklieren pas verwijderd 
wanneer zich klinisch lymfekliermetastasering voordoet. Nadeel van de 
electieve lymfeklierdissectie is de invasiviteit; 80% van de patiënten heeft geen 
lymfekliermetastasering, maar ondergaat wel een operatie met signiﬁ cante 
morbiditeit. 
Het zou een goed alternatief zijn om alleen die lymfeklier te verwijderen die 
direct draineert vanaf de tumor, de schildwachtklier. Het schildwachtklierconcept 
is gebaseerd op de gedachte dat maligne cellen zich volgens een vaste 
systematiek  verspreiden door het lymfestelsel naar een speciﬁ eke lymfeklier. 
Het veronderstelt dat vroege metastasering via het lymfestelsel, indien 
aanwezig, altijd wordt gevonden in de eerste lymfeklier die direct draineert 
vanaf de tumor, de schildwachtklier. Een tumor-negatieve schildwachtklier zou 
dus de afwezigheid van metastasen in de rest van de lymfeklieren in hetzelfde 
tumor-drainerende basin voorspellen. Dit zou de noodzaak tot electieve 
lymfeklierdissectie tenietdoen. 
Sinds de introductie van de schildwachtklierprocedure in het VU medisch 
centrum in 1993, hebben wij meer dan 600 procedures verricht. De gegevens 
van al deze patiënten worden bijgehouden in een database. Door het accurate 
werk van arts-onderzoekers en medisch studenten zijn er nauwelijks patiënten 
verloren uit de follow-up.  
In dit proefschrift worden de klinische en technische aspecten van de schildwacht- 
klierprocedure bij het melanoom van de huid beschreven. Daarnaast werd er 
een model ontwikkeld om te voorspellen in hoeverre niet-schildwachtklieren in 
hetzelfde lymfeklierstation een metastase zouden kunnen bevatten. Al deze studies 
zijn gebaseerd op patiënteninformatie uit de hiervoor genoemde database. 
Naast deze studies over de klinische aspecten van de schildwachtklierprocedure, 
is er een immunologische onderzoekslijn opgezet. Hierin werd onderzocht of 
de immunologische suppressie, zoals aanwezig in de schildwachtklier, kon 
worden overwonnen door melanoompatiënten te behandelen met middelen die 
de immunologische afweer stimuleren. Deze immunologische studies worden 
beschreven in het laatste deel van dit proefschrift. 
In Hoofdstuk 2 wordt de accuraatheid van de schildwachtklierprocedure 
beschreven. Daarnaast wordt de klinische uitkomst van melanoompatiënten, 
die een schildwachtklierprocedure ondergingen, onderzocht na een follow-up 
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van tenminste 60 maanden. Verder worden factoren beschreven die een relatie 
hebben met overleving. Het succespercentage van de schildwachtklierprocedure 
in deze serie was 99,5%; bij slechts 1 patiënt hebben we de schildwacht-
klier niet verwijderd alhoewel de schildwachtklier wel was ontdekt met de 
lymfoscintigraﬁ e en met de gammadetectie probe. Deze schildwachtklier was 
gelokaliseerd in de parotis. Verwijdering van deze schildwachtklier zou een zeer 
groot risico op morbiditeit veroorzaken. Daarom is besloten deze schildwacht-
klier niet te verwijderen. 
Veertig patiënten (19%) hadden een positieve schildwachtklier. Het vals-
negatief percentage was 9%. Vier van 168 patiënten die initieel een negatieve 
schildwachtklier hadden, ontwikkelden een recidief in hetzelfde drainerende 
lymfeklierstation. Wij hebben aangetoond dat patiënten met een negatieve 
schildwachtklier een signiﬁ cant betere overleving hadden in vergelijking tot 
schildwachtklier-positieve patiënten. De 5-jaar ziektevrije overleving was 
respectievelijk 88% versus 50%. De totale 5-jaars overleving was respectievelijk 
92% versus 67%. Niet alle patiënten met een positieve schildwachtklier hadden 
een slechte prognose. In deze studie waren alle patiënten met een positieve 
schildwachtklier en een Breslow dikte <1.00 mm tot op dat moment in leven. 
Overleving kan worden voorspeld deze 2 factoren te combineren. Multivariate 
analyse van factoren die zijn gerelateerd met ziektevrije overleving en totale 
overleving, toont aan dat Breslow dikte, schildwachtklierstatus en lymfatische 
invasie signiﬁ cant en onafhankelijk zijn gecorreleerd met ziektevrije overleving 
en totale overleving. 
Van de melanoompatiënten met een positieve schildwachtklier, heeft 60-80% 
geen uitzaaiingen in additionele lymfeklieren. Echter, ze worden allemaal 
onderworpen aan een aanvullende lymfeklierdissectie met bijbehorende 
morbiditeit. In Hoofdstuk 3 werd een model gecreëerd om de afwezigheid 
van metastasen in additionele lymfeklieren te voorspellen bij patiënten met 
een positieve schildwachtklier. Hiervoor gebruikten wij kenmerken van de 
primaire tumor en de ‘tumormassa’ in de schildwachtklier. De tumormassa in de 
schildwachtklier werd bepaald door het totale oppervlakte van de metastase in 
de schildwachtklier te berekenen met behulp van gecomputeriseerde morfometrie. 
Er werden 71 schildwachtklier-positieve patiënten geanalyseerd, waarvan er 
52 alleen metastasen in de schildwachtklier hadden. Negentien patiënten 
hadden metastasen in één of meerdere additionele lymfeklieren. De gemiddelde 
metastase-oppervlakte in de schildwachtklier was in deze groepen respectievelijk 
1.18 mm2 en 3.39 mm2 (P=0.003). De metastase-oppervlakte was de enige 
signiﬁ cante en onafhankelijke factor na multivariate analyse om de aanwezigheid 
van metastasen in additionele lymfeklieren te voorspellen (P=0.02). Geen van 
de patiënten met een Breslow dikte <2.5 mm èn een metastase-oppervlakte in 
de schildwachtklier <0.3 mm2, hadden positieve additionele lymfeklieren. Deze 
patiënten hadden een uitstekende overleving, vergelijkbaar met schildwachtklier-
negatieve patiënten. 
Met behulp van dit model kan de groep schildwachtklier-positieve patiënten 
worden verdeeld in subgroepen. Sommigen hebben geen baat bij een 
additionele lymfeklierdissectie, omdat het niet waarschijnlijk is dat zij positieve 
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additionele lymfeklieren zullen hebben. Bij deze patiënten zou een additionele 
lymfeklierdissectie achterwege kunnen blijven. Grotere gerandomiseerde studies 
zijn nodig om het nut van een additionele lymfeklierdissectie aan te tonen bij 
subgroepen van schildwachtklier-positieve patiënten.  
Om immunologische functies in lymfeklieren te bestuderen, zijn levende  
(viabele) cellen nodig. Idealiter wordt een stukje lymfeklier gedissocieerd om 
levende cellen te verkrijgen. Echter, door uitgebreide diagnostische procedures, 
is het verkrijgen van een stukje schildwachtklier om levende cellen te isoleren 
middels dissociatie, veelal onmogelijk. In Hoofdstuk 4 wordt daarom 
een alternatieve methode om levende cellen uit een lymfeklier te isoleren, 
beschreven. We vergeleken het schrapen van het snijvlak van een gehalveerde 
lymfeklier met een chirurgisch scalpel met het dissociëren van een lymfeklier. 
Van 5 oncologische patiënten werden tumordrainerende lymfeklieren verwijderd 
en onderzocht. De geïsoleerde dendritische cellen en T cellen werden 
fenotypisch en functioneel gekarakteriseerd met behulp van de FACS analyse en 
IFN-c ELISPOT-analyses. 
Viabiliteit, frequenties en fenotypische karakteristieken van de geïsoleerde 
cellen waren volledig vergelijkbaar tussen beide methoden. De gemiddelde 
celopbrengst na schrapen van de lymfeklier was 8.2 x106 (2.8 x106 – 20 x106) 
cellen. De gemiddelde viabiliteit van deze cellen was 91% (86% - 96%). 
Ongeveer 0.5% van de viabele lymfekliercellen bij beide isolatiemethoden 
bestond uit CD1a+ dendritische cellen. T cellen werden met beide methoden 
in gelijke hoeveelheden verkregen. Er was een bijna exacte correlatie tussen 
CD4/CD8-ratio’s van T cellen verkregen door dissociatie of schrapen. T cel 
functionaliteit van beide methoden was vergelijkbaar, dat wil zeggen met gelijke 
T cel expansie factoren en met gelijke frequenties cytotoxische T cellen die 
speciﬁ ek het M1 matrix eiwit van Inﬂ uenza Haemophilus of het tumorantigeen 
Her-2/neu herkennen. 
Het schrapen van lymfeklieren ter verkrijging van cellen voor de analyse van 
immunologische functies in lymfeklieren is uitvoerbaar en blijkt een goed 
alternatief voor dissociatie van lymfeklieren te zijn. Deze techniek is ideaal 
voor immunologische tests in schildwachtklieren. Het interfereert niet met het 
pathologisch onderzoek van de schildwachtklier. Wij gebruikten deze techniek in 
alle verdere immunologische studies van de schildwachtklier. 
De laatste 2 hoofdstukken beschrijven de resultaten van een klinische pilot studie 
die werd uitgevoerd. Om de immunologische suppressie in de schildwachtklier 
te overwinnen, werden melanoompatiënten lokaal behandeld met granulocyte 
macrophage-colony stimulating factor (GM-CSF). Twaalf stadium 1 melanoom-
patiënten kregen gedurende 4 dagen vóór de schildwachtklierprocedure een 
intradermale injectie met GM-CSF of fysiologisch zout daar waar de primaire 
tumor had gezeten. Na de schildwachtklier te hebben verwijderd, werden 
schildwachtkliercellen geïsoleerd door middel van de schraapmethode zoals 
beschreven in Hoofdstuk 4. 
Hoofdstuk 5 beschrijft de effecten van de behandeling met GM-CSF op de 
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myeloïde dendritische cellen in de schildwachtklier. Intradermale toediening 
van GM-CSF ter plaatse van de excisie van primaire stadium 1 melanomen 
verhoogde het aantal èn de activatiestaat van dendritische cellen in de 
paracorticale gebieden van de schildwachtklier. Daarnaast intensiveerde het de 
binding van dendritische cellen aan T cellen. De gemiddelde percentages rijpe 
CD1a+ schildwachtklier-dendritische cellen waren respectievelijk 0.68% (0.31 tot 
1.03%) en 0.15% (0.02 tot 0.35%) voor de GM-CSF-behandelde groep en de 
controle groep (P<0.05). 
Het effect van GM-CSF op tumorantigeen-speciﬁ eke T cel responsen wordt 
beschreven in Hoofdstuk 6. CD8+ T cellen uit de schildwachtklier en uit 
perifeer bloed werden getest op reactiviteit in een IFN-c ELISPOT-analyse 
tegen het volledige MART-1 antigeen en tegen een aantal HLA-A1/HLA-A2/HLA-
A3-gerestricteerde epitopen afgeleid van een aantal melanoom-geassocieerde 
antigenen. Bij één van de in totaal zes patiënten uit de controle groep 
werden melanoom-speciﬁ eke CD8+ T cel responsen in de schildwachtklier 
aangetroffen. Bij de GM-CSF-behandelde patiënten was dit het geval bij 
vier van de zes patiënten. Slechts één patiënt had detecteerbare tumor-
speciﬁ eke CD8+ T cellen in het bloed, echter met lagere frequenties dan in de 
schildwachtklier. Melanoom-speciﬁ eke CD8+ T cel reactiviteit, zoals bepaald 
met IFN-c ELISPOT-analyses, kon over het algemeen worden bevestigd met 
HLA-A2-tetrameer analyses. Alle patiënten met detecteerbare tumor-speciﬁ eke 
CD8+ T cellen hadden een bovengemiddeld percentage (>0.33%) CD1a+ 
schildwachtklier-dendritische cellen. Dit suggereert dat de stijgende frequentie 
van dendritische cellen in de schildwachtklier onder invloed van GM-CSF leidt 
tot het ontstaan van meer melanoom-speciﬁ eke effector T cellen. 
Conclusies 
Het echte therapeutische voordeel van de schildwachtklierprocedure 
moet nog worden bepaald. Er wordt nog steeds gediscussieerd of de 
schildwachtklierprocedure met alleen adjuvante therapie voor schildwacht-
klier-positieve patiënten effectiever is dan alleen klinische follow-up met 
therapeutische lymfeklierdissectie wanneer er klinische lymfekliermetastasering 
wordt geconstateerd. Er bestaan studies die aantonen dat vroege verwijdering 
van lymfekliermetastasen de overleving verbetert.1,2 De Intergroup Trial 
suggereert dat electieve lymfeklierdissectie zinvol zou zijn bij patiënten van wie 
de tumoren geen ulceratie vertonen, met primaire tumoren op de extremiteiten, 
met tumoren met een Breslow dikte tussen 1 en 2 mm, en die jonger zijn dan 
60 jaar.3,4  
De schildwachtklierprocedure is een minimaal invasieve procedure om die 
patiënten te identiﬁ ceren die een subklinisch stadium 3 melanoom hebben 
met een grote kans om metastasen elders te ontwikkelen. De huidige klinische 
trials proberen de therapeutische waarde van de schildwachtklierprocedure 
te bepalen. In 2006 worden de deﬁ nitieve resultaten van de Multicenter 
Selective Lymphadenectomy Trial verwacht. Deze trial vergelijkt de 
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schildwachtklierprocedure met alleen observatie. Het therapeutisch voordeel van 
de schildwachtklierprocedure zou door deze studie moeten worden aangetoond. 
Interim analyses, gepresenteerd tijdens het International Sentinel Lymph Node 
congres in Los Angeles in 2004, suggereren dat de schildwachtklierprocedure 
een klein overlevingsvoordeel toont ten opzichte van alleen observatie. Tot 
dusverre werden alleen data betreffende de accuratesse en de morbiditeit van 
de schildwachtklierprocedure gepubliceerd.5
De schildwachtklierprocedure heeft een aantal grote voordelen. Ten eerste, en 
misschien wel het belangrijkste voordeel, leidt de detectie van micrometastasen 
met behulp van de schildwachtklierprocedure tot een meer accurate 
stadiëring. De schildwachtklierstatus is een sterke en signiﬁ cant onafhankelijke 
prognostische factor. Ten tweede bespaart de schildwachtklierprocedure 
lymfeklier-negatieve patiënten een aanvullende lymfeklierdissectie welke is 
geassocieerd met signiﬁ cante morbiditeit. Ten derde maakt het een consistente 
interpretatie van klinische trials mogelijk, doordat er een ware pathologische 
stadiëring mogelijk is. Ten vierde zorgt de schildwachtklierprocedure voor een 
meer accurate kennis van de lymfatische drainage patronen. Als vijfde is er een 
zeer belangrijk psychologisch voordeel, met name voor die patiënten waarbij de 
schildwachtklier negatief is. Tot slot, geeft het een instrument om patiënten te 
selecteren voor adjuvante trials. Vanwege deze redenen, dient in onze ogen de 
schildwachtklierprocedure altijd te worden uitgevoerd bij melanoompatiënten. 
Zoals aangetoond in diverse studies, vindt de eerste immunologische response 
tegen tumorantigenen plaats in de schildwachtklier.6-11 Schildwachtklieren zijn 
immunologisch onderdrukt en zijn als resultaat hiervan kwetsbaar voor het 
ontstaan van metastasen.12-17 Zoals aangetoond in dit proefschrift, zou lokale 
behandeling met GM-CSF deze immuun suppressie teniet kunnen doen. 
Conclusies die getrokken kunnen worden uit het in dit proefschrift beschreven 
onderzoek:
• De drieledige schildwachtklierprocedure is een accurate en betrouwbare 
procedure.  
• Selectieve lymfeklierdissectie, ofwel de schildwachtklierprocedure, is 
potentieel therapeutisch voor een relatief groot deel van de patiënten.  
• Ook al zou de schildwachtklierprocedure de overleving niet verbeteren, het 
is van grote waarde en zou moeten worden uitgevoerd totdat er een andere, 
minder invasieve stadiëringsmethode wordt ontwikkeld met vergelijkbare 
voorspellende waarde. Schildwachtklierstatus is één van de meest krachtige 
prognostische factoren. 
• Patiënten met een positieve schildwachtklier zijn een heterogene groep; niet 
alle schildwachtklier-positieve patiënten hebben een slechte prognose. 
• Metastase-oppervlakte in de schildwachtklier kan gebruikt worden om de 
aan-/afwezigheid van additionele positieve lymfeklieren te voorspellen. 
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• Gebaseerd op metastase-oppervlakte in de schildwachtklier en Breslow 
dikte, kunnen de schildwachtklier-positieve patiënten worden onderverdeeld 
in subgroepen welke niet allemaal voordeel zullen hebben bij een additionele 
lymfeklierdissectie. 
• Het schrapen van het snijvlak van een gehalveerde lymfeklier met een 
chirurgische scalpel om viabele cellen voor immunologische analyses 
te verkrijgen is makkelijk uitvoerbaar. Het is een goed alternatief voor 
dissociatie van lymfeklieren. Schrapen lijkt dus nuttig voor het monitoren 
van immunologische responsen in de schildwachtklier zonder daarbij het 
diagnostisch onderzoek door de patholoog-anatoom te verstoren. 
• Lokale behandeling van melanoompatiënten met GM-CSF zorgt voor 
een milieu in de schildwachtklier waardoor het aantal dendritische cellen 
toeneemt. Dit kan leiden tot de generatie van T cel-gemedieerde antitumor 
immuniteit met potentieel therapeutisch voordeel. 
• Het aantal melanoom-speciﬁ eke cytotoxische T cellen is hoger in 
de schildwachtklier in vergelijking tot het aantal melanoom-speciﬁ eke 
cytotoxische T cellen in bloed. Dit is een bewijs dat de stimulatie van 
tumor-speciﬁ eke cytotoxische T cellen begint in de schildwachtklier. 
• Lokaal gestimuleerde antitumor T cel responsen in de schildwachtklier 
zijn reeds aantoonbaar in stadium 1 van de melanoomontwikkeling. Deze 
kunnen worden versterkt door de toename van dendritische cellen in de 
schildwachtklier onder invloed van GM-CSF.  
de Toekomst
Recentelijk werd er hevig gedebatteerd over het ontstaan van recidieven 
na een schildwachtklierprocedure. Sommige groepen suggereren dat de 
schildwachtklierprocedure het risico op lokale en intransit metastasen bij 
melanoompatiënten verhoogd, en dus zou moeten worden verlaten.18-21 Wij, 
samen met anderen, zijn het niet eens met deze conclusies, omdat zorgvuldige 
bestudering van de data deze conclusie niet ondersteunt.22-24 Patiëntengroepen 
zijn niet correct vergeleken, of de data van vergeleken groepen zijn tegenstrijdig. 
Patiënten die alleen een ruime excisie hadden ondergaan zijn vergeleken met 
schildwachtklier-negatieve patiënten of met schildwachtklier-positieve patiënten. 
Aangezien de schildwachtklierstatus van patiënten die alleen een ruime excisie 
hadden ondergaan onbekend is, is deze groep alleen vergelijkbaar met de totale 
groep die een schildwachtklierprocedure heeft ondergaan. Verder excludeerden 
sommige trials patiënten met een Breslow dikte groter dan 2 mm, terwijl deze 
trials werden vergeleken met trials, betreffende de schildwachtklierprocedure, 
waarin wel patiënten met een Breslow dikte groter dan 2 mm waren geïncludeerd. 
Aangezien Breslow dikte een sterke onafhankelijke prognostische factor is, maakt 
dat deze data onvergelijkbaar zijn. De fase 3 Multicenter Selective Lymphad-
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enectomy Trial zal deﬁ nitief duidelijkheid verschaffen omtrent dit vraagstuk; tot 
dan zal de schildwachtklierprocedure, de meest accurate stageringsprocedure 
voor melanomen, moeten worden uitgevoerd. 
Schildwachtklier-positieve patiënten zijn een heterogene groep. Zoals wij 
hebben aangetoond, hebben niet al deze patiënten metastasen in additionele 
lymfeklieren.25-29 Daarom geloven wij dat niet alle schildwachtklier-positieve 
patiënten een aanvullende lymfeklierdissectie, welke is geassocieerd met 
signiﬁ cante morbiditeit, moeten ondergaan. Wij toonden aan dat niet alle 
schildwachtklier-positieve patiënten een slechte prognose hebben.30,31 Sommige 
van deze subgroepen hebben zelfs een overleving van rond de 100%. Misschien 
komt dit doordat al deze patiënten juist een aanvullende lymfeklierdissectie 
hebben ondergaan welke mogelijk therapeutisch is geweest? Dit wordt echter 
niet ondersteund door onze ongepubliceerde data van 5 patiënten die een 
micrometastase hadden in de schildwachtklier en zelf besloten geen aanvullende 
lymfeklierdissectie te ondergaan. Zij zijn tot op heden namelijk allemaal in leven 
zonder tekenen van een recidief.  
Het gebruik van modellen om de aanwezigheid van metastasen in additionele 
lymfeklieren te voorspellen kan subgroepen identiﬁ ceren en selecteren die wel of 
geen aanvullende lymfeklierdissectie moeten ondergaan.30,32-35 Om dit vraagstuk 
te kunnen beantwoorden, zouden prospectieve studies moeten worden gedaan 
die randomiseren tussen aanvullende lymfeklierdissectie of geen aanvullende 
lymfeklierdissectie bij schildwachtklier-positieve patiënten. Om deze reden is 
er een vervolg op de Multiticenter Selective Lymphadenectomy Trial gekomen, 
namelijk de MSLT 2 trial. In deze studie worden schildwachtklier-positieve 
patiënten gerandomiseerd tussen aanvullende lymfeklierdissectie en observatie.12
Een andere motivatie om geen aanvullende lymfeklierdissectie uit te voeren 
bij alle schildwachtklier-positieve patiënten, is van immunologische aard. 
Tumor-drainerende lymfeklieren, met name de schildwachtklier, zijn de eerste 
plaats waar de immunologische afweer tegen maligne cellen wordt geïnitieerd. 
De schildwachtklier, en de tweede en derde echelon lymfeklieren, vertonen 
tekenen van immuunsuppressie. Waarom zouden we alle lymfeklieren weghalen 
als de kans op metastasen in aanvullende lymfeklieren zo laag is? We zouden 
deze lymfeklieren kunnen gebruiken om immuniteit tegen tumoren te initiëren 
via immuuntherapie. Hiermee zou metastasering kunnen worden voorkomen. 
De schildwachtklier-procedure voorziet in een unieke mogelijkheid om 
immuuntherapeutische benaderingen, zoals onder andere beschreven in dit 
proefschrift, te onderzoeken bij melanoompatiënten in een vroeg stadium. 
Er worden vele immunologische studies verricht bij melanoompatiënten. 
De meeste van deze studies worden verricht bij melanoompatiënten met 
systemische metastasen. Bij deze patiënten wordt over het algemeen een 
minimale klinische response gezien. Idealiter zou immuuntherapie moeten 
worden toegepast bij melanomen in een vroeg stadium. De immunologische 
afweer is bij deze patiënten minder verstoord in vergelijking tot melanoom-
patiënten met systemische metastasen. Immuuntherapie zou tot betere klinische 
resultaten bij deze melanoompatiënten met een vroeg stadium kunnen leiden. 
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Wij hebben de immuunresponsen in de schildwachtklieren van stadium 1 
melanoompatiënten gestimuleerd door intradermale injecties met GM-CSF. Of 
dit klinische consequenties zal hebben, moet worden onderzocht in toekomstige 
prospectieve studies. 
Hoe is de immuunsuppressie in de schildwachtklier als er sprake is van een 
metastase in de schildwachtklier? Zijn er andere immuunstimulerende middelen, 
naast GM-CSF, die we kunnen gebruiken? Wij hopen deze en andere vragen te 
beantwoorden in toekomstige trials. 
Als vervolg op de studie die in dit proefschrift is beschreven, is er een grotere 
prospectieve studie verricht in het VU medisch centrum. De inclusie is geëindigd 
en de resultaten worden op dit moment geanalyseerd. In deze studie zijn klinisch 
stadium 1 en 2 melanoompatiënten behandeld met fysiologisch zout of CpG, een 
ander immuunstimulerend middel. CpG stimuleert effector T cellen mogelijk via 
plasmacytoïde dendritische cellen, in plaats van via myeloïde dendritische cellen 
zoals bij GM-CSF. Er werden uitgebreide immunologische analyses gedaan van 
de schildwachtklieren van patiënten uit deze studie. Deze studie bevatte ook 
patiënten met metastasen in de schildwachtklier. Verwacht wordt een sterkere 
immuunsuppressie in de schildwachtklier van deze patiënten te vinden in 
vergelijking tot schildwachtklier-negatieve patiënten.  
De schildwachtklierprocedure is met name belangrijk voor de stadiëring van 
melanoompatiënten en dus voor het bepalen van de prognose. Daarnaast 
is het een uniek instrument om immunologische functies en adjuvante 
immuuntherapeutische opties te bestuderen. Wij zullen moeten wachten op de 
resultaten van lopende prospectieve studies om het therapeutische voordeel van 
de schildwachtklierprocedure deﬁ nitief vast te stellen. 
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Mede dankzij de inspanningen van een groot aantal medewerkers in het VU 
medisch centrum is dit proefschrift tot stand gekomen. Niet alleen medewerkers
van de vakgroep Heelkunde ben ik heel dankbaar, maar ook van de vakgroep 
Pathologie voor de mogelijkheden die mij werden geboden dit onderzoek gestalte 
te geven. Daarnaast was dit onderzoek natuurlijk niet mogelijk geweest zonder de 
vrijwillige medewerking van patiënten. Bedankt. 
Een aantal mensen wil ik graag in het bijzonder bedanken. 
Allereerst mijn promotor prof.dr. P.A.M. van Leeuwen. Beste Paul, door jou 
ben ik binnengekomen bij de Heelkunde. Eerst als medisch student voor mijn 
wetenschappelijke stage, en later als arts-onderzoeker. Het is bewonderenswaardig 
hoe jij onderzoekslijnen uitzet en in stand houdt. Jij kunt als geen ander de rode 
draad uit een manuscript halen. Daarnaast heb je een gave als het gaat om de 
inschatting van plaatsingsmogelijkheden van manuscripten. Bedankt voor al je 
steun en toewijding, ook op persoonlijk vlak. 
Prof.dr. S. Meijer, promotor. Beste professor, dank voor al uw inzet en interesse. 
In mijn ogen bent u een echte nestor van de vakgroep Chirurgische Oncologie. 
Trots als een pauw als er weer presentaties van onze groep waren op internationale
congressen, maar tegelijkertijd kritisch en bescheiden. Het was en is een voorrecht 
om met u samen te werken. 
Prof.dr. R.J. Scheper, promotor. Beste Rik, dankzij jou ben ik in het laboratorium 
beland om basaal wetenschappelijk onderzoek te doen. Voor mijn wetenschappelijke
ontwikkeling is dit erg belangrijk geweest. Ik zal nooit onze werkbesprekingen 
vergeten waarbij ik  iedere keer na aﬂ oop naar buiten kwam met diverse A4-tjes vol 
nieuwe ideeën en plannen die we er wel even bij konden doen. Dit kenmerkt jouw 
enorme enthousiasme wat altijd stimulerend werkt. Dank voor al je inzet en support. 
Dr. T.D. de Gruijl, copromotor. Beste Tanja, wat een kei ben jij! Jouw bijdrage 
voor dit proefschrift is zeer groot geweest. Je hebt me wegwijs gemaakt in 
het laboratorium; van het maken van kweekmedia tot het FACS-en van cellen. 
Daarnaast was je altijd bereid om manuscripten aandachtig te lezen en kritisch te 
beoordelen. Ik ken maar weinig mensen die zich het “wetenschappelijk Engels” zo 
meester zijn als jij. Kortom, je was mijn denktank voor dit onderzoek. 
Bedankt voor alles. 
Leden van de lees-/promotiecommissie: prof.dr. A.M.M. Eggermont, prof.dr. P.J. 
van Diest, prof.dr. B.B.R. Kroon, prof.dr. W.J. Mooi, dr. A.J.M. van den Eertwegh 
en dr. J.J. Bonenkamp. Bedankt voor het lezen van het manuscript en het voeren 
van de oppositie. 
Prof.dr. P.J. van Diest, patholoog-anatoom. Beste Paul, bedankt voor je 
enthousiasme en  adviezen. Jij had altijd tijd voor overleg en kwam vaak met 
creatieve oplossingen als er praktische zaken geregeld moesten worden. 
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Tammo de Vries Reilingh, paranimf. Beste Tammo, ik kan je nu al vertellen dat 
het een heerlijk gevoel is om dit af te ronden. Succes met jouw laatste loodjes. Ik 
ben blij met onze vriendschap die sinds onze studie steeds hechter is geworden. 
Bedankt dat je mijn paranimf hebt willen zijn. 
Gaby Bes, paranimf. Beste Gaby, we hebben elkaar al weer jaren geleden leren 
kennen via onze wederhelften. Sindsdien is er een mooie vriendschap gegroeid. 
Je stond altijd klaar in moeilijke tijden en vandaag staan wij hier samen in gelukkige
tijden. Ik vind dat heel bijzonder. Daarnaast spreek ik mijn bewondering uit hoe 
jij je, als ﬁ scalist, de materie van dit proefschrift eigen hebt gemaakt. Je snapt 
nagenoeg alles en plaatst zelfs zinnige opmerkingen… Bedankt. 
Markwin Statius Muller, voorganger. Beste Markwin, ik heb het onderzoek destijds 
van jou overgenomen. Jij had reeds de eerste aanzet gemaakt om de immunologie 
in de schildwachtklier te gaan onderzoeken. Bedankt voor je betrokkenheid, èn 
gezelschap op diverse internationale congressen die we samen hebben bezocht. 
Barbara Molenkamp, opvolgster. Beste Barbara, jij hebt het stokje van mij 
overgenomen en bent inmiddels al weer met je opleiding tot chirurg begonnen. 
Ik heb bewondering voor je hoe snel je data hebt vergaard en je manuscripten op 
de rails hebt gekregen. Succes met het afronden en bedankt voor jouw bijdrage in 
‘mijn’ deel van het onderzoek. 
Pepijn Wijnands, analist. Beste Pepijn, jij hebt bergen werk verzet in het 
laboratorium. Zonder jouw hulp was het allemaal niet zo vlot gegaan. Ik weet dat 
ik de lat af en toe hoog kon leggen met bijvoorbeeld strakgeplande ELISPOT-
analyses. Jij sloeg je er iedere keer doorheen. Bedankt daarvoor. 
De Fritz Ahlqvist Foundation stimuleert wetenschappelijk onderzoek op het gebied 
van het maligne melanoom. Ik ben de familie Ahlqvist en de overige bestuursleden 
van de stichting zeer dankbaar voor hun bijdrage en interesse in het onderzoek 
zoals wij dat hebben uitgevoerd en nog steeds uitvoeren. Zonder hen was dit niet 
mogelijk geweest. 
Dr. P.J. Borgstein, chirurg. Beste Paul, bedankt dat we de “Borg-index” verder 
hebben kunnen uitwerken.
De onderzoeksgang Heelkunde: Taco Blokhuis, Robert Nijveldt, Manuel Koppe, 
Petra Boelens, Frank Termaat, Michiel Siroen, Francis Wu, Floris Vos, Clarissa 
van Vlijmen, Sabine van Harten, Robert-Jan Derksen, Steven Oosterling en 
Gerdien Melis. Bedankt voor jullie gezelligheid. 
Ron de Hoon, stafmedewerker. Beste Ron, bedankt voor al je steun en hulp. Jouw 
deur staat altijd open en je bent altijd geïnteresseerd in zaken die ons bezighouden.
Hans Torrenga, reisgenoot. Beste Hans, jij hebt dit al achter de rug. Bedankt voor 
je gezelligheid tijdens onze reizen over de wereld. Succes met je carrière. 
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De afdeling Pathologie: Sinéad, Hetty, Jan, Anita, Wim, Adrie, en de andere 
medewerkers van de 2e etage, bedankt voor al jullie hulp en interesse. 
De afdeling Heelkunde, staﬂ eden, fellows, CHIVO’s en arts-assistenten van het VU 
medisch centrum, bedankt voor alle interesse en steun. 
De medisch studenten die met name veel tijd in de database hebben gestoken: 
bedankt. 
Josée Zijlstra-Baalbergen, prof.dr. G.J. Ossenkoppele, en alle andere hematologen 
uit het VU medisch centrum wil ik bedanken voor de speciale manier waarop zij 
hebben bijgedragen aan de totstandkoming van dit proefschrift. Dankzij jullie inzet 
in een bijzondere periode van mijn leven, ben ik in staat geweest mijn promotie-
onderzoek af te ronden. Voor mij is jullie bijdrage van levensbelang geweest! 
Lieve Pap, Mam, Johan en Betty, de manier waarop jullie altijd voor ons gezin 
klaar staan, is goud waard. 
Lieve Max en Tess, eigenwijs stel, het is fantastisch om jullie te zien opgroeien. 
Lieve Lotte, jouw kritische noot houdt mij altijd scherp. Ik heb bewondering voor 
je wilskracht. In moeilijke tijden was jij degene die de kar trok en alles op de rails 
hield. Ik hoop dat we elkaar nog heel lang zullen stimuleren, aanvullen en liefhebben. 
Ik hou van jullie. 
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Ronald Vuylsteke was born on October 28th 1972 in Waddinxveen, the 
Netherlands. From 1985 to 1988 he attended high school in Gouda 
(Gymnasium, Coornhert Gymnasium), and ﬁ nished high school in Woerden 
(Atheneum, Minkema Scholengemeenschap) in 1991. 
After this he entered Medical School in Amsterdam at the Vrije Universiteit. 
For one of his internships, he attended the department of Traumatology at the 
University of the Orange Free State in Bloemfontein, South-Africa. He graduated 
in 1999 and started as a surgical resident (AGNIO) at the Ziekenhuis Hilversum 
in Hilversum. In 2000 he became a research-fellow at the department of Surgical 
Oncology (prof.dr. S. Meijer) at the VU University Medical Center in Amsterdam 
under supervision of prof.dr. P.A.M. van Leeuwen. For his scientiﬁ c achievement 
he was awarded with the Young Investigator Award (3rd International Sentinel 
Node Congress, Yokohama, Japan, 2002) and the Chris Meijerprijs 2003 (VU 
University Medical Center Institute for Cancer and Immunology; V-ICI). 
He started with his surgical training in 2003 at the VU University Medical Center 
(prof.dr. J.A. Rauwerda). From January 2005, he continued his surgical training 
at the Kennemer Gasthuis in Haarlem (dr. H.L.F. Brom).  
He is married to Lotte, and they have two children, Max and Tess. 
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